<?xml version="1.0" encoding="UTF-8"?>
<!DOCTYPE article PUBLIC "-//NLM//DTD JATS (Z39.96) Journal Publishing DTD v1.3 20210610//EN" "JATS-journalpublishing1-3.dtd">
<article article-type="research-article" dtd-version="1.3" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xml:lang="ru"><front><journal-meta><journal-id journal-id-type="publisher-id">evrazkar</journal-id><journal-title-group><journal-title xml:lang="ru">Евразийский Кардиологический Журнал</journal-title><trans-title-group xml:lang="en"><trans-title>Eurasian heart journal</trans-title></trans-title-group></journal-title-group><issn pub-type="ppub">2225-1685</issn><issn pub-type="epub">2305-0748</issn><publisher><publisher-name>Евразийская ассоциация кардиологов</publisher-name></publisher></journal-meta><article-meta><article-id pub-id-type="doi">10.38109/2225-1685-2022-1-6-79</article-id><article-id custom-type="elpub" pub-id-type="custom">evrazkar-6303</article-id><article-categories><subj-group subj-group-type="heading"><subject>Research Article</subject></subj-group><subj-group subj-group-type="section-heading" xml:lang="ru"><subject>КЛИНИЧЕСКИЕ РЕКОМЕНДАЦИИ</subject></subj-group><subj-group subj-group-type="section-heading" xml:lang="en"><subject>CLINICAL GUIDELINES</subject></subj-group></article-categories><title-group><article-title>Евразийские клинические рекомендации по диагностике, профилактике и лечению сердечно-сосудистых осложнений при противоопухолевой терапии (2022)</article-title><trans-title-group xml:lang="en"><trans-title>Eurasian clinical guidelines for cardiovascular complications of cancer treatments: diagnosis, prevention and treatment (2022)</trans-title></trans-title-group></title-group><contrib-group><contrib contrib-type="author" corresp="yes"><contrib-id contrib-id-type="orcid">https://orcid.org/0000-0002-1576-4877</contrib-id><name-alternatives><name name-style="eastern" xml:lang="ru"><surname>Чазова</surname><given-names>И. Е.</given-names></name><name name-style="western" xml:lang="en"><surname>Chazova</surname><given-names>I. E.</given-names></name></name-alternatives><bio xml:lang="ru"><p>Чазова Ирина Евгеньевна, д.м.н., профессор, академик РАН, заместитель генерального директора по научно-экспертной работе, руководитель отдела гипертонии</p><p>Москва</p></bio><bio xml:lang="en"><p>Irina E. Chazova, Dr. of Sci. (Med.), Academician of RAS, Deputy General Director for Scientific and Expert Work, Head of the Hypertension Department</p><p>Moscow</p></bio><xref ref-type="aff" rid="aff-1"/></contrib><contrib contrib-type="author" corresp="yes"><contrib-id contrib-id-type="orcid">https://orcid.org/0000-0003-4369-1393</contrib-id><name-alternatives><name name-style="eastern" xml:lang="ru"><surname>Агеев</surname><given-names>Ф. Т.</given-names></name><name name-style="western" xml:lang="en"><surname>Ageev</surname><given-names>F. T.</given-names></name></name-alternatives><bio xml:lang="ru"><p>Агеев Фаиль Таипович, д.м.н., профессор, главный научный сотрудник отдела амбулаторных лечебно-диагностических технологий</p><p>Москва</p></bio><bio xml:lang="en"><p>Fail’ T. Ageev, Dr. of Sci. (Med.)</p><p>Moscow</p></bio><xref ref-type="aff" rid="aff-2"/></contrib><contrib contrib-type="author" corresp="yes"><contrib-id contrib-id-type="orcid">https://orcid.org/0000-0001-8048-4882</contrib-id><name-alternatives><name name-style="eastern" xml:lang="ru"><surname>Аксенова</surname><given-names>А. В.</given-names></name><name name-style="western" xml:lang="en"><surname>Aksenova</surname><given-names>A. V.</given-names></name></name-alternatives><bio xml:lang="ru"><p>Аксенова Анна Владимировна, к.м.н., старший научный сотрудник отдела гипертонии </p><p> 121552, Москва, ул. 3-я Черепковская, д. 15 а</p></bio><bio xml:lang="en"><p>Anna V. Aksenova, Cand. of Sci. (Med.)</p><p> st. 3rd Cherepkovskaya, 15a, Moscow, 121552</p></bio><email xlink:type="simple">aksenovaannav@gmail.com</email><xref ref-type="aff" rid="aff-2"/></contrib><contrib contrib-type="author" corresp="yes"><contrib-id contrib-id-type="orcid">https://orcid.org/0000-0003-1996-3416</contrib-id><name-alternatives><name name-style="eastern" xml:lang="ru"><surname>Виценя</surname><given-names>М. В.</given-names></name><name name-style="western" xml:lang="en"><surname>Vicenya</surname><given-names>M. V.</given-names></name></name-alternatives><bio xml:lang="ru"><p>Виценя Марина Вячеславна, к.м.н., старший научный сотрудник отдела амбулаторных лечебно-диагностических технологий</p><p>Москва</p></bio><bio xml:lang="en"><p>Marina V. Vicenya, Cand. of Sci. (Med.)</p><p>Moscow</p></bio><xref ref-type="aff" rid="aff-2"/></contrib><contrib contrib-type="author" corresp="yes"><contrib-id contrib-id-type="orcid">https://orcid.org/0000-0002-2870-3301</contrib-id><name-alternatives><name name-style="eastern" xml:lang="ru"><surname>Гиляров</surname><given-names>М. Ю.</given-names></name><name name-style="western" xml:lang="en"><surname>Gilyarov</surname><given-names>M. Yu.</given-names></name></name-alternatives><bio xml:lang="ru"><p>Гиляров Михаил Юрьевич, д.м.н., профессор, заместитель главного врача по терапевтической помощи</p><p>Москва</p></bio><bio xml:lang="en"><p>Mihail Yu. Gilyarov, Dr. of Sci. (Med.), Deputy Chief Physician for Therapeutic Care</p><p>Moscow</p></bio><xref ref-type="aff" rid="aff-3"/></contrib><contrib contrib-type="author" corresp="yes"><contrib-id contrib-id-type="orcid">https://orcid.org/0000-0002-9022-8097</contrib-id><name-alternatives><name name-style="eastern" xml:lang="ru"><surname>Мартынюк</surname><given-names>Т. В.</given-names></name><name name-style="western" xml:lang="en"><surname>Martynyuk</surname><given-names>T. V.</given-names></name></name-alternatives><bio xml:lang="ru"><p>Мартынюк Тамила Витальевна, д.м.н., профессор, руководитель отдела легочной гипертензии и заболеваний сердца</p><p>Москва</p></bio><bio xml:lang="en"><p>Tamila V. Martynyuk, Dr. of Sci. (Med.), Head of the Department of Pulmonary Hypertension and Cardiac Diseases</p><p>Moscow</p></bio><xref ref-type="aff" rid="aff-4"/></contrib><contrib contrib-type="author" corresp="yes"><contrib-id contrib-id-type="orcid">https://orcid.org/0000-0002-9158-2522</contrib-id><name-alternatives><name name-style="eastern" xml:lang="ru"><surname>Панченко</surname><given-names>Е. П.</given-names></name><name name-style="western" xml:lang="en"><surname>Panchenko</surname><given-names>E. P.</given-names></name></name-alternatives><bio xml:lang="ru"><p>Панченко Елизавета Павловна, д.м.н., профессор, руководитель отдела клинических проблем атеротромбоза</p><p>Москва</p></bio><bio xml:lang="en"><p>Elizaveta P. Panchenko, Dr. of Sci. (Med.), Professor, Head of the Department of Clinical Problems of Atherothrombosis</p><p>Moscow</p></bio><xref ref-type="aff" rid="aff-1"/></contrib><contrib contrib-type="author" corresp="yes"><contrib-id contrib-id-type="orcid">https://orcid.org/0000-0003-4463-2897</contrib-id><name-alternatives><name name-style="eastern" xml:lang="ru"><surname>Полтавская</surname><given-names>М. Г.</given-names></name><name name-style="western" xml:lang="en"><surname>Poltavskaya</surname><given-names>M. G.</given-names></name></name-alternatives><bio xml:lang="ru"><p>Полтавская Мария Георгиевна, д.м.н., профессор, профессор кафедры прикладной психологии и медико-биологических основ физического воспитания</p><p>Москва</p></bio><bio xml:lang="en"><p>Mariya G. Poltavskaya, Dr. of Sci. (Med.), Professor at the Department of Applied Psychology and Biomedical Fundamentals of Physical Education</p><p>Moscow</p></bio><xref ref-type="aff" rid="aff-5"/></contrib><contrib contrib-type="author" corresp="yes"><contrib-id contrib-id-type="orcid">https://orcid.org/0000-0002-2459-7273</contrib-id><name-alternatives><name name-style="eastern" xml:lang="ru"><surname>Потиевская</surname><given-names>В. И.</given-names></name><name name-style="western" xml:lang="en"><surname>Potievskaya</surname><given-names>V. I.</given-names></name></name-alternatives><bio xml:lang="ru"><p>Потиевская Вера Исааковна, д.м.н., профессор, заведующая отделением кардиологии и медицинской реабилитации, заведующая научной группой кардиоонкологии</p><p>Москва</p></bio><bio xml:lang="en"><p>Vera I. Potievskaya, Dr. of Sci. (Med.), Head of the Department of Cardiology and Medical Rehabilitation, Head of the Scientific Group of Cardio-Oncology</p><p>Moscow </p></bio><xref ref-type="aff" rid="aff-6"/></contrib><contrib contrib-type="author" corresp="yes"><contrib-id contrib-id-type="orcid">https://orcid.org/0000-0002-7204-370X</contrib-id><name-alternatives><name name-style="eastern" xml:lang="ru"><surname>Трофимова</surname><given-names>О. П.</given-names></name><name name-style="western" xml:lang="en"><surname>Trofimova</surname><given-names>O. P.</given-names></name></name-alternatives><bio xml:lang="ru"><p>Трофимова Оксана Петровна, д.м.н., профессор, ведущий научный сотрудник, врач-радиотерапевт</p><p>Москва</p></bio><bio xml:lang="en"><p>Oksana P. Trofimova, Dr. of Sci. (Med.), Leading Researcher, Radiotherapist</p><p>Moscow</p></bio><xref ref-type="aff" rid="aff-7"/></contrib><contrib contrib-type="author" corresp="yes"><contrib-id contrib-id-type="orcid">https://orcid.org/0000-0002-4562-1471</contrib-id><name-alternatives><name name-style="eastern" xml:lang="ru"><surname>Федоткина</surname><given-names>Ю. А.</given-names></name><name name-style="western" xml:lang="en"><surname>Fedotkina</surname><given-names>Yu. A.</given-names></name></name-alternatives><bio xml:lang="ru"><p>Федоткина Юлия Александровна, к.м.н., научный сотрудник отдела ангиологии</p><p>Москва</p></bio><bio xml:lang="en"><p>Yuliya A. Fedotkina, Cand. of Sci. (Med.), Researcher, Department of Angiology</p><p>Moscow</p></bio><xref ref-type="aff" rid="aff-1"/></contrib></contrib-group><aff-alternatives id="aff-1"><aff xml:lang="ru"><institution>Институт клинической кардиологии им. А.Л. Мясникова, ФГБУ «НМИЦ Кардиологии» Минздрава России</institution><country>Россия</country></aff><aff xml:lang="en"><institution>Institute of Clinical Cardiology, National Medical Research Center of Cardiology</institution><country>Russian Federation</country></aff></aff-alternatives><aff-alternatives id="aff-2"><aff xml:lang="ru"><institution>Институт клинической кардиологии им. А.Л. Мясникова, ФГБУ «НМИЦ Кардиологии» Минздрава России</institution><country>Россия</country></aff><aff xml:lang="en"><institution>Myasnikov Institute of Clinical Cardiology, National Medical Research Center of Cardiology of the Ministry of Health of Russia</institution><country>Russian Federation</country></aff></aff-alternatives><aff-alternatives id="aff-3"><aff xml:lang="ru"><institution>Первая Градская больница им. Н. И. Пирогова</institution><country>Россия</country></aff><aff xml:lang="en"><institution>Pirogov First City Hospital</institution><country>Russian Federation</country></aff></aff-alternatives><aff-alternatives id="aff-4"><aff xml:lang="ru"><institution>Институт клинической кардиологии им. А.Л. Мясникова ФГБУ «НМИЦ кардиологии» Минздрава России</institution><country>Россия</country></aff><aff xml:lang="en"><institution>Myasnikov Institute of Clinical Cardiology, National Medical Research Center of Cardiology of the Ministry of Health of Russia</institution><country>Russian Federation</country></aff></aff-alternatives><aff-alternatives id="aff-5"><aff xml:lang="ru"><institution>Первый МГМУ имени И.М. Сеченова Минздрава России (Сеченовский Университет)</institution><country>Россия</country></aff><aff xml:lang="en"><institution>I.M. Sechenov First Moscow State Medical University of the Ministry of Health of the Russian Federation (Sechenov University)</institution><country>Russian Federation</country></aff></aff-alternatives><aff-alternatives id="aff-6"><aff xml:lang="ru"><institution>МНИОИ им П.А. Герцена – филиала ФГБУ «НМИЦ радиологии» МЗ РФ</institution><country>Россия</country></aff><aff xml:lang="en"><institution>P.A. Herzen Moscow Research Institute of Oncology – Branch of the National Medical Research Radiological Centre of the Ministry of Health of the Russian Federation</institution><country>Russian Federation</country></aff></aff-alternatives><aff-alternatives id="aff-7"><aff xml:lang="ru"><institution>ФГБУ «НМИЦ онкологии им. Н.Н. Блохина» Минздрава России</institution><country>Россия</country></aff><aff xml:lang="en"><institution>N.N. Blokhin National Research Center of Oncology of the Ministry of Health of Russia</institution><country>Russian Federation</country></aff></aff-alternatives><pub-date pub-type="collection"><year>2022</year></pub-date><pub-date pub-type="epub"><day>07</day><month>03</month><year>2022</year></pub-date><volume>0</volume><issue>1</issue><fpage>6</fpage><lpage>79</lpage><permissions><copyright-statement>Copyright &amp;#x00A9; Чазова И.Е., Агеев Ф.Т., Аксенова А.В., Виценя М.В., Гиляров М.Ю., Мартынюк Т.В., Панченко Е.П., Полтавская М.Г., Потиевская В.И., Трофимова О.П., Федоткина Ю.А., 2022</copyright-statement><copyright-year>2022</copyright-year><copyright-holder xml:lang="ru">Чазова И.Е., Агеев Ф.Т., Аксенова А.В., Виценя М.В., Гиляров М.Ю., Мартынюк Т.В., Панченко Е.П., Полтавская М.Г., Потиевская В.И., Трофимова О.П., Федоткина Ю.А.</copyright-holder><copyright-holder xml:lang="en">Chazova I.E., Ageev F.T., Aksenova A.V., Vicenya M.V., Gilyarov M.Y., Martynyuk T.V., Panchenko E.P., Poltavskaya M.G., Potievskaya V.I., Trofimova O.P., Fedotkina Y.A.</copyright-holder><license xml:lang="ru" license-type="creative-commons-attribution" xlink:href="https://creativecommons.org/licenses/by/4.0/" xlink:type="simple"><license-p>Данная работа распространяется под лицензией Creative Commons Attribution 4.0.</license-p></license><license xml:lang="en" license-type="creative-commons-attribution" xlink:href="https://creativecommons.org/licenses/by/4.0/" xlink:type="simple"><license-p>This work is licensed under a Creative Commons Attribution 4.0 License.</license-p></license></permissions><self-uri xlink:href="https://www.heartj.asia/jour/article/view/6303">https://www.heartj.asia/jour/article/view/6303</self-uri><abstract><p>Отказ от ответственности. Рекомендации ЕАК отражают точку зрения ЕАК и были подготовлены после тщательного изучения научных и медицинских данных, имеющихся на момент их публикации. ЕАК не несут ответственности в случае какого-либо противоречия, несоответствия и / или неоднозначности между Рекомендациями ЕАК и любыми другими официальными рекомендациями или руководствами, выпущенными соответствующими органами общественного здравоохранения, в частности, в отношении правильного использования медицинских или терапевтических стратегий. Медицинским работникам рекомендуется в полной мере учитывать Рекомендации ЕАК при оценке своего клинического суждения, а также при определении и реализации профилактических, диагностических или терапевтических медицинских стратегий. Тем не менее, Рекомендации ЕАК никоим образом не отменяют индивидуальную ответственность медицинских работников за принятие надлежащих и точных решений с учетом состояния здоровья каждого пациента и в консультации с этим пациентом и, при необходимости и / или необходимости, опекуна пациента. Рекомендации ЕАК не освобождают медицинских работников от полного и тщательного рассмотрения соответствующих официальных обновленных рекомендаций или руководств, выпущенных компетентными органами общественного здравоохранения, для рассмотрения каждого медицинского случая в свете современных научно обоснованных рекомендаций в соответствии с их этическими и профессиональными обязательствами. Кроме того, медицинский работник обязан проверять действующие правила и положения, касающиеся лекарств и медицинских изделий, на момент назначения по рецепту.</p></abstract><trans-abstract xml:lang="en"><p>Disclaimer. The EAC Guidelines represent the views of the EAC, and were produced after careful consideration of the scientific and medical knowledge, and the evidence available at the time of their publication. The EAC is not responsible in the event of any contradiction, discrepancy, and/or ambiguity between the EAC Guidelines and any other official recommendations or guidelines issued by the relevant public health authorities, in particular in relation to good use of healthcare or therapeutic strategies. Health professionals are encouraged to take the EAC Guidelines fully into account when exercising their clinical judgment, as well as in the determination and the implementation of preventive, diagnostic, or therapeutic medical strategies; however, the EAC Guidelines do not override, in any way whatsoever, the individual responsibility of health professionals to make appropriate and accurate decisions in consideration of each patient’s health condition and in consultation with that patient and, where appropriate and/or necessary, the patient’s caregiver. Nor do the EAC Guidelines exempt health professionals from taking into full and careful consideration the relevant official updated recommendations or guidelines issued by the competent public health authorities, in order to manage each patient’s case in light of the scientifically accepted data pursuant to their respective ethical and professional obligations. It is also the health professional’s responsibility to verify the applicable rules and regulations relating to drugs and medical devices at the time of prescription.</p></trans-abstract><kwd-group xml:lang="ru"><kwd>артериальная гипертония</kwd><kwd>дисфункция левого желудочка</kwd><kwd>Евразийская ассоциация кардиологов</kwd><kwd>ишемическая болезнь сердца</kwd><kwd>кардиотоксичность</kwd><kwd>клинические рекомендации</kwd><kwd>легочная артериальная гипертензия</kwd><kwd>лучевая терапия</kwd><kwd>нарушение ритма и проводимости сердца</kwd><kwd>периоперационное ведение</kwd><kwd>противоопухолевая терапия</kwd><kwd>сердечная недостаточность</kwd><kwd>терапия ингибиторами контрольных точек иммунного ответа</kwd><kwd>терапия рака</kwd><kwd>тромбозы</kwd><kwd>химиотерапия.</kwd></kwd-group><kwd-group xml:lang="en"><kwd>arterial hypertension left ventricular dysfunction</kwd><kwd>Eurasian Association of Cardiologists</kwd><kwd>cardiac ischemia</kwd><kwd>cardiotoxicity</kwd><kwd>clinical guidelines</kwd><kwd>pulmonary arterial hypertension</kwd><kwd>radiation therapy</kwd><kwd>arrhythmias</kwd><kwd>perioperative management</kwd><kwd>anticancer therapy</kwd><kwd>heart failure</kwd><kwd>immune checkpoint inhibitors</kwd><kwd>cancer therapy</kwd><kwd>thrombosis</kwd><kwd>chemotherapy.</kwd></kwd-group></article-meta></front><back><ref-list><title>References</title><ref id="cit1"><label>1</label><citation-alternatives><mixed-citation xml:lang="ru">Ewer MS, Ewer SM. Cardiotoxicity of anticancer treatments. Nat Rev Cardiol. 2015;12(11):620. https://doi.org/10.1038/nrcardio.2015.133</mixed-citation><mixed-citation xml:lang="en">Ewer MS, Ewer SM. Cardiotoxicity of anticancer treatments. Nat Rev Cardiol. 2015;12(11):620. https://doi.org/10.1038/nrcardio.2015.133</mixed-citation></citation-alternatives></ref><ref id="cit2"><label>2</label><citation-alternatives><mixed-citation xml:lang="ru">Zamorano JL, Lancellotti P, Rodriguez Muñoz D, et al. 2016 ESC Position Paper on cancer treatments and cardiovascular toxicity developed under the auspices of the ESC Committee for Practice Guidelines: The Task Force for cancer treatments and cardiovascular toxicity of the European Society of Cardiology (ESC) [published correction appears in Eur Heart J. 2016 Dec 24;:]. Eur Heart J. 2016;37(36):2768-2801. https://doi.org/10.1093/eurheartj/ehw211</mixed-citation><mixed-citation xml:lang="en">Zamorano JL, Lancellotti P, Rodriguez Muñoz D, et al. 2016 ESC Position Paper on cancer treatments and cardiovascular toxicity developed under the auspices of the ESC Committee for Practice Guidelines: The Task Force for cancer treatments and cardiovascular toxicity of the European Society of Cardiology (ESC) [published correction appears in Eur Heart J. 2016 Dec 24;:]. Eur Heart J. 2016;37(36):2768-2801. https://doi.org/10.1093/eurheartj/ehw211</mixed-citation></citation-alternatives></ref><ref id="cit3"><label>3</label><citation-alternatives><mixed-citation xml:lang="ru">Chen MH, Colan SD, Diller L. Cardiovascular disease: cause of morbidity and mortality in adult survivors of childhood cancers [published correction appears in Circ Res. 2011 Apr 15;108(8):e11]. Circ Res. 2011;108(5):619-628. https://doi.org/10.1161/CIRCRESAHA.110.224519</mixed-citation><mixed-citation xml:lang="en">Chen MH, Colan SD, Diller L. Cardiovascular disease: cause of morbidity and mortality in adult survivors of childhood cancers [published correction appears in Circ Res. 2011 Apr 15;108(8):e11]. Circ Res. 2011;108(5):619-628. https://doi.org/10.1161/CIRCRESAHA.110.224519</mixed-citation></citation-alternatives></ref><ref id="cit4"><label>4</label><citation-alternatives><mixed-citation xml:lang="ru">Sawyer D, Lenihan D. Managing heart failure in cancer patients. In: Mann D., Felker G. Heart Failure: A Companion to Braunwald’s Heart Disease, 3rd ed. Philadelphia, Elsevier, 2016;p. 689–96.</mixed-citation><mixed-citation xml:lang="en">Sawyer D, Lenihan D. Managing heart failure in cancer patients. In: Mann D., Felker G. Heart Failure: A Companion to Braunwald’s Heart Disease, 3rd ed. Philadelphia, Elsevier, 2016;p. 689–96.</mixed-citation></citation-alternatives></ref><ref id="cit5"><label>5</label><citation-alternatives><mixed-citation xml:lang="ru">Cardinale D, Sandri MT, Colombo A, et al. Prognostic value of troponin I in cardiac risk stratifcation of cancer patients undergoing highdose chemotherapy. Circulation. 2004;109(22):2749-2754. https://doi.org/10.1161/01.CIR.0000130926.51766.CC</mixed-citation><mixed-citation xml:lang="en">Cardinale D, Sandri MT, Colombo A, et al. Prognostic value of troponin I in cardiac risk stratifcation of cancer patients undergoing highdose chemotherapy. Circulation. 2004;109(22):2749-2754. https://doi.org/10.1161/01.CIR.0000130926.51766.CC</mixed-citation></citation-alternatives></ref><ref id="cit6"><label>6</label><citation-alternatives><mixed-citation xml:lang="ru">Von Hoff DD, Layard MW, Basa P, et al. Risk factors for doxorubicin-induced congestive heart failure. Ann Intern Med. 1979;91(5):710-717. https://doi.org/10.7326/0003-4819-91-5-710</mixed-citation><mixed-citation xml:lang="en">Von Hoff DD, Layard MW, Basa P, et al. Risk factors for doxorubicin-induced congestive heart failure. Ann Intern Med. 1979;91(5):710-717. https://doi.org/10.7326/0003-4819-91-5-710</mixed-citation></citation-alternatives></ref><ref id="cit7"><label>7</label><citation-alternatives><mixed-citation xml:lang="ru">Cardinale D, Colombo A, Bacchiani G, et al. Early detection of anthracycline cardiotoxicity and improvement with heart failure therapy. Circulation. 2015;131(22):1981-1988. https://doi.org/10.1161/CIRCULATIONAHA.114.013777</mixed-citation><mixed-citation xml:lang="en">Cardinale D, Colombo A, Bacchiani G, et al. Early detection of anthracycline cardiotoxicity and improvement with heart failure therapy. Circulation. 2015;131(22):1981-1988. https://doi.org/10.1161/CIRCULATIONAHA.114.013777</mixed-citation></citation-alternatives></ref><ref id="cit8"><label>8</label><citation-alternatives><mixed-citation xml:lang="ru">Ryberg M, Nielsen D, Skovsgaard T, Hansen J, Jensen BV, Dombernowsky P. Epirubicin cardiotoxicity: an analysis of 469 patients with metastatic breast cancer. J Clin Oncol. 1998;16(11):3502-3508. https://doi.org/10.1200/JCO.1998.16.11.3502</mixed-citation><mixed-citation xml:lang="en">Ryberg M, Nielsen D, Skovsgaard T, Hansen J, Jensen BV, Dombernowsky P. Epirubicin cardiotoxicity: an analysis of 469 patients with metastatic breast cancer. J Clin Oncol. 1998;16(11):3502-3508. https://doi.org/10.1200/JCO.1998.16.11.3502</mixed-citation></citation-alternatives></ref><ref id="cit9"><label>9</label><citation-alternatives><mixed-citation xml:lang="ru">Nielsen D, Jensen JB, Dombernowsky P, et al. Epirubicin cardiotoxicity: a study of 135 patients with advanced breast cancer. J Clin Oncol. 1990;8(11):1806-1810. https://doi.org/10.1200/JCO.1990.8.11.1806</mixed-citation><mixed-citation xml:lang="en">Nielsen D, Jensen JB, Dombernowsky P, et al. Epirubicin cardiotoxicity: a study of 135 patients with advanced breast cancer. J Clin Oncol. 1990;8(11):1806-1810. https://doi.org/10.1200/JCO.1990.8.11.1806</mixed-citation></citation-alternatives></ref><ref id="cit10"><label>10</label><citation-alternatives><mixed-citation xml:lang="ru">Felker GM, Thompson RE, Hare JM, et al. Underlying causes and long-term survival in patients with initially unexplained cardiomyopathy. N Engl J Med. 2000;342(15):1077-1084. https://doi.org/10.1056/NEJM200004133421502</mixed-citation><mixed-citation xml:lang="en">Felker GM, Thompson RE, Hare JM, et al. Underlying causes and long-term survival in patients with initially unexplained cardiomyopathy. N Engl J Med. 2000;342(15):1077-1084. https://doi.org/10.1056/NEJM200004133421502</mixed-citation></citation-alternatives></ref><ref id="cit11"><label>11</label><citation-alternatives><mixed-citation xml:lang="ru">Kuramochi Y, Cote GM, Guo X, et al. Cardiac endothelial cells regulate reactive oxygen species-induced cardiomyocyte apoptosis through neuregulin-1beta/erbB4 signaling. J Biol Chem. 2004;279(49):51141-51147. https://doi.org/10.1074/jbc.M408662200</mixed-citation><mixed-citation xml:lang="en">Kuramochi Y, Cote GM, Guo X, et al. Cardiac endothelial cells regulate reactive oxygen species-induced cardiomyocyte apoptosis through neuregulin-1beta/erbB4 signaling. J Biol Chem. 2004;279(49):51141-51147. https://doi.org/10.1074/jbc.M408662200</mixed-citation></citation-alternatives></ref><ref id="cit12"><label>12</label><citation-alternatives><mixed-citation xml:lang="ru">Hedhli N, Huang Q, Kalinowski A, et al. Endothelium-derived neuregulin protects the heart against ischemic injury. Circulation. 2011;123(20):2254-2262. https://doi.org/10.1161/CIRCULATIONAHA.110.991125</mixed-citation><mixed-citation xml:lang="en">Hedhli N, Huang Q, Kalinowski A, et al. Endothelium-derived neuregulin protects the heart against ischemic injury. Circulation. 2011;123(20):2254-2262. https://doi.org/10.1161/CIRCULATIONAHA.110.991125</mixed-citation></citation-alternatives></ref><ref id="cit13"><label>13</label><citation-alternatives><mixed-citation xml:lang="ru">Graus-Porta D, Beerli RR, Daly JM, Hynes NE. ErbB-2, the preferred heterodimerization partner of all ErbB receptors, is a mediator of lateral signaling. EMBO J. 1997;16(7):1647-1655. https://doi.org/10.1093/emboj/16.7.1647</mixed-citation><mixed-citation xml:lang="en">Graus-Porta D, Beerli RR, Daly JM, Hynes NE. ErbB-2, the preferred heterodimerization partner of all ErbB receptors, is a mediator of lateral signaling. EMBO J. 1997;16(7):1647-1655. https://doi.org/10.1093/emboj/16.7.1647</mixed-citation></citation-alternatives></ref><ref id="cit14"><label>14</label><citation-alternatives><mixed-citation xml:lang="ru">Procter M, Suter TM, de Azambuja E, et al. Longer-term assessment of trastuzumab-related cardiac adverse events in the Herceptin Adjuvant (HERA) trial. J Clin Oncol. 2010;28(21):3422-3428. https://doi.org/10.1200/JCO.2009.26.0463</mixed-citation><mixed-citation xml:lang="en">Procter M, Suter TM, de Azambuja E, et al. Longer-term assessment of trastuzumab-related cardiac adverse events in the Herceptin Adjuvant (HERA) trial. J Clin Oncol. 2010;28(21):3422-3428. https://doi.org/10.1200/JCO.2009.26.0463</mixed-citation></citation-alternatives></ref><ref id="cit15"><label>15</label><citation-alternatives><mixed-citation xml:lang="ru">Ewer MS, Vooletich MT, Durand JB et al. Reversibility of trastuzumab-related cardiotoxicity: new insights based on clinical course and response to medical treatment. J Clin Oncol. 2005 Nov 1;23(31):7820-6. https://doi.org/10.1200/JCO.2005.13.300 PMID: 16258084.</mixed-citation><mixed-citation xml:lang="en">Ewer MS, Vooletich MT, Durand JB et al. Reversibility of trastuzumab-related cardiotoxicity: new insights based on clinical course and response to medical treatment. J Clin Oncol. 2005 Nov 1;23(31):7820-6. https://doi.org/10.1200/JCO.2005.13.300 PMID: 16258084.</mixed-citation></citation-alternatives></ref><ref id="cit16"><label>16</label><citation-alternatives><mixed-citation xml:lang="ru">Curigliano G, Lenihan D, Fradley M, et al. Management of cardiac disease in cancer patients throughout oncological treatment: ESMO consensus recommendations. Ann Oncol. 2020;31(2):171-190. https://doi.org/10.1016/j.annonc.2019.10.023</mixed-citation><mixed-citation xml:lang="en">Curigliano G, Lenihan D, Fradley M, et al. Management of cardiac disease in cancer patients throughout oncological treatment: ESMO consensus recommendations. Ann Oncol. 2020;31(2):171-190. https://doi.org/10.1016/j.annonc.2019.10.023</mixed-citation></citation-alternatives></ref><ref id="cit17"><label>17</label><citation-alternatives><mixed-citation xml:lang="ru">Lenihan D, Suter T, Brammer M, Neate C, Ross G, Baselga J. Pooled analysis of cardiac safety in patients with cancer treated with pertuzumab [published correction appears in Ann Oncol. 2019 Jun 1;30(6):1021]. Ann Oncol. 2012;23(3):791-800. https://doi.org/10.1093/annonc/mdr294.</mixed-citation><mixed-citation xml:lang="en">Lenihan D, Suter T, Brammer M, Neate C, Ross G, Baselga J. Pooled analysis of cardiac safety in patients with cancer treated with pertuzumab [published correction appears in Ann Oncol. 2019 Jun 1;30(6):1021]. Ann Oncol. 2012;23(3):791-800. https://doi.org/10.1093/annonc/mdr294.</mixed-citation></citation-alternatives></ref><ref id="cit18"><label>18</label><citation-alternatives><mixed-citation xml:lang="ru">Perez EA, Koehler M, Byrne J, Preston AJ, Rappold E, Ewer MS. Cardiac safety of lapatinib: pooled analysis of 3689 patients enrolled in clinical trials. Mayo Clin Proc. 2008;83(6):679-686. https://doi.org/10.4065/83.6.679</mixed-citation><mixed-citation xml:lang="en">Perez EA, Koehler M, Byrne J, Preston AJ, Rappold E, Ewer MS. Cardiac safety of lapatinib: pooled analysis of 3689 patients enrolled in clinical trials. Mayo Clin Proc. 2008;83(6):679-686. https://doi.org/10.4065/83.6.679</mixed-citation></citation-alternatives></ref><ref id="cit19"><label>19</label><citation-alternatives><mixed-citation xml:lang="ru">Speyer JL, Green MD, Zeleniuch-Jacquotte A, et al. ICRF-187 permits longer treatment with doxorubicin in women with breast cancer [published correction appears in J Clin Oncol 1992 May;10(5):867]. J Clin Oncol. 1992;10(1):117-127. https://doi.org/10.1200/JCO.1992.10.1.117</mixed-citation><mixed-citation xml:lang="en">Speyer JL, Green MD, Zeleniuch-Jacquotte A, et al. ICRF-187 permits longer treatment with doxorubicin in women with breast cancer [published correction appears in J Clin Oncol 1992 May;10(5):867]. J Clin Oncol. 1992;10(1):117-127. https://doi.org/10.1200/JCO.1992.10.1.117</mixed-citation></citation-alternatives></ref><ref id="cit20"><label>20</label><citation-alternatives><mixed-citation xml:lang="ru">Swain SM, Whaley FS, Ewer MS. Congestive heart failure in patients treated with doxorubicin: a retrospective analysis of three trials. Cancer. 2003;97(11):2869-2879. https://doi.org/10.1002/cncr.11407</mixed-citation><mixed-citation xml:lang="en">Swain SM, Whaley FS, Ewer MS. Congestive heart failure in patients treated with doxorubicin: a retrospective analysis of three trials. Cancer. 2003;97(11):2869-2879. https://doi.org/10.1002/cncr.11407</mixed-citation></citation-alternatives></ref><ref id="cit21"><label>21</label><citation-alternatives><mixed-citation xml:lang="ru">van Nimwegen FA, Schaapveld M, Janus CP, et al. Cardiovascular disease after Hodgkin lymphoma treatment: 40-year disease risk. JAMA Intern Med. 2015;175(6):1007-1017. https://doi.org/10.1001/jamainternmed.2015.1180</mixed-citation><mixed-citation xml:lang="en">van Nimwegen FA, Schaapveld M, Janus CP, et al. Cardiovascular disease after Hodgkin lymphoma treatment: 40-year disease risk. JAMA Intern Med. 2015;175(6):1007-1017. https://doi.org/10.1001/jamainternmed.2015.1180</mixed-citation></citation-alternatives></ref><ref id="cit22"><label>22</label><citation-alternatives><mixed-citation xml:lang="ru">Armenian SH, Sun CL, Shannon T, et al. Incidence and predictors of congestive heart failure after autologous hematopoietic cell transplantation. Blood. 2011;118(23):6023-6029. https://doi.org/10.1182/blood-2011-06-358226</mixed-citation><mixed-citation xml:lang="en">Armenian SH, Sun CL, Shannon T, et al. Incidence and predictors of congestive heart failure after autologous hematopoietic cell transplantation. Blood. 2011;118(23):6023-6029. https://doi.org/10.1182/blood-2011-06-358226</mixed-citation></citation-alternatives></ref><ref id="cit23"><label>23</label><citation-alternatives><mixed-citation xml:lang="ru">Baldini E, Prochilo T, Salvadori B, et al. Multicenter randomized phase III trial of epirubicin plus paclitaxel vs epirubicin followed by paclitaxel in metastatic breast cancer patients: focus on cardiac safety. Br J Cancer. 2004;91(1):45-49. https://doi.org/10.1038/sj.bjc.6601883</mixed-citation><mixed-citation xml:lang="en">Baldini E, Prochilo T, Salvadori B, et al. Multicenter randomized phase III trial of epirubicin plus paclitaxel vs epirubicin followed by paclitaxel in metastatic breast cancer patients: focus on cardiac safety. Br J Cancer. 2004;91(1):45-49. https://doi.org/10.1038/sj.bjc.6601883</mixed-citation></citation-alternatives></ref><ref id="cit24"><label>24</label><citation-alternatives><mixed-citation xml:lang="ru">Fumoleau P, Roché H, Kerbrat P, et al. Long-term cardiac toxicity after adjuvant epirubicin-based chemotherapy in early breast cancer: French Adjuvant Study Group results. Ann Oncol. 2006;17(1):85-92. https://doi.org/10.1093/annonc/mdj034</mixed-citation><mixed-citation xml:lang="en">Fumoleau P, Roché H, Kerbrat P, et al. Long-term cardiac toxicity after adjuvant epirubicin-based chemotherapy in early breast cancer: French Adjuvant Study Group results. Ann Oncol. 2006;17(1):85-92. https://doi.org/10.1093/annonc/mdj034</mixed-citation></citation-alternatives></ref><ref id="cit25"><label>25</label><citation-alternatives><mixed-citation xml:lang="ru">Ryberg M, Nielsen D, Cortese G, Nielsen G, Skovsgaard T, Andersen PK. New insight into epirubicin cardiac toxicity: competing risks analysis of 1097 breast cancer patients. J Natl Cancer Inst. 2008;100(15):1058-1067. https://doi.org/10.1093/jnci/djn206</mixed-citation><mixed-citation xml:lang="en">Ryberg M, Nielsen D, Cortese G, Nielsen G, Skovsgaard T, Andersen PK. New insight into epirubicin cardiac toxicity: competing risks analysis of 1097 breast cancer patients. J Natl Cancer Inst. 2008;100(15):1058-1067. https://doi.org/10.1093/jnci/djn206</mixed-citation></citation-alternatives></ref><ref id="cit26"><label>26</label><citation-alternatives><mixed-citation xml:lang="ru">van der Pal HJ, van Dalen EC, van Delden E, et al. High risk of symptomatic cardiac events in childhood cancer survivors. J Clin Oncol. 2012;30(13):1429-1437. https://doi.org/10.1200/JCO.2010.33.4730</mixed-citation><mixed-citation xml:lang="en">van der Pal HJ, van Dalen EC, van Delden E, et al. High risk of symptomatic cardiac events in childhood cancer survivors. J Clin Oncol. 2012;30(13):1429-1437. https://doi.org/10.1200/JCO.2010.33.4730</mixed-citation></citation-alternatives></ref><ref id="cit27"><label>27</label><citation-alternatives><mixed-citation xml:lang="ru">Di Cosimo S. Heart to heart with trastuzumab: a review on cardiac toxicity. Target Oncol. 2011;6(4):189-195. https://doi.org/10.1007/s11523-011-0203-8</mixed-citation><mixed-citation xml:lang="en">Di Cosimo S. Heart to heart with trastuzumab: a review on cardiac toxicity. Target Oncol. 2011;6(4):189-195. https://doi.org/10.1007/s11523-011-0203-8</mixed-citation></citation-alternatives></ref><ref id="cit28"><label>28</label><citation-alternatives><mixed-citation xml:lang="ru">Zeglinski M, Ludke A, Jassal D et al. Trastuzumab-induced cardiac dysfunction: A «dual-hit». Exp Clin Cardiol 2011;16:70–4.</mixed-citation><mixed-citation xml:lang="en">Zeglinski M, Ludke A, Jassal D et al. Trastuzumab-induced cardiac dysfunction: A «dual-hit». Exp Clin Cardiol 2011;16:70–4.</mixed-citation></citation-alternatives></ref><ref id="cit29"><label>29</label><citation-alternatives><mixed-citation xml:lang="ru">Клинические рекомендации. Рак молочной железы. Рубрикатор КР (minzdrav.gov.ru).</mixed-citation><mixed-citation xml:lang="en">Клинические рекомендации. Рак молочной железы. Рубрикатор КР (minzdrav.gov.ru).</mixed-citation></citation-alternatives></ref><ref id="cit30"><label>30</label><citation-alternatives><mixed-citation xml:lang="ru">Piccart-Gebhart MJ, Procter M, Leyland-Jones B et al. Herceptin Adjuvant Trial Study Team. Trastuzumab after adjuvant chemotherapy in HER2-positive breast cancer. N Engl J Med 2005; 353:1659–72.</mixed-citation><mixed-citation xml:lang="en">Piccart-Gebhart MJ, Procter M, Leyland-Jones B et al. Herceptin Adjuvant Trial Study Team. Trastuzumab after adjuvant chemotherapy in HER2-positive breast cancer. N Engl J Med 2005; 353:1659–72.</mixed-citation></citation-alternatives></ref><ref id="cit31"><label>31</label><citation-alternatives><mixed-citation xml:lang="ru">Bowles EJ, Wellman R, Feigelson HS et al. Risk of heart failure in breast cancer patients after anthracycline and trastuzumab treatment: A retrospective cohort study. J Natl Cancer Inst 2012; 104:1293–305.</mixed-citation><mixed-citation xml:lang="en">Bowles EJ, Wellman R, Feigelson HS et al. Risk of heart failure in breast cancer patients after anthracycline and trastuzumab treatment: A retrospective cohort study. J Natl Cancer Inst 2012; 104:1293–305.</mixed-citation></citation-alternatives></ref><ref id="cit32"><label>32</label><citation-alternatives><mixed-citation xml:lang="ru">Farolf A, Melegari E, Aquilina M, et al. Trastuzumab-induced cardiotoxicity in early breast cancer patients: a retrospective study of possible risk and protective factors. Heart. 2013;99(9):634-639. https://doi.org/10.1136/heartjnl-2012-303151</mixed-citation><mixed-citation xml:lang="en">Farolf A, Melegari E, Aquilina M, et al. Trastuzumab-induced cardiotoxicity in early breast cancer patients: a retrospective study of possible risk and protective factors. Heart. 2013;99(9):634-639. https://doi.org/10.1136/heartjnl-2012-303151</mixed-citation></citation-alternatives></ref><ref id="cit33"><label>33</label><citation-alternatives><mixed-citation xml:lang="ru">Robert N, Leyland-Jones B, Asmar L et al. Randomized phase III study of trastuzumab, paclitaxel, and carboplatin compared with trastuzumab and paclitaxel in women with HER-2-overexpressing metastatic breast cancer. J Clin Oncol 2006; 24:2786–92.</mixed-citation><mixed-citation xml:lang="en">Robert N, Leyland-Jones B, Asmar L et al. Randomized phase III study of trastuzumab, paclitaxel, and carboplatin compared with trastuzumab and paclitaxel in women with HER-2-overexpressing metastatic breast cancer. J Clin Oncol 2006; 24:2786–92.</mixed-citation></citation-alternatives></ref><ref id="cit34"><label>34</label><citation-alternatives><mixed-citation xml:lang="ru">Burstein H, Kuter I, Campos S et al. Clinical activity of trastuzumab and vinorelbine in women with HER2-overexpressing metastatic breast cancer. J Clin Oncol 2001; 19: 2722–30.</mixed-citation><mixed-citation xml:lang="en">Burstein H, Kuter I, Campos S et al. Clinical activity of trastuzumab and vinorelbine in women with HER2-overexpressing metastatic breast cancer. J Clin Oncol 2001; 19: 2722–30.</mixed-citation></citation-alternatives></ref><ref id="cit35"><label>35</label><citation-alternatives><mixed-citation xml:lang="ru">Advani PP, Ballman KV, Dockter TJ, Colon-Otero G, Perez EA. LongTerm Cardiac Safety Analysis of NCCTG N9831 (Alliance) Adjuvant Trastuzumab Trial. J Clin Oncol. 2016;34(6):581-587. https://doi.org/10.1200/JCO.2015.61.8413</mixed-citation><mixed-citation xml:lang="en">Advani PP, Ballman KV, Dockter TJ, Colon-Otero G, Perez EA. LongTerm Cardiac Safety Analysis of NCCTG N9831 (Alliance) Adjuvant Trastuzumab Trial. J Clin Oncol. 2016;34(6):581-587. https://doi.org/10.1200/JCO.2015.61.8413</mixed-citation></citation-alternatives></ref><ref id="cit36"><label>36</label><citation-alternatives><mixed-citation xml:lang="ru">Romond EH, Jeong JH, Rastogi P, et al. Seven-year follow-up assessment of cardiac function in NSABP B-31, a randomized trial comparing doxorubicin and cyclophosphamide followed by paclitaxel (ACP) with ACP plus trastuzumab as adjuvant therapy for patients with node-positive, human epidermal growth factor receptor 2-positive breast cancer. J Clin Oncol. 2012;30(31):3792-3799. https://doi.org/10.1200/JCO.2011.40.0010</mixed-citation><mixed-citation xml:lang="en">Romond EH, Jeong JH, Rastogi P, et al. Seven-year follow-up assessment of cardiac function in NSABP B-31, a randomized trial comparing doxorubicin and cyclophosphamide followed by paclitaxel (ACP) with ACP plus trastuzumab as adjuvant therapy for patients with node-positive, human epidermal growth factor receptor 2-positive breast cancer. J Clin Oncol. 2012;30(31):3792-3799. https://doi.org/10.1200/JCO.2011.40.0010</mixed-citation></citation-alternatives></ref><ref id="cit37"><label>37</label><citation-alternatives><mixed-citation xml:lang="ru">Pinder MC, Duan Z, Goodwin JS, Hortobagyi GN, Giordano SH. Congestive heart failure in older women treated with adjuvant anthracycline chemotherapy for breast cancer. J Clin Oncol. 2007;25(25):3808-3815. https://doi.org/10.1200/JCO.2006.10.4976</mixed-citation><mixed-citation xml:lang="en">Pinder MC, Duan Z, Goodwin JS, Hortobagyi GN, Giordano SH. Congestive heart failure in older women treated with adjuvant anthracycline chemotherapy for breast cancer. J Clin Oncol. 2007;25(25):3808-3815. https://doi.org/10.1200/JCO.2006.10.4976</mixed-citation></citation-alternatives></ref><ref id="cit38"><label>38</label><citation-alternatives><mixed-citation xml:lang="ru">Chow EJ, Baker KS, Lee SJ, et al. Inﬂuence of conventional cardiovascular risk factors and lifestyle characteristics on cardiovascular disease after hematopoietic cell transplantation. J Clin Oncol. 2014;32(3):191-198. https://doi.org/10.1200/JCO.2013.52.6582</mixed-citation><mixed-citation xml:lang="en">Chow EJ, Baker KS, Lee SJ, et al. Inﬂuence of conventional cardiovascular risk factors and lifestyle characteristics on cardiovascular disease after hematopoietic cell transplantation. J Clin Oncol. 2014;32(3):191-198. https://doi.org/10.1200/JCO.2013.52.6582</mixed-citation></citation-alternatives></ref><ref id="cit39"><label>39</label><citation-alternatives><mixed-citation xml:lang="ru">Armenian SH, Xu L, Ky B, et al. Cardiovascular Disease Among Survivors of Adult-Onset Cancer: A Community-Based Retrospective Cohort Study. J Clin Oncol. 2016;34(10):1122-1130. https://doi.org/10.1200/JCO.2015.64.0409</mixed-citation><mixed-citation xml:lang="en">Armenian SH, Xu L, Ky B, et al. Cardiovascular Disease Among Survivors of Adult-Onset Cancer: A Community-Based Retrospective Cohort Study. J Clin Oncol. 2016;34(10):1122-1130. https://doi.org/10.1200/JCO.2015.64.0409</mixed-citation></citation-alternatives></ref><ref id="cit40"><label>40</label><citation-alternatives><mixed-citation xml:lang="ru">Chavez-MacGregor M, Zhang N, Buchholz TA, et al. Trastuzumab-related cardiotoxicity among older patients with breast cancer. J Clin Oncol. 2013;31(33):4222-4228. https://doi.org/10.1200/JCO.2013.48.7884</mixed-citation><mixed-citation xml:lang="en">Chavez-MacGregor M, Zhang N, Buchholz TA, et al. Trastuzumab-related cardiotoxicity among older patients with breast cancer. J Clin Oncol. 2013;31(33):4222-4228. https://doi.org/10.1200/JCO.2013.48.7884</mixed-citation></citation-alternatives></ref><ref id="cit41"><label>41</label><citation-alternatives><mixed-citation xml:lang="ru">Mantarro S, Rossi M, Bonifazi M, et al. Risk of severe cardiotoxicity following treatment with trastuzumab: a meta-analysis of randomized and cohort studies of 29,000 women with breast cancer. Intern Emerg Med. 2016;11(1):123-140. https://doi.org/10.1007/s11739-015-1362-x</mixed-citation><mixed-citation xml:lang="en">Mantarro S, Rossi M, Bonifazi M, et al. Risk of severe cardiotoxicity following treatment with trastuzumab: a meta-analysis of randomized and cohort studies of 29,000 women with breast cancer. Intern Emerg Med. 2016;11(1):123-140. https://doi.org/10.1007/s11739-015-1362-x</mixed-citation></citation-alternatives></ref><ref id="cit42"><label>42</label><citation-alternatives><mixed-citation xml:lang="ru">Gunaldi M, Duman B, Afsar C et al. Risk factors for developing cardiotoxicity of trastuzumab in breast cancer patients: An observational single-centre study. J Oncol Pharm Pract 2016; 22:242–7.</mixed-citation><mixed-citation xml:lang="en">Gunaldi M, Duman B, Afsar C et al. Risk factors for developing cardiotoxicity of trastuzumab in breast cancer patients: An observational single-centre study. J Oncol Pharm Pract 2016; 22:242–7.</mixed-citation></citation-alternatives></ref><ref id="cit43"><label>43</label><citation-alternatives><mixed-citation xml:lang="ru">Lemieux J, Diorio C, Cote M et al. Alcohol and HER2 polymorphisms as risk factor for cardiotoxicity in breast cancer treated with trastuzumab. Anticancer Res 2013; 33:2569–76.</mixed-citation><mixed-citation xml:lang="en">Lemieux J, Diorio C, Cote M et al. Alcohol and HER2 polymorphisms as risk factor for cardiotoxicity in breast cancer treated with trastuzumab. Anticancer Res 2013; 33:2569–76.</mixed-citation></citation-alternatives></ref><ref id="cit44"><label>44</label><citation-alternatives><mixed-citation xml:lang="ru">Ewer MS, Ewer SM. Cardiotoxicity of anticancer treatments: what the cardiologist needs to know. Nat Rev Cardiol. 2010;7(10):564-575. https://doi.org/10.1038/nrcardio.2010.121</mixed-citation><mixed-citation xml:lang="en">Ewer MS, Ewer SM. Cardiotoxicity of anticancer treatments: what the cardiologist needs to know. Nat Rev Cardiol. 2010;7(10):564-575. https://doi.org/10.1038/nrcardio.2010.121</mixed-citation></citation-alternatives></ref><ref id="cit45"><label>45</label><citation-alternatives><mixed-citation xml:lang="ru">Pivot X, Suter T, Nabholtz JM, et al. Cardiac toxicity events in the PHARE trial, an adjuvant trastuzumab randomised phase III study. Eur J Cancer. 2015;51(13):1660-1666. https://doi.org/10.1016/j.ejca.2015.05.028</mixed-citation><mixed-citation xml:lang="en">Pivot X, Suter T, Nabholtz JM, et al. Cardiac toxicity events in the PHARE trial, an adjuvant trastuzumab randomised phase III study. Eur J Cancer. 2015;51(13):1660-1666. https://doi.org/10.1016/j.ejca.2015.05.028</mixed-citation></citation-alternatives></ref><ref id="cit46"><label>46</label><citation-alternatives><mixed-citation xml:lang="ru">Plana JC, Galderisi M, Barac A, et al. Expert consensus for multimodality imaging evaluation of adult patients during and after cancer therapy: a report from the American Society of Echocardiography and the European Association of Cardiovascular Imaging. J Am Soc Echocardiogr. 2014;27(9):911-939. https://doi.org/10.1016/j.echo.2014.07.012</mixed-citation><mixed-citation xml:lang="en">Plana JC, Galderisi M, Barac A, et al. Expert consensus for multimodality imaging evaluation of adult patients during and after cancer therapy: a report from the American Society of Echocardiography and the European Association of Cardiovascular Imaging. J Am Soc Echocardiogr. 2014;27(9):911-939. https://doi.org/10.1016/j.echo.2014.07.012</mixed-citation></citation-alternatives></ref><ref id="cit47"><label>47</label><citation-alternatives><mixed-citation xml:lang="ru">Lyon AR, Dent S, Stanway S, et al. Baseline cardiovascular risk assessment in cancer patients scheduled to receive cardiotoxic cancer therapies: a position statement and new risk assessment tools from the Cardio-Oncology Study Group of the Heart Failure Association of the European Society of Cardiology in collaboration with the International Cardio-Oncology Society. Eur J Heart Fail. 2020;22(11):1945-1960. https://doi.org/10.1002/ejhf.1920</mixed-citation><mixed-citation xml:lang="en">Lyon AR, Dent S, Stanway S, et al. Baseline cardiovascular risk assessment in cancer patients scheduled to receive cardiotoxic cancer therapies: a position statement and new risk assessment tools from the Cardio-Oncology Study Group of the Heart Failure Association of the European Society of Cardiology in collaboration with the International Cardio-Oncology Society. Eur J Heart Fail. 2020;22(11):1945-1960. https://doi.org/10.1002/ejhf.1920</mixed-citation></citation-alternatives></ref><ref id="cit48"><label>48</label><citation-alternatives><mixed-citation xml:lang="ru">Виценя М. В., Агеев Ф. Т., Гиляров М. Ю., и соавт. Злокачественные опухоли: Практические рекомендации RUSSCO #3s2, 2020 (том 10).41, https://rosoncoweb.ru/standarts/RUSSCO/2020/2020-41.pdf</mixed-citation><mixed-citation xml:lang="en">Виценя М. В., Агеев Ф. Т., Гиляров М. Ю., и соавт. Злокачественные опухоли: Практические рекомендации RUSSCO #3s2, 2020 (том 10).41, https://rosoncoweb.ru/standarts/RUSSCO/2020/2020-41.pdf</mixed-citation></citation-alternatives></ref><ref id="cit49"><label>49</label><citation-alternatives><mixed-citation xml:lang="ru">Thavendiranathan P, Grant AD, Negishi T, Plana JC, Popović ZB, Marwick TH. Reproducibility of echocardiographic techniques for sequential assessment of left ventricular ejection fraction and volumes: application to patients undergoing cancer chemotherapy. J Am Coll Cardiol. 2013;61(1):77-84. https://doi.org/10.1016/j.jacc.2012.09.035</mixed-citation><mixed-citation xml:lang="en">Thavendiranathan P, Grant AD, Negishi T, Plana JC, Popović ZB, Marwick TH. Reproducibility of echocardiographic techniques for sequential assessment of left ventricular ejection fraction and volumes: application to patients undergoing cancer chemotherapy. J Am Coll Cardiol. 2013;61(1):77-84. https://doi.org/10.1016/j.jacc.2012.09.035</mixed-citation></citation-alternatives></ref><ref id="cit50"><label>50</label><citation-alternatives><mixed-citation xml:lang="ru">Allen LA, Yood MU, Wagner EH, et al. Performance of claims-based algorithms for identifying heart failure and cardiomyopathy among patients diagnosed with breast cancer. Med Care. 2014;52(5):e30-e38. https://doi.org/10.1097/MLR.0b013e31825a8c22</mixed-citation><mixed-citation xml:lang="en">Allen LA, Yood MU, Wagner EH, et al. Performance of claims-based algorithms for identifying heart failure and cardiomyopathy among patients diagnosed with breast cancer. Med Care. 2014;52(5):e30-e38. https://doi.org/10.1097/MLR.0b013e31825a8c22</mixed-citation></citation-alternatives></ref><ref id="cit51"><label>51</label><citation-alternatives><mixed-citation xml:lang="ru">Sawaya H, Sebag IA, Plana JC, et al. Assessment of echocardiography and biomarkers for the extended prediction of cardiotoxicity in patients treated with anthracyclines, taxanes, and trastuzumab. Circ Cardiovasc Imaging. 2012;5(5):596-603. https://doi.org/10.1161/CIRCIMAGING.112.973321</mixed-citation><mixed-citation xml:lang="en">Sawaya H, Sebag IA, Plana JC, et al. Assessment of echocardiography and biomarkers for the extended prediction of cardiotoxicity in patients treated with anthracyclines, taxanes, and trastuzumab. Circ Cardiovasc Imaging. 2012;5(5):596-603. https://doi.org/10.1161/CIRCIMAGING.112.973321</mixed-citation></citation-alternatives></ref><ref id="cit52"><label>52</label><citation-alternatives><mixed-citation xml:lang="ru">Thavendiranathan P, Poulin F, Lim KD, Plana JC, Woo A, Marwick TH. Use of myocardial strain imaging by echocardiography for the early detection of cardiotoxicity in patients during and after cancer chemotherapy: a systematic review. J Am Coll Cardiol. 2014;63(25 Pt A):2751-2768. https://doi.org/10.1016/j.jacc.2014.01.073</mixed-citation><mixed-citation xml:lang="en">Thavendiranathan P, Poulin F, Lim KD, Plana JC, Woo A, Marwick TH. Use of myocardial strain imaging by echocardiography for the early detection of cardiotoxicity in patients during and after cancer chemotherapy: a systematic review. J Am Coll Cardiol. 2014;63(25 Pt A):2751-2768. https://doi.org/10.1016/j.jacc.2014.01.073</mixed-citation></citation-alternatives></ref><ref id="cit53"><label>53</label><citation-alternatives><mixed-citation xml:lang="ru">Negishi K, Negishi T, Haluska BA, Hare JL, Plana JC, Marwick TH. Use of speckle strain to assess left ventricular responses to cardiotoxic chemotherapy and cardioprotection. Eur Heart J Cardiovasc Imaging. 2014;15(3):324-331. https://doi.org/10.1093/ehjci/jet159</mixed-citation><mixed-citation xml:lang="en">Negishi K, Negishi T, Haluska BA, Hare JL, Plana JC, Marwick TH. Use of speckle strain to assess left ventricular responses to cardiotoxic chemotherapy and cardioprotection. Eur Heart J Cardiovasc Imaging. 2014;15(3):324-331. https://doi.org/10.1093/ehjci/jet159</mixed-citation></citation-alternatives></ref><ref id="cit54"><label>54</label><citation-alternatives><mixed-citation xml:lang="ru">Baron T, Berglund L, Hedin EM, Flachskampf FA. Test-retest reliability of new and conventional echocardiographic parameters of left ventricular systolic function. Clin Res Cardiol. 2019;108(4):355-365. https://doi.org/10.1007/s00392-018-1363-7</mixed-citation><mixed-citation xml:lang="en">Baron T, Berglund L, Hedin EM, Flachskampf FA. Test-retest reliability of new and conventional echocardiographic parameters of left ventricular systolic function. Clin Res Cardiol. 2019;108(4):355-365. https://doi.org/10.1007/s00392-018-1363-7</mixed-citation></citation-alternatives></ref><ref id="cit55"><label>55</label><citation-alternatives><mixed-citation xml:lang="ru">Čelutkienė J, Pudil R, López-Fernández T, et al. Role of cardiovascular imaging in cancer patients receiving cardiotoxic therapies: a position statement on behalf of the Heart Failure Association (HFA), the European Association of Cardiovascular Imaging (EACVI) and the Cardio-Oncology Council of the European Society of Cardiology (ESC) [published correction appears in Eur J Heart Fail. 2021 Feb;23(2):345]. Eur J Heart Fail. 2020;22(9):1504-1524. https://doi.org/10.1002/ejhf.1957</mixed-citation><mixed-citation xml:lang="en">Čelutkienė J, Pudil R, López-Fernández T, et al. Role of cardiovascular imaging in cancer patients receiving cardiotoxic therapies: a position statement on behalf of the Heart Failure Association (HFA), the European Association of Cardiovascular Imaging (EACVI) and the Cardio-Oncology Council of the European Society of Cardiology (ESC) [published correction appears in Eur J Heart Fail. 2021 Feb;23(2):345]. Eur J Heart Fail. 2020;22(9):1504-1524. https://doi.org/10.1002/ejhf.1957</mixed-citation></citation-alternatives></ref><ref id="cit56"><label>56</label><citation-alternatives><mixed-citation xml:lang="ru">Touyz RM, Herrmann J. Cardiotoxicity with vascular endothelial growth factor inhibitor therapy. NPJ Precis Oncol. 2018;2:13. Published 2018 May 8. https://doi.org/10.1038/s41698-018-0056-z</mixed-citation><mixed-citation xml:lang="en">Touyz RM, Herrmann J. Cardiotoxicity with vascular endothelial growth factor inhibitor therapy. NPJ Precis Oncol. 2018;2:13. Published 2018 May 8. https://doi.org/10.1038/s41698-018-0056-z</mixed-citation></citation-alternatives></ref><ref id="cit57"><label>57</label><citation-alternatives><mixed-citation xml:lang="ru">Curigliano G, Cardinale D, Dent S, et al. Cardiotoxicity of anticancer treatments: Epidemiology, detection, and management. CA Cancer J Clin. 2016;66(4):309-325. https://doi.org/10.3322/caac.21341</mixed-citation><mixed-citation xml:lang="en">Curigliano G, Cardinale D, Dent S, et al. Cardiotoxicity of anticancer treatments: Epidemiology, detection, and management. CA Cancer J Clin. 2016;66(4):309-325. https://doi.org/10.3322/caac.21341</mixed-citation></citation-alternatives></ref><ref id="cit58"><label>58</label><citation-alternatives><mixed-citation xml:lang="ru">Pudil R, Mueller C, Čelutkienė J, et al. Role of serum biomarkers in cancer patients receiving cardiotoxic cancer therapies: a position statement from the Cardio-Oncology Study Group of the Heart Failure Association and the Cardio-Oncology Council of the European Society of Cardiology. Eur J Heart Fail. 2020;22(11):1966-1983. https://doi.org/10.1002/ejhf.2017</mixed-citation><mixed-citation xml:lang="en">Pudil R, Mueller C, Čelutkienė J, et al. Role of serum biomarkers in cancer patients receiving cardiotoxic cancer therapies: a position statement from the Cardio-Oncology Study Group of the Heart Failure Association and the Cardio-Oncology Council of the European Society of Cardiology. Eur J Heart Fail. 2020;22(11):1966-1983. https://doi.org/10.1002/ejhf.2017</mixed-citation></citation-alternatives></ref><ref id="cit59"><label>59</label><citation-alternatives><mixed-citation xml:lang="ru">Cardinale D, Colombo A, Torrisi R, et al. Trastuzumab-induced cardiotoxicity: clinical and prognostic implications of troponin I evaluation. J Clin Oncol. 2010;28(25):3910-3916. https://doi.org/10.1200/JCO.2009.27.3615</mixed-citation><mixed-citation xml:lang="en">Cardinale D, Colombo A, Torrisi R, et al. Trastuzumab-induced cardiotoxicity: clinical and prognostic implications of troponin I evaluation. J Clin Oncol. 2010;28(25):3910-3916. https://doi.org/10.1200/JCO.2009.27.3615</mixed-citation></citation-alternatives></ref><ref id="cit60"><label>60</label><citation-alternatives><mixed-citation xml:lang="ru">Ky B, Putt M, Sawaya H, et al. Early increases in multiple biomarkers predict subsequent cardiotoxicity in patients with breast cancer treated with doxorubicin, taxanes, and trastuzumab [published correction appears in J Am Coll Cardiol. 2016 Mar 22;67(11):1385]. J Am Coll Cardiol. 2014;63(8):809-816. https://doi.org/10.1016/j.jacc.2013.10.061</mixed-citation><mixed-citation xml:lang="en">Ky B, Putt M, Sawaya H, et al. Early increases in multiple biomarkers predict subsequent cardiotoxicity in patients with breast cancer treated with doxorubicin, taxanes, and trastuzumab [published correction appears in J Am Coll Cardiol. 2016 Mar 22;67(11):1385]. J Am Coll Cardiol. 2014;63(8):809-816. https://doi.org/10.1016/j.jacc.2013.10.061</mixed-citation></citation-alternatives></ref><ref id="cit61"><label>61</label><citation-alternatives><mixed-citation xml:lang="ru">Sawaya H, Sebag IA, Plana JC, et al. Early detection and prediction of cardiotoxicity in chemotherapy-treated patients. Am J Cardiol. 2011;107(9):1375-1380. https://doi.org/10.1016/j.amjcard.2011.01.006</mixed-citation><mixed-citation xml:lang="en">Sawaya H, Sebag IA, Plana JC, et al. Early detection and prediction of cardiotoxicity in chemotherapy-treated patients. Am J Cardiol. 2011;107(9):1375-1380. https://doi.org/10.1016/j.amjcard.2011.01.006</mixed-citation></citation-alternatives></ref><ref id="cit62"><label>62</label><citation-alternatives><mixed-citation xml:lang="ru">Ponikowski P, Voors AA, Anker SD, et al. 2016 ESC Guidelines for the diagnosis and treatment of acute and chronic heart failure: The Task Force for the diagnosis and treatment of acute and chronic heart failure of the European Society of Cardiology (ESC). Developed with the special contribution of the Heart Failure Association (HFA) of the ESC. Eur J Heart Fail. 2016;18(8):891-975. https://doi.org/10.1002/ejhf.592</mixed-citation><mixed-citation xml:lang="en">Ponikowski P, Voors AA, Anker SD, et al. 2016 ESC Guidelines for the diagnosis and treatment of acute and chronic heart failure: The Task Force for the diagnosis and treatment of acute and chronic heart failure of the European Society of Cardiology (ESC). Developed with the special contribution of the Heart Failure Association (HFA) of the ESC. Eur J Heart Fail. 2016;18(8):891-975. https://doi.org/10.1002/ejhf.592</mixed-citation></citation-alternatives></ref><ref id="cit63"><label>63</label><citation-alternatives><mixed-citation xml:lang="ru">Christenson ES, James T, Agrawal V, Park BH. Use of biomarkers for the assessment of chemotherapy-induced cardiac toxicity. Clin Biochem. 2015;48(4-5):223-235. https://doi.org/10.1016/j.clinbiochem.2014.10.013</mixed-citation><mixed-citation xml:lang="en">Christenson ES, James T, Agrawal V, Park BH. Use of biomarkers for the assessment of chemotherapy-induced cardiac toxicity. Clin Biochem. 2015;48(4-5):223-235. https://doi.org/10.1016/j.clinbiochem.2014.10.013</mixed-citation></citation-alternatives></ref><ref id="cit64"><label>64</label><citation-alternatives><mixed-citation xml:lang="ru">Thavendiranathan P, Wintersperger BJ, Flamm SD, Marwick TH. Cardiac MRI in the assessment of cardiac injury and toxicity from cancer chemotherapy: a systematic review. Circ Cardiovasc Imaging. 2013;6(6):1080-1091. https://doi.org/10.1161/CIRCIMAGING.113.000899</mixed-citation><mixed-citation xml:lang="en">Thavendiranathan P, Wintersperger BJ, Flamm SD, Marwick TH. Cardiac MRI in the assessment of cardiac injury and toxicity from cancer chemotherapy: a systematic review. Circ Cardiovasc Imaging. 2013;6(6):1080-1091. https://doi.org/10.1161/CIRCIMAGING.113.000899</mixed-citation></citation-alternatives></ref><ref id="cit65"><label>65</label><citation-alternatives><mixed-citation xml:lang="ru">Saunderson C.E.D, Plein S, Manisty CH. Role of cardiovascular magnetic resonance imaging in cardio-oncology, European Heart Journal - Cardiovascular Imaging, Volume 22, Issue 4, April 2021, Pages 383–396, https://doi.org/10.1093/ehjci/jeaa345</mixed-citation><mixed-citation xml:lang="en">Saunderson C.E.D, Plein S, Manisty CH. Role of cardiovascular magnetic resonance imaging in cardio-oncology, European Heart Journal - Cardiovascular Imaging, Volume 22, Issue 4, April 2021, Pages 383–396, https://doi.org/10.1093/ehjci/jeaa345</mixed-citation></citation-alternatives></ref><ref id="cit66"><label>66</label><citation-alternatives><mixed-citation xml:lang="ru">Armenian SH, Lacchetti C, Barac A, et al. Prevention and monitoring of cardiac dysfunction in survivors of adult cancers: American Society of Clinical Oncology clinical practice guideline. J Clin Oncol. 2017;35:893–911. https://doi.org/10.1200/JCO.2016.70.5400</mixed-citation><mixed-citation xml:lang="en">Armenian SH, Lacchetti C, Barac A, et al. Prevention and monitoring of cardiac dysfunction in survivors of adult cancers: American Society of Clinical Oncology clinical practice guideline. J Clin Oncol. 2017;35:893–911. https://doi.org/10.1200/JCO.2016.70.5400</mixed-citation></citation-alternatives></ref><ref id="cit67"><label>67</label><citation-alternatives><mixed-citation xml:lang="ru">Gilchrist SC, Barac A, Ades PA, et al. Cardio-Oncology Rehabilitation to Manage Cardiovascular Outcomes in Cancer Patients and Survivors: A Scientifc Statement From the American Heart Association. Circulation 2019;139(21):e997-e1012. https://doi.org/10.1161/CIR.0000000000000679</mixed-citation><mixed-citation xml:lang="en">Gilchrist SC, Barac A, Ades PA, et al. Cardio-Oncology Rehabilitation to Manage Cardiovascular Outcomes in Cancer Patients and Survivors: A Scientifc Statement From the American Heart Association. Circulation 2019;139(21):e997-e1012. https://doi.org/10.1161/CIR.0000000000000679</mixed-citation></citation-alternatives></ref><ref id="cit68"><label>68</label><citation-alternatives><mixed-citation xml:lang="ru">Sturgeon KM, Ky B, Libonati JR, Schmitz KH. The effects of exercise on cardiovascular outcomes before, during, and after treatment for breast cancer. Breast Cancer Res Treat. 2014;143(2):219-226. https://doi.org/10.1007/s10549-013-2808-3</mixed-citation><mixed-citation xml:lang="en">Sturgeon KM, Ky B, Libonati JR, Schmitz KH. The effects of exercise on cardiovascular outcomes before, during, and after treatment for breast cancer. Breast Cancer Res Treat. 2014;143(2):219-226. https://doi.org/10.1007/s10549-013-2808-3</mixed-citation></citation-alternatives></ref><ref id="cit69"><label>69</label><citation-alternatives><mixed-citation xml:lang="ru">Kirkham AA, Davis MK. Exercise Prevention of Cardiovascular Disease in Breast Cancer Survivors. J Oncol. 2015;2015:917606. https://doi.org/10.1155/2015/917606</mixed-citation><mixed-citation xml:lang="en">Kirkham AA, Davis MK. Exercise Prevention of Cardiovascular Disease in Breast Cancer Survivors. J Oncol. 2015;2015:917606. https://doi.org/10.1155/2015/917606</mixed-citation></citation-alternatives></ref><ref id="cit70"><label>70</label><citation-alternatives><mixed-citation xml:lang="ru">Scott JM, Nilsen TS, Gupta D, Jones LW. Exercise therapy and cardiovascular toxicity in cancer. Circulation. 2018;137:1176–1191. https://doi.org/10.1161/CIRCULATIONAHA.117.024671</mixed-citation><mixed-citation xml:lang="en">Scott JM, Nilsen TS, Gupta D, Jones LW. Exercise therapy and cardiovascular toxicity in cancer. Circulation. 2018;137:1176–1191. https://doi.org/10.1161/CIRCULATIONAHA.117.024671</mixed-citation></citation-alternatives></ref><ref id="cit71"><label>71</label><citation-alternatives><mixed-citation xml:lang="ru">Scott JM, Zabor EC, Schwitzer E, et al. Effcacy of exercise therapy on cardiorespiratory ftness in patients with cancer: a systematic review and meta-analysis. J Clin Oncol. 2018;36:2297–2305. https://doi.org/10.1200/JCO.2017.77.5809</mixed-citation><mixed-citation xml:lang="en">Scott JM, Zabor EC, Schwitzer E, et al. Effcacy of exercise therapy on cardiorespiratory ftness in patients with cancer: a systematic review and meta-analysis. J Clin Oncol. 2018;36:2297–2305. https://doi.org/10.1200/JCO.2017.77.5809</mixed-citation></citation-alternatives></ref><ref id="cit72"><label>72</label><citation-alternatives><mixed-citation xml:lang="ru">Dittus KL, Lakoski SG, Savage PD, et al. Exercise-based oncology rehabilitation: leveraging the cardiac rehabilitation model. J CardiopulmRehabil Prev. 2015;35:130–139. https://doi.org/10.1097/HCR.0000000000000091</mixed-citation><mixed-citation xml:lang="en">Dittus KL, Lakoski SG, Savage PD, et al. Exercise-based oncology rehabilitation: leveraging the cardiac rehabilitation model. J CardiopulmRehabil Prev. 2015;35:130–139. https://doi.org/10.1097/HCR.0000000000000091</mixed-citation></citation-alternatives></ref><ref id="cit73"><label>73</label><citation-alternatives><mixed-citation xml:lang="ru">Schmid D, Leitzmann M F. Cardiorespiratory ftness as predictor of cancer mortality: a systematic review and meta-analysis. Ann Oncol 2015 Feb;26(2):272-8. https://doi.org/10.1093/annonc/mdu250.</mixed-citation><mixed-citation xml:lang="en">Schmid D, Leitzmann M F. Cardiorespiratory ftness as predictor of cancer mortality: a systematic review and meta-analysis. Ann Oncol 2015 Feb;26(2):272-8. https://doi.org/10.1093/annonc/mdu250.</mixed-citation></citation-alternatives></ref><ref id="cit74"><label>74</label><citation-alternatives><mixed-citation xml:lang="ru">Lipsetta A., Barretta S, Harunaa F, et al. The impact of exercise during adjuvant radiotherapy for breast cancer on fatigue and quality of life: A systematic review and meta-analysis. The Breast. Volume 32, April 2017, Pages 144-155.</mixed-citation><mixed-citation xml:lang="en">Lipsetta A., Barretta S, Harunaa F, et al. The impact of exercise during adjuvant radiotherapy for breast cancer on fatigue and quality of life: A systematic review and meta-analysis. The Breast. Volume 32, April 2017, Pages 144-155.</mixed-citation></citation-alternatives></ref><ref id="cit75"><label>75</label><citation-alternatives><mixed-citation xml:lang="ru">Lahart IM, Metsios GS, Nevill AM, Carmichael AR. Physical activity for women with breast cancer after adjuvant therapy. Cochrane Database Syst Rev. 2018 Jan 29;1(1):CD011292. https://doi.org/0.1002/14651858.CD011292.pub2</mixed-citation><mixed-citation xml:lang="en">Lahart IM, Metsios GS, Nevill AM, Carmichael AR. Physical activity for women with breast cancer after adjuvant therapy. Cochrane Database Syst Rev. 2018 Jan 29;1(1):CD011292. https://doi.org/0.1002/14651858.CD011292.pub2</mixed-citation></citation-alternatives></ref><ref id="cit76"><label>76</label><citation-alternatives><mixed-citation xml:lang="ru">Jones LW, Habel LA, Weltzien E et al. Exercise and risk of cardiovascular events in women with nonmetastatic breast cancer. J Clin Oncol 2016; 34:2743–9. https://doi.org/10.1200/JCO.2015.65.6603</mixed-citation><mixed-citation xml:lang="en">Jones LW, Habel LA, Weltzien E et al. Exercise and risk of cardiovascular events in women with nonmetastatic breast cancer. J Clin Oncol 2016; 34:2743–9. https://doi.org/10.1200/JCO.2015.65.6603</mixed-citation></citation-alternatives></ref><ref id="cit77"><label>77</label><citation-alternatives><mixed-citation xml:lang="ru">Jones LW, Liu Q, Armstrong GT et al. Exercise and risk of major cardiovascular events in adult survivors of childhood Hodgkin lymphoma: a report from the Childhood Cancer Survivor Study. J Clin Oncol 2014; 32:3643–50.</mixed-citation><mixed-citation xml:lang="en">Jones LW, Liu Q, Armstrong GT et al. Exercise and risk of major cardiovascular events in adult survivors of childhood Hodgkin lymphoma: a report from the Childhood Cancer Survivor Study. J Clin Oncol 2014; 32:3643–50.</mixed-citation></citation-alternatives></ref><ref id="cit78"><label>78</label><citation-alternatives><mixed-citation xml:lang="ru">Hayes SC, Spence RR, Galvao DA et al. Australian Association for Exercise and Sport Science position stand: optimising cancer outcomes through exercise. J Sci Med Sport 2009; 12:428–34.</mixed-citation><mixed-citation xml:lang="en">Hayes SC, Spence RR, Galvao DA et al. Australian Association for Exercise and Sport Science position stand: optimising cancer outcomes through exercise. J Sci Med Sport 2009; 12:428–34.</mixed-citation></citation-alternatives></ref><ref id="cit79"><label>79</label><citation-alternatives><mixed-citation xml:lang="ru">Pacciarini MA, Barbieri B, Colombo T et al. Distribution and antitumor activity of adria-mycin given in a high-dose and a repeated low-dose schedule to mice. Cancer Treat Rep 1978; 62:791–800.</mixed-citation><mixed-citation xml:lang="en">Pacciarini MA, Barbieri B, Colombo T et al. Distribution and antitumor activity of adria-mycin given in a high-dose and a repeated low-dose schedule to mice. Cancer Treat Rep 1978; 62:791–800.</mixed-citation></citation-alternatives></ref><ref id="cit80"><label>80</label><citation-alternatives><mixed-citation xml:lang="ru">Valdivieso M, Burgess MA, Ewer MS et al. Increased therapeutic index of weekly doxorubicin in the therapy of non-small cell lung cancer: a prospective, randomized study. J Clin Oncol 1984;2:207–14.</mixed-citation><mixed-citation xml:lang="en">Valdivieso M, Burgess MA, Ewer MS et al. Increased therapeutic index of weekly doxorubicin in the therapy of non-small cell lung cancer: a prospective, randomized study. J Clin Oncol 1984;2:207–14.</mixed-citation></citation-alternatives></ref><ref id="cit81"><label>81</label><citation-alternatives><mixed-citation xml:lang="ru">Legha SS, Benjamin RS, Mackay B et al. Reduction of Doxorubicin Cardiotoxicity by Prolonged Continuous Intravenous Infusion. Ann Intern Med 1982; 96:133–9.</mixed-citation><mixed-citation xml:lang="en">Legha SS, Benjamin RS, Mackay B et al. Reduction of Doxorubicin Cardiotoxicity by Prolonged Continuous Intravenous Infusion. Ann Intern Med 1982; 96:133–9.</mixed-citation></citation-alternatives></ref><ref id="cit82"><label>82</label><citation-alternatives><mixed-citation xml:lang="ru">Smith LA, Cornelius VR, Plummer CJ, et al. Cardiotoxicity of anthracycline agents for the treatment of cancer: systematic review and meta-analysis of randomised controlled trials. BMC Cancer. 2010;10:337. Published 2010 Jun 29. https://doi.org/10.1186/1471-2407-10-337</mixed-citation><mixed-citation xml:lang="en">Smith LA, Cornelius VR, Plummer CJ, et al. Cardiotoxicity of anthracycline agents for the treatment of cancer: systematic review and meta-analysis of randomised controlled trials. BMC Cancer. 2010;10:337. Published 2010 Jun 29. https://doi.org/10.1186/1471-2407-10-337</mixed-citation></citation-alternatives></ref><ref id="cit83"><label>83</label><citation-alternatives><mixed-citation xml:lang="ru">van Dalen EC, Michiels EM, Caron HN, Kremer LC. Different anthracycline derivates for reducing cardiotoxicity in cancer patients. Cochrane Database Syst Rev. 2010;2010(5):CD005006. Published 2010 May 12. https://doi.org/10.1002/14651858.CD005006.pub4</mixed-citation><mixed-citation xml:lang="en">van Dalen EC, Michiels EM, Caron HN, Kremer LC. Different anthracycline derivates for reducing cardiotoxicity in cancer patients. Cochrane Database Syst Rev. 2010;2010(5):CD005006. Published 2010 May 12. https://doi.org/10.1002/14651858.CD005006.pub4</mixed-citation></citation-alternatives></ref><ref id="cit84"><label>84</label><citation-alternatives><mixed-citation xml:lang="ru">Rafyath SM, Rasul M, Lee B, Wei G, Lamba G, Liu D. Comparison of safety and toxicity of liposomal doxorubicin vs. conventional anthracyclines: a metaanalysis. Exp Hematol Oncol. 2012;1(1):10. Published 2012 Apr 23. https://doi.org/10.1186/2162-3619-1-10</mixed-citation><mixed-citation xml:lang="en">Rafyath SM, Rasul M, Lee B, Wei G, Lamba G, Liu D. Comparison of safety and toxicity of liposomal doxorubicin vs. conventional anthracyclines: a metaanalysis. Exp Hematol Oncol. 2012;1(1):10. Published 2012 Apr 23. https://doi.org/10.1186/2162-3619-1-10</mixed-citation></citation-alternatives></ref><ref id="cit85"><label>85</label><citation-alternatives><mixed-citation xml:lang="ru">U.S. Food and Drug Administration. Drug safety and availability. FDA statement on DOXIL (doxorubicin HCl liposome injection) for intravenous infusion. Available at: http://www.ac--cessdata.fda.gov/drugsatfda_docs/label/2012/050718s043lbl.pdf.</mixed-citation><mixed-citation xml:lang="en">U.S. Food and Drug Administration. Drug safety and availability. FDA statement on DOXIL (doxorubicin HCl liposome injection) for intravenous infusion. Available at: http://www.ac--cessdata.fda.gov/drugsatfda_docs/label/2012/050718s043lbl.pdf.</mixed-citation></citation-alternatives></ref><ref id="cit86"><label>86</label><citation-alternatives><mixed-citation xml:lang="ru">Curigliano G, Cardinale D, Suter T, et al. Cardiovascular toxicity induced by chemotherapy, targeted agents and radiotherapy: ESMO Clinical Practice Guidelines. Ann Oncol. 2012;23 Suppl 7:vii155-vii166. https://doi.org/10.1093/annonc/mds293</mixed-citation><mixed-citation xml:lang="en">Curigliano G, Cardinale D, Suter T, et al. Cardiovascular toxicity induced by chemotherapy, targeted agents and radiotherapy: ESMO Clinical Practice Guidelines. Ann Oncol. 2012;23 Suppl 7:vii155-vii166. https://doi.org/10.1093/annonc/mds293</mixed-citation></citation-alternatives></ref><ref id="cit87"><label>87</label><citation-alternatives><mixed-citation xml:lang="ru">Slamon D, Eiermann W, Robert N et al. Phase III randomized trial comparing doxorubicin and cyclophosphamide followed by docetaxel (AC_T) with doxorubicin and cyclophosphamide followed by docetaxel and trastuzumab (AC_TH) with docetaxel, carboplatin and trastuzumab (TCH) in Her-2/neupositive early breast cancer patients: BCIRG 006 Study. 32nd Annual San Antonio Breast Cancer Symposium 2009. Abstr. 62.</mixed-citation><mixed-citation xml:lang="en">Slamon D, Eiermann W, Robert N et al. Phase III randomized trial comparing doxorubicin and cyclophosphamide followed by docetaxel (AC_T) with doxorubicin and cyclophosphamide followed by docetaxel and trastuzumab (AC_TH) with docetaxel, carboplatin and trastuzumab (TCH) in Her-2/neupositive early breast cancer patients: BCIRG 006 Study. 32nd Annual San Antonio Breast Cancer Symposium 2009. Abstr. 62.</mixed-citation></citation-alternatives></ref><ref id="cit88"><label>88</label><citation-alternatives><mixed-citation xml:lang="ru">Avila MS, Ayub-Ferreira SM, de Barros Wanderley MR Jr, et al. Carvedilol for Prevention of Chemotherapy-Related Cardiotoxicity: The CECCY Trial. J Am Coll Cardiol. 2018;71(20):2281-2290. https://doi.org/10.1016/j.jacc.2018.02.049</mixed-citation><mixed-citation xml:lang="en">Avila MS, Ayub-Ferreira SM, de Barros Wanderley MR Jr, et al. Carvedilol for Prevention of Chemotherapy-Related Cardiotoxicity: The CECCY Trial. J Am Coll Cardiol. 2018;71(20):2281-2290. https://doi.org/10.1016/j.jacc.2018.02.049</mixed-citation></citation-alternatives></ref><ref id="cit89"><label>89</label><citation-alternatives><mixed-citation xml:lang="ru">Kaya MG, Ozkan M, Gunebakmaz O, et al. Protective effects of nebivolol against anthracycline-induced cardiomyopathy: a randomized control study. Int J Cardiol. 2013;167(5):2306-2310. https://doi.org/10.1016/j.ijcard.2012.06.023</mixed-citation><mixed-citation xml:lang="en">Kaya MG, Ozkan M, Gunebakmaz O, et al. Protective effects of nebivolol against anthracycline-induced cardiomyopathy: a randomized control study. Int J Cardiol. 2013;167(5):2306-2310. https://doi.org/10.1016/j.ijcard.2012.06.023</mixed-citation></citation-alternatives></ref><ref id="cit90"><label>90</label><citation-alternatives><mixed-citation xml:lang="ru">Guglin M, Krischer J, Tamura R, et al. Randomized Trial of Lisinopril Versus Carvedilol to Prevent Trastuzumab Cardiotoxicity in Patients With Breast Cancer. J Am Coll Cardiol. 2019;73(22):2859-2868. https://doi.org/10.1016/j.jacc.2019.03.495</mixed-citation><mixed-citation xml:lang="en">Guglin M, Krischer J, Tamura R, et al. Randomized Trial of Lisinopril Versus Carvedilol to Prevent Trastuzumab Cardiotoxicity in Patients With Breast Cancer. J Am Coll Cardiol. 2019;73(22):2859-2868. https://doi.org/10.1016/j.jacc.2019.03.495</mixed-citation></citation-alternatives></ref><ref id="cit91"><label>91</label><citation-alternatives><mixed-citation xml:lang="ru">Pituskin E, Mackey JR, Koshman S, et al. Multidisciplinary Approach to Novel Therapies in Cardio-Oncology Research (MANTICORE 101-Breast): A Randomized Trial for the Prevention of Trastuzumab-Associated Cardiotoxicity. J Clin Oncol. 2017;35(8):870-877. https://doi.org/10.1200/JCO.2016.68.7830</mixed-citation><mixed-citation xml:lang="en">Pituskin E, Mackey JR, Koshman S, et al. Multidisciplinary Approach to Novel Therapies in Cardio-Oncology Research (MANTICORE 101-Breast): A Randomized Trial for the Prevention of Trastuzumab-Associated Cardiotoxicity. J Clin Oncol. 2017;35(8):870-877. https://doi.org/10.1200/JCO.2016.68.7830</mixed-citation></citation-alternatives></ref><ref id="cit92"><label>92</label><citation-alternatives><mixed-citation xml:lang="ru">Gulati G, Heck SL, Ree AH et al. Prevention of cardiac dysfunction during adjuvant breast cancer therapy (PRADA): a 2ơ2 factorial, randomized, placebo-controlled, double-blind clinical trial of candesartan and metoprolol. Eur Heart J 2016; 37:1671–80</mixed-citation><mixed-citation xml:lang="en">Gulati G, Heck SL, Ree AH et al. Prevention of cardiac dysfunction during adjuvant breast cancer therapy (PRADA): a 2ơ2 factorial, randomized, placebo-controlled, double-blind clinical trial of candesartan and metoprolol. Eur Heart J 2016; 37:1671–80</mixed-citation></citation-alternatives></ref><ref id="cit93"><label>93</label><citation-alternatives><mixed-citation xml:lang="ru">Heck SL, Mecinaj A, Ree AH, et al. Prevention of Cardiac Dysfunction During Adjuvant Breast Cancer Therapy (PRADA) Extended Follow-Up of a 2×2 Factorial, Randomized, Placebo-Controlled, Double-Blind Clinical Trial of Candesartan and Metoprolol. Circulation. 2021 May 16. https://doi.org/10.1161/CIRCULATIONAHA.121.054698 Epub ahead of print. PMID:33993702.</mixed-citation><mixed-citation xml:lang="en">Heck SL, Mecinaj A, Ree AH, et al. Prevention of Cardiac Dysfunction During Adjuvant Breast Cancer Therapy (PRADA) Extended Follow-Up of a 2×2 Factorial, Randomized, Placebo-Controlled, Double-Blind Clinical Trial of Candesartan and Metoprolol. Circulation. 2021 May 16. https://doi.org/10.1161/CIRCULATIONAHA.121.054698 Epub ahead of print. PMID:33993702.</mixed-citation></citation-alternatives></ref><ref id="cit94"><label>94</label><citation-alternatives><mixed-citation xml:lang="ru">Boekhout AH, Gietema JA, Milojkovic Kerklaan B, et al. Angiotensin IIReceptor Inhibition With Candesartan to Prevent Trastuzumab-Related Cardiotoxic Effects in Patients With Early Breast Cancer: A Randomized Clinical Trial. JAMA Oncol. 2016;2(8):1030-1037. https://doi.org/10.1001/jamaoncol.2016.1726</mixed-citation><mixed-citation xml:lang="en">Boekhout AH, Gietema JA, Milojkovic Kerklaan B, et al. Angiotensin IIReceptor Inhibition With Candesartan to Prevent Trastuzumab-Related Cardiotoxic Effects in Patients With Early Breast Cancer: A Randomized Clinical Trial. JAMA Oncol. 2016;2(8):1030-1037. https://doi.org/10.1001/jamaoncol.2016.1726</mixed-citation></citation-alternatives></ref><ref id="cit95"><label>95</label><citation-alternatives><mixed-citation xml:lang="ru">Georgakopoulos P, Roussou P, Matsakas E, et al. Cardioprotective effect of metoprolol and enalapril in doxorubicin-treated lymphoma patients: a prospective, parallel-group, randomized, controlled study with 36-month follow-up. Am J Hematol. 2010;85(11):894-896. https://doi.org/10.1002/ajh.21840</mixed-citation><mixed-citation xml:lang="en">Georgakopoulos P, Roussou P, Matsakas E, et al. Cardioprotective effect of metoprolol and enalapril in doxorubicin-treated lymphoma patients: a prospective, parallel-group, randomized, controlled study with 36-month follow-up. Am J Hematol. 2010;85(11):894-896. https://doi.org/10.1002/ajh.21840</mixed-citation></citation-alternatives></ref><ref id="cit96"><label>96</label><citation-alternatives><mixed-citation xml:lang="ru">Bosch X, Rovira M, Sitges M, et al. Enalapril and carvedilol for preventing chemotherapy-induced left ventricular systolic dysfunction in patients with malignant hemopathies: the OVERCOME trial (preventiOn of left Ventricular dysfunction with Enalapril and caRvedilol in patients submitted to intensive ChemOtherapy for the treatment of Malignant hEmopathies). J Am Coll Cardiol. 2013;61(23):2355-2362. https://doi.org/10.1016/j.jacc.2013.02.072</mixed-citation><mixed-citation xml:lang="en">Bosch X, Rovira M, Sitges M, et al. Enalapril and carvedilol for preventing chemotherapy-induced left ventricular systolic dysfunction in patients with malignant hemopathies: the OVERCOME trial (preventiOn of left Ventricular dysfunction with Enalapril and caRvedilol in patients submitted to intensive ChemOtherapy for the treatment of Malignant hEmopathies). J Am Coll Cardiol. 2013;61(23):2355-2362. https://doi.org/10.1016/j.jacc.2013.02.072</mixed-citation></citation-alternatives></ref><ref id="cit97"><label>97</label><citation-alternatives><mixed-citation xml:lang="ru">Seicean S, Seicean A, Alan N, Plana JC, Budd GT, Marwick TH. Cardioprotective effect of β-adrenoceptor blockade in patients with breast cancer undergoing chemotherapy: follow-up study of heart failure. Circ Heart Fail. 2013;6(3):420-426. https://doi.org/10.1161/CIRCHEARTFAILURE.112.000055</mixed-citation><mixed-citation xml:lang="en">Seicean S, Seicean A, Alan N, Plana JC, Budd GT, Marwick TH. Cardioprotective effect of β-adrenoceptor blockade in patients with breast cancer undergoing chemotherapy: follow-up study of heart failure. Circ Heart Fail. 2013;6(3):420-426. https://doi.org/10.1161/CIRCHEARTFAILURE.112.000055</mixed-citation></citation-alternatives></ref><ref id="cit98"><label>98</label><citation-alternatives><mixed-citation xml:lang="ru">Akpek M, Ozdogru I, Sahin O, et al. Protective effects of spironolactone against anthracycline-induced cardiomyopathy. Eur J Heart Fail. 2015;17(1):81-89. https://doi.org/10.1002/ejhf.196</mixed-citation><mixed-citation xml:lang="en">Akpek M, Ozdogru I, Sahin O, et al. Protective effects of spironolactone against anthracycline-induced cardiomyopathy. Eur J Heart Fail. 2015;17(1):81-89. https://doi.org/10.1002/ejhf.196</mixed-citation></citation-alternatives></ref><ref id="cit99"><label>99</label><citation-alternatives><mixed-citation xml:lang="ru">Seicean S, Seicean A, Plana JC, Budd GT, Marwick TH. Effect of statin therapy on the risk for incident heart failure in patients with breast cancer receiving anthracycline chemotherapy: an observational clinical cohort study. J Am Coll Cardiol. 2012;60(23):2384-2390. https://doi.org/10.1016/j.jacc.2012.07.067</mixed-citation><mixed-citation xml:lang="en">Seicean S, Seicean A, Plana JC, Budd GT, Marwick TH. Effect of statin therapy on the risk for incident heart failure in patients with breast cancer receiving anthracycline chemotherapy: an observational clinical cohort study. J Am Coll Cardiol. 2012;60(23):2384-2390. https://doi.org/10.1016/j.jacc.2012.07.067</mixed-citation></citation-alternatives></ref><ref id="cit100"><label>100</label><citation-alternatives><mixed-citation xml:lang="ru">Abdel-Qadir H, Bobrowski D, Zhou L, et al. Statin Exposure and Risk of Heart Failure After Anthracycline- or Trastuzumab-Based Chemotherapy for Early Breast Cancer: A Propensity ScoreơMatched Cohort Study. J Am Heart Assoc. 2021;10(2):e018393. https://doi.org/10.1161/JAHA.119.018393</mixed-citation><mixed-citation xml:lang="en">Abdel-Qadir H, Bobrowski D, Zhou L, et al. Statin Exposure and Risk of Heart Failure After Anthracycline- or Trastuzumab-Based Chemotherapy for Early Breast Cancer: A Propensity ScoreơMatched Cohort Study. J Am Heart Assoc. 2021;10(2):e018393. https://doi.org/10.1161/JAHA.119.018393</mixed-citation></citation-alternatives></ref><ref id="cit101"><label>101</label><citation-alternatives><mixed-citation xml:lang="ru">Acar Z, Kale A, Turgut M, et al. Effciency of atorvastatin in the protection of anthracycline-induced cardiomyopathy. J Am Coll Cardiol. 2011;58(9):988-989. https://doi.org/10.1016/j.jacc.2011.05.025</mixed-citation><mixed-citation xml:lang="en">Acar Z, Kale A, Turgut M, et al. Effciency of atorvastatin in the protection of anthracycline-induced cardiomyopathy. J Am Coll Cardiol. 2011;58(9):988-989. https://doi.org/10.1016/j.jacc.2011.05.025</mixed-citation></citation-alternatives></ref><ref id="cit102"><label>102</label><citation-alternatives><mixed-citation xml:lang="ru">Strumia E, Pelliccia F, D’Ambrosio G. Creatine phosphate: pharmacological and clinical perspectives. Adv Ther. 2012;29(2):99-123. https://doi.org/10.1007/s12325-011-0091-4.</mixed-citation><mixed-citation xml:lang="en">Strumia E, Pelliccia F, D’Ambrosio G. Creatine phosphate: pharmacological and clinical perspectives. Adv Ther. 2012;29(2):99-123. https://doi.org/10.1007/s12325-011-0091-4.</mixed-citation></citation-alternatives></ref><ref id="cit103"><label>103</label><citation-alternatives><mixed-citation xml:lang="ru">Wang W., Feng Z, Bai1 J. Cardioprotective effects of creatine phosphate sodium in elderly breast cancer patients under epirubicin adjuvant chemotherapy. Int J Clin Exp Med 2019;12(10):12418-12425 http://www.ijcem.com/ISSN:1940-5901/IJCEM0094064</mixed-citation><mixed-citation xml:lang="en">Wang W., Feng Z, Bai1 J. Cardioprotective effects of creatine phosphate sodium in elderly breast cancer patients under epirubicin adjuvant chemotherapy. Int J Clin Exp Med 2019;12(10):12418-12425 http://www.ijcem.com/ISSN:1940-5901/IJCEM0094064</mixed-citation></citation-alternatives></ref><ref id="cit104"><label>104</label><citation-alternatives><mixed-citation xml:lang="ru">U.S. Food and Drug Administration. Drug Safety and Availability. FDA statement on dexrazo-xane. Jul 20, 2011. Available at: http://www.fda.gov/Drugs/DrugSafety/ucm263729.htm</mixed-citation><mixed-citation xml:lang="en">U.S. Food and Drug Administration. Drug Safety and Availability. FDA statement on dexrazo-xane. Jul 20, 2011. Available at: http://www.fda.gov/Drugs/DrugSafety/ucm263729.htm</mixed-citation></citation-alternatives></ref><ref id="cit105"><label>105</label><citation-alternatives><mixed-citation xml:lang="ru">Lyu YL, Kerrigan JE, Lin CP, et al. Topoisomerase IIbeta mediated DNA double-strand breaks: implications in doxorubicin cardiotoxicity and prevention by dexrazoxane. Cancer Res. 2007;67(18):8839-8846. https://doi.org/10.1158/0008-5472.CAN-07-1649</mixed-citation><mixed-citation xml:lang="en">Lyu YL, Kerrigan JE, Lin CP, et al. Topoisomerase IIbeta mediated DNA double-strand breaks: implications in doxorubicin cardiotoxicity and prevention by dexrazoxane. Cancer Res. 2007;67(18):8839-8846. https://doi.org/10.1158/0008-5472.CAN-07-1649</mixed-citation></citation-alternatives></ref><ref id="cit106"><label>106</label><citation-alternatives><mixed-citation xml:lang="ru">Vejpongsa P, Yeh ET. Prevention of anthracycline-induced cardiotoxicity: challenges and opportunities. J Am Coll Cardiol. 2014;64(9):938-945. https://doi.org/10.1016/j.jacc.2014.06.1167</mixed-citation><mixed-citation xml:lang="en">Vejpongsa P, Yeh ET. Prevention of anthracycline-induced cardiotoxicity: challenges and opportunities. J Am Coll Cardiol. 2014;64(9):938-945. https://doi.org/10.1016/j.jacc.2014.06.1167</mixed-citation></citation-alternatives></ref><ref id="cit107"><label>107</label><citation-alternatives><mixed-citation xml:lang="ru">Swain SM, Whaley FS, Gerber MC, et al. Cardioprotection with dexrazoxane for doxorubicin-containing therapy in advanced breast cancer. J Clin Oncol. 1997;15(4):1318-1332. https://doi.org/10.1200/JCO.1997.15.4.1318</mixed-citation><mixed-citation xml:lang="en">Swain SM, Whaley FS, Gerber MC, et al. Cardioprotection with dexrazoxane for doxorubicin-containing therapy in advanced breast cancer. J Clin Oncol. 1997;15(4):1318-1332. https://doi.org/10.1200/JCO.1997.15.4.1318</mixed-citation></citation-alternatives></ref><ref id="cit108"><label>108</label><citation-alternatives><mixed-citation xml:lang="ru">Marty M, Espie M, Llombart A, et al. Multicenter randomized phase III study of the cardioprotective effect of dexrazoxane (Cardioxane) in advanced/metastatic breast cancer patients treated with anthracycline-based chemotherapy. Ann Oncol. 2006;17(4):614–22.https://doi.org/10.1093/annonc/mdj134</mixed-citation><mixed-citation xml:lang="en">Marty M, Espie M, Llombart A, et al. Multicenter randomized phase III study of the cardioprotective effect of dexrazoxane (Cardioxane) in advanced/metastatic breast cancer patients treated with anthracycline-based chemotherapy. Ann Oncol. 2006;17(4):614–22.https://doi.org/10.1093/annonc/mdj134</mixed-citation></citation-alternatives></ref><ref id="cit109"><label>109</label><citation-alternatives><mixed-citation xml:lang="ru">van Dalen EC, Caron HN, Dickinson HO, Kremer LC. Cardioprotective interventions for cancer patients receiving anthracyclines. Cochrane Database Syst Rev. 2011;2011(6):CD003917. Published 2011 Jun 15. https://doi.org/10.1002/14651858.CD003917.pub4</mixed-citation><mixed-citation xml:lang="en">van Dalen EC, Caron HN, Dickinson HO, Kremer LC. Cardioprotective interventions for cancer patients receiving anthracyclines. Cochrane Database Syst Rev. 2011;2011(6):CD003917. Published 2011 Jun 15. https://doi.org/10.1002/14651858.CD003917.pub4</mixed-citation></citation-alternatives></ref><ref id="cit110"><label>110</label><citation-alternatives><mixed-citation xml:lang="ru">Lipshultz SE, Scully RE, Lipsitz SR, et al. Assessment of dexrazoxane as a cardioprotectant in doxorubicin-treated children with high-risk acute lymphoblastic leukaemia: long-term follow-up of a prospective, randomised, multicentre trial. Lancet Oncol. 2010;11(10):950-961. https://doi.org/10.1016/S1470-2045(10)70204-7</mixed-citation><mixed-citation xml:lang="en">Lipshultz SE, Scully RE, Lipsitz SR, et al. Assessment of dexrazoxane as a cardioprotectant in doxorubicin-treated children with high-risk acute lymphoblastic leukaemia: long-term follow-up of a prospective, randomised, multicentre trial. Lancet Oncol. 2010;11(10):950-961. https://doi.org/10.1016/S1470-2045(10)70204-7</mixed-citation></citation-alternatives></ref><ref id="cit111"><label>111</label><citation-alternatives><mixed-citation xml:lang="ru">Hensley ML, Hagerty KL, Kewalramani T, et al. American Society of Clinical Oncology 2008 clinical practice guideline update: use of chemotherapy and radiation therapy protectants. J Clin Oncol. 2009;27(1):127-145. https://doi.org/10.1200/JCO.2008.17.2627</mixed-citation><mixed-citation xml:lang="en">Hensley ML, Hagerty KL, Kewalramani T, et al. American Society of Clinical Oncology 2008 clinical practice guideline update: use of chemotherapy and radiation therapy protectants. J Clin Oncol. 2009;27(1):127-145. https://doi.org/10.1200/JCO.2008.17.2627</mixed-citation></citation-alternatives></ref><ref id="cit112"><label>112</label><citation-alternatives><mixed-citation xml:lang="ru">European Medicines Agency. Questions and answers on the review of dexrazoxane-contai-ning medicines, powder for solution for infusion, 500 mg. Outcome of a procedure underArticle 31 of Directive 2001/83/EC as amended. http://www.ema.europa.eu/docs/en_GB/docu-ment_library/Referralsdocument/Dexrazoxane_31/WC500108011.pdf.</mixed-citation><mixed-citation xml:lang="en">European Medicines Agency. Questions and answers on the review of dexrazoxane-contai-ning medicines, powder for solution for infusion, 500 mg. Outcome of a procedure underArticle 31 of Directive 2001/83/EC as amended. http://www.ema.europa.eu/docs/en_GB/docu-ment_library/Referralsdocument/Dexrazoxane_31/WC500108011.pdf.</mixed-citation></citation-alternatives></ref><ref id="cit113"><label>113</label><citation-alternatives><mixed-citation xml:lang="ru">Cardinale D, Colombo A, Sandri MT, et al. Prevention of high-dose chemotherapy-induced cardiotoxicity in high-risk patients by angiotensinconverting enzyme inhibition. Circulation. 2006;114(23):2474-2481. https://doi.org/10.1161/CIRCULATIONAHA.106.635144</mixed-citation><mixed-citation xml:lang="en">Cardinale D, Colombo A, Sandri MT, et al. Prevention of high-dose chemotherapy-induced cardiotoxicity in high-risk patients by angiotensinconverting enzyme inhibition. Circulation. 2006;114(23):2474-2481. https://doi.org/10.1161/CIRCULATIONAHA.106.635144</mixed-citation></citation-alternatives></ref><ref id="cit114"><label>114</label><citation-alternatives><mixed-citation xml:lang="ru">Cardinale D, Ciceri F, Latini R, et al. Anthracycline-induced cardiotoxicity: A multicenter randomised trial comparing two strategies for guiding prevention with enalapril: The International CardioOncology Society-one trial. Eur J Cancer. 2018;94:126-137. https://doi.org/10.1016/j.ejca.2018.02.005</mixed-citation><mixed-citation xml:lang="en">Cardinale D, Ciceri F, Latini R, et al. Anthracycline-induced cardiotoxicity: A multicenter randomised trial comparing two strategies for guiding prevention with enalapril: The International CardioOncology Society-one trial. Eur J Cancer. 2018;94:126-137. https://doi.org/10.1016/j.ejca.2018.02.005</mixed-citation></citation-alternatives></ref><ref id="cit115"><label>115</label><citation-alternatives><mixed-citation xml:lang="ru">Santoro C, Esposito R, Lembo M, et al. Strain-oriented strategy for guiding cardioprotection initiation of breast cancer patients experiencing cardiac dysfunction. Eur Heart J Cardiovasc Imaging. 2019;20(12):1345-1352. https://doi.org/10.1093/ehjci/jez194</mixed-citation><mixed-citation xml:lang="en">Santoro C, Esposito R, Lembo M, et al. Strain-oriented strategy for guiding cardioprotection initiation of breast cancer patients experiencing cardiac dysfunction. Eur Heart J Cardiovasc Imaging. 2019;20(12):1345-1352. https://doi.org/10.1093/ehjci/jez194</mixed-citation></citation-alternatives></ref><ref id="cit116"><label>116</label><citation-alternatives><mixed-citation xml:lang="ru">Thavendiranathan P, Negishi T, Somerset E et al. SUCCOUR Investigators. Strain-Guided Management of Potentially Cardiotoxic Cancer Therapy. J Am Coll Cardiol. 2021 Feb 2;77(4):392-401. https://doi.org/10.1016/j.jacc.2020.11.020 Epub 2020 Nov 18. PMID: 33220426.</mixed-citation><mixed-citation xml:lang="en">Thavendiranathan P, Negishi T, Somerset E et al. SUCCOUR Investigators. Strain-Guided Management of Potentially Cardiotoxic Cancer Therapy. J Am Coll Cardiol. 2021 Feb 2;77(4):392-401. https://doi.org/10.1016/j.jacc.2020.11.020 Epub 2020 Nov 18. PMID: 33220426.</mixed-citation></citation-alternatives></ref><ref id="cit117"><label>117</label><citation-alternatives><mixed-citation xml:lang="ru">Pareek N, Cevallos J, Moliner P, et al. Activity and outcomes of a cardiooncology service in the United Kingdom-a fve-year experience. Eur J Heart Fail. 2018;20(12):1721-1731. https://doi.org/10.1002/ejhf.1292</mixed-citation><mixed-citation xml:lang="en">Pareek N, Cevallos J, Moliner P, et al. Activity and outcomes of a cardiooncology service in the United Kingdom-a fve-year experience. Eur J Heart Fail. 2018;20(12):1721-1731. https://doi.org/10.1002/ejhf.1292</mixed-citation></citation-alternatives></ref><ref id="cit118"><label>118</label><citation-alternatives><mixed-citation xml:lang="ru">Hamo CE, Bloom MW, Cardinale D, et al. Cancer Therapy-Related Cardiac Dysfunction and Heart Failure: Part 2: Prevention, Treatment, Guidelines, and Future Directions. Circ Heart Fail. 2016;9(2):e002843. https://doi.org/10.1161/CIRCHEARTFAILURE.115.002843</mixed-citation><mixed-citation xml:lang="en">Hamo CE, Bloom MW, Cardinale D, et al. Cancer Therapy-Related Cardiac Dysfunction and Heart Failure: Part 2: Prevention, Treatment, Guidelines, and Future Directions. Circ Heart Fail. 2016;9(2):e002843. https://doi.org/10.1161/CIRCHEARTFAILURE.115.002843</mixed-citation></citation-alternatives></ref><ref id="cit119"><label>119</label><citation-alternatives><mixed-citation xml:lang="ru">Мареев В.Ю., Фомин И.В., Агеев Ф.Т. и соавт. Клинические рекомендации ОССН–РКО–РНМОТ. Сердечная недостаточность: хроническая (ХСН) и острая декомпенсированная (ОДСН). Диагностика, профилактика и лечение. Кардиология. 2018;58(6S):8-158 [Mareev V.Yu., Fomin I.V., Ageev F.T., et al. Russian Heart Failure Society, Russian Society of Cardiology. Russian Scientifc Medical Society of Internal Medicine Guidelines for Heart failure: chronic (CHF) and acute decompensated (ADHF). Diagnosis, prevention and treatment. Kardiologiia. 2018;58(6S):8-158 (In Russ.)] https://doi.org/10.18087/cardio.2475</mixed-citation><mixed-citation xml:lang="en">Мареев В.Ю., Фомин И.В., Агеев Ф.Т. и соавт. Клинические рекомендации ОССН–РКО–РНМОТ. Сердечная недостаточность: хроническая (ХСН) и острая декомпенсированная (ОДСН). Диагностика, профилактика и лечение. Кардиология. 2018;58(6S):8-158 [Mareev V.Yu., Fomin I.V., Ageev F.T., et al. Russian Heart Failure Society, Russian Society of Cardiology. Russian Scientifc Medical Society of Internal Medicine Guidelines for Heart failure: chronic (CHF) and acute decompensated (ADHF). Diagnosis, prevention and treatment. Kardiologiia. 2018;58(6S):8-158 (In Russ.)] https://doi.org/10.18087/cardio.2475</mixed-citation></citation-alternatives></ref><ref id="cit120"><label>120</label><citation-alternatives><mixed-citation xml:lang="ru">Cardinale D, Colombo A, Lamantia G et al. Anthracycline-induced cardiomyopathy: clinical relevance and response to pharmacologic therapy. J Am Coll Cardiol. 2010 Jan 19;55(3):213-20. https://doi.org/10.1016/j.jacc.2009.03.095 PMID: 20117401</mixed-citation><mixed-citation xml:lang="en">Cardinale D, Colombo A, Lamantia G et al. Anthracycline-induced cardiomyopathy: clinical relevance and response to pharmacologic therapy. J Am Coll Cardiol. 2010 Jan 19;55(3):213-20. https://doi.org/10.1016/j.jacc.2009.03.095 PMID: 20117401</mixed-citation></citation-alternatives></ref><ref id="cit121"><label>121</label><citation-alternatives><mixed-citation xml:lang="ru">Gregorietti V, Rojo A, Coronel R et al. Use of sacubitril valsartan in heart failure due to postchemotherapy symptomatic ventricular dysfunction. Eur J Heart Fail 2018; 20 (Suppl/S1).Abstract: P2123.</mixed-citation><mixed-citation xml:lang="en">Gregorietti V, Rojo A, Coronel R et al. Use of sacubitril valsartan in heart failure due to postchemotherapy symptomatic ventricular dysfunction. Eur J Heart Fail 2018; 20 (Suppl/S1). Abstract: P2123.</mixed-citation></citation-alternatives></ref><ref id="cit122"><label>122</label><citation-alternatives><mixed-citation xml:lang="ru">Виценя М.В., Потехина А.В., Гаврюшина С.В., и соавт. Профилактика и лечение дисфункции левого желудочка и сердечной недостаточности, связанных с противоопухолевой терапией: возможности и перспективы. Эффективная фармакотерапия 2020; 16(8): 108-120. https://doi.org/10.33978/2307-3586-2020-16-18-108-120</mixed-citation><mixed-citation xml:lang="en">Виценя М.В., Потехина А.В., Гаврюшина С.В., и соавт. Профилактика и лечение дисфункции левого желудочка и сердечной недостаточности, связанных с противоопухолевой терапией: возможности и перспективы. Эффективная фармакотерапия 2020; 16(8): 108-120. https://doi.org/10.33978/2307-3586-2020-16-18-108-120</mixed-citation></citation-alternatives></ref><ref id="cit123"><label>123</label><citation-alternatives><mixed-citation xml:lang="ru">Oliva S, Cioff G, Frattini S, et al. Administration of angiotensin-converting enzyme inhibitors and β-blockers during adjuvant trastuzumab chemotherapy for nonmetastatic breast cancer: marker of risk or cardioprotection in the real world?. Oncologist. 2012;17(7):917-924. https://doi.org/10.1634/theoncologist.2011-0445</mixed-citation><mixed-citation xml:lang="en">Oliva S, Cioff G, Frattini S, et al. Administration of angiotensin-converting enzyme inhibitors and β-blockers during adjuvant trastuzumab chemotherapy for nonmetastatic breast cancer: marker of risk or cardioprotection in the real world?. Oncologist. 2012;17(7):917-924. https://doi.org/10.1634/theoncologist.2011-0445</mixed-citation></citation-alternatives></ref><ref id="cit124"><label>124</label><citation-alternatives><mixed-citation xml:lang="ru">Oliveira GH, Dupont M, Naftel D, et al. Increased need for right ventricular support in patients with chemotherapy-induced cardiomyopathy undergoing mechanical circulatory support: outcomes from the INTERMACS Registry (Interagency Registry for Mechanically Assisted Circulatory Support). J Am Coll Cardiol. 2014;63(3):240-248. https://doi.org/10.1016/j.jacc.2013.09.040</mixed-citation><mixed-citation xml:lang="en">Oliveira GH, Dupont M, Naftel D, et al. Increased need for right ventricular support in patients with chemotherapy-induced cardiomyopathy undergoing mechanical circulatory support: outcomes from the INTERMACS Registry (Interagency Registry for Mechanically Assisted Circulatory Support). J Am Coll Cardiol. 2014;63(3):240-248. https://doi.org/10.1016/j.jacc.2013.09.040</mixed-citation></citation-alternatives></ref><ref id="cit125"><label>125</label><citation-alternatives><mixed-citation xml:lang="ru">Oliveira GH, Hardaway BW, Kucheryavaya AY, Stehlik J, Edwards LB, Taylor DO. Characteristics and survival of patients with chemotherapy-induced cardiomyopathy undergoing heart transplantation. J Heart Lung Transplant. 2012;31(8):805-810. https://doi.org/10.1016/j.healun.2012.03.018</mixed-citation><mixed-citation xml:lang="en">Oliveira GH, Hardaway BW, Kucheryavaya AY, Stehlik J, Edwards LB, Taylor DO. Characteristics and survival of patients with chemotherapy-induced cardiomyopathy undergoing heart transplantation. J Heart Lung Transplant. 2012;31(8):805-810. https://doi.org/10.1016/j.healun.2012.03.018</mixed-citation></citation-alternatives></ref><ref id="cit126"><label>126</label><citation-alternatives><mixed-citation xml:lang="ru">Rickard J, Kumbhani DJ, Baranowski B et al. Usefulness of cardiac resynchronization therapy in patients with adriamycin-induced cardiomyopathy. Am J Cardiol 2010; 105:522–6. https://doi.org/10.1016/j.amjcard.2009.10.024</mixed-citation><mixed-citation xml:lang="en">Rickard J, Kumbhani DJ, Baranowski B et al. Usefulness of cardiac resynchronization therapy in patients with adriamycin-induced cardiomyopathy. Am J Cardiol 2010; 105:522–6. https://doi.org/10.1016/j.amjcard.2009.10.024</mixed-citation></citation-alternatives></ref><ref id="cit127"><label>127</label><citation-alternatives><mixed-citation xml:lang="ru">Lenneman AJ, Wang L, Wigger M, et al. Heart transplant survival outcomes for adriamycin-dilated cardiomyopathy. Am J Cardiol. 2013;111(4):609-612. https://doi.org/10.1016/j.amjcard.2012.10.048</mixed-citation><mixed-citation xml:lang="en">Lenneman AJ, Wang L, Wigger M, et al. Heart transplant survival outcomes for adriamycin-dilated cardiomyopathy. Am J Cardiol. 2013;111(4):609-612. https://doi.org/10.1016/j.amjcard.2012.10.048</mixed-citation></citation-alternatives></ref><ref id="cit128"><label>128</label><citation-alternatives><mixed-citation xml:lang="ru">Jensen BV, Skovsgaard T, Nielsen SL. Functional monitoring of anthracycline cardiotoxicity: a prospective, blinded, long-term observational study of outcome in 120 patients. Ann Oncol. 2002;13(5):699-709. https://doi.org/10.1093/annonc/mdf132</mixed-citation><mixed-citation xml:lang="en">Jensen BV, Skovsgaard T, Nielsen SL. Functional monitoring of anthracycline cardiotoxicity: a prospective, blinded, long-term observational study of outcome in 120 patients. Ann Oncol. 2002;13(5):699-709. https://doi.org/10.1093/annonc/mdf132</mixed-citation></citation-alternatives></ref><ref id="cit129"><label>129</label><citation-alternatives><mixed-citation xml:lang="ru">Nousiainen T, Jantunen E, Vanninen E, Hartikainen J. Early decline in left ventricular ejection fraction predicts doxorubicin cardiotoxicity in lymphoma patients. Br J Cancer. 2002;86(11):1697-1700. https://doi.org/10.1038/sj.bjc.6600346</mixed-citation><mixed-citation xml:lang="en">Nousiainen T, Jantunen E, Vanninen E, Hartikainen J. Early decline in left ventricular ejection fraction predicts doxorubicin cardiotoxicity in lymphoma patients. Br J Cancer. 2002;86(11):1697-1700. https://doi.org/10.1038/sj.bjc.6600346</mixed-citation></citation-alternatives></ref><ref id="cit130"><label>130</label><citation-alternatives><mixed-citation xml:lang="ru">Lyon A.R., Habibian M., Evertz R. et al. Diagnosis and treatment of left ventricular dysfunction and heart failure in cancer patients. e-Journal of Cardiology Practice 2019; Vol. 16, N° 40.</mixed-citation><mixed-citation xml:lang="en">Lyon A.R., Habibian M., Evertz R. et al. Diagnosis and treatment of left ventricular dysfunction and heart failure in cancer patients. e-Journal of Cardiology Practice 2019; Vol. 16, N° 40.</mixed-citation></citation-alternatives></ref><ref id="cit131"><label>131</label><citation-alternatives><mixed-citation xml:lang="ru">Ganatra S, Nohria A, Shah S, et al. Upfront dexrazoxane for the reduction of anthracycline-induced cardiotoxicity in adults with preexisting cardiomyopathy and cancer: a consecutive case series. Cardiooncology. 2019;5:1. Published 2019 Jan 29. https://doi.org/10.1186/s40959-019-0036-7</mixed-citation><mixed-citation xml:lang="en">Ganatra S, Nohria A, Shah S, et al. Upfront dexrazoxane for the reduction of anthracycline-induced cardiotoxicity in adults with preexisting cardiomyopathy and cancer: a consecutive case series. Cardiooncology. 2019;5:1. Published 2019 Jan 29. https://doi.org/10.1186/s40959-019-0036-7</mixed-citation></citation-alternatives></ref><ref id="cit132"><label>132</label><citation-alternatives><mixed-citation xml:lang="ru">Lynce F, Barac A, Geng X, et al. Prospective evaluation of the cardiac safety of HER2-targeted therapies in patients with HER2-positive breast cancer and compromised heart function: the SAFE-HEaRt study. Breast Cancer Res Treat. 2019;175(3):595-603. https://doi.org/10.1007/s10549-019-05191-2</mixed-citation><mixed-citation xml:lang="en">Lynce F, Barac A, Geng X, et al. Prospective evaluation of the cardiac safety of HER2-targeted therapies in patients with HER2-positive breast cancer and compromised heart function: the SAFE-HEaRt study. Breast Cancer Res Treat. 2019;175(3):595-603. https://doi.org/10.1007/s10549-019-05191-2</mixed-citation></citation-alternatives></ref><ref id="cit133"><label>133</label><citation-alternatives><mixed-citation xml:lang="ru">Leong DP, Cosman T, Alhussein MM, et al. Safety of Continuing Trastuzumab Despite Mild Cardiotoxicity: A Phase I Trial. JACC CardioOncol. 2019;1(1):1-10. Published 2019 Jul 17. https://doi.org/10.1016/j.jaccao.2019.06.004</mixed-citation><mixed-citation xml:lang="en">Leong DP, Cosman T, Alhussein MM, et al. Safety of Continuing Trastuzumab Despite Mild Cardiotoxicity: A Phase I Trial. JACC CardioOncol. 2019;1(1):1-10. Published 2019 Jul 17. https://doi.org/10.1016/j.jaccao.2019.06.004</mixed-citation></citation-alternatives></ref><ref id="cit134"><label>134</label><citation-alternatives><mixed-citation xml:lang="ru">Chang HM, Moudgil R, Scarabelli T, Okwuosa TM, Yeh ETH. Cardiovascular Complications of Cancer Therapy: Best Practices in Diagnosis, Prevention, and Management: Part 1 [published correction appears in J Am Coll Cardiol. 2018 Feb 6;71(5):587]. J Am Coll Cardiol. 2017;70(20):2536-2551. https://doi.org/10.1016/j.jacc.2017.09.1096</mixed-citation><mixed-citation xml:lang="en">Chang HM, Moudgil R, Scarabelli T, Okwuosa TM, Yeh ETH. Cardiovascular Complications of Cancer Therapy: Best Practices in Diagnosis, Prevention, and Management: Part 1 [published correction appears in J Am Coll Cardiol. 2018 Feb 6;71(5):587]. J Am Coll Cardiol. 2017;70(20):2536-2551. https://doi.org/10.1016/j.jacc.2017.09.1096</mixed-citation></citation-alternatives></ref><ref id="cit135"><label>135</label><citation-alternatives><mixed-citation xml:lang="ru">Herrmann J, Yang EH, Iliescu CA, et al. Vascular Toxicities of Cancer Therapies: The Old and the New--An Evolving Avenue. Circulation. 2016;133(13):1272-1289. https://doi.org/10.1161/CIRCULATIONAHA.115.018347</mixed-citation><mixed-citation xml:lang="en">Herrmann J, Yang EH, Iliescu CA, et al. Vascular Toxicities of Cancer Therapies: The Old and the New--An Evolving Avenue. Circulation. 2016;133(13):1272-1289. https://doi.org/10.1161/CIRCULATIONAHA.115.018347</mixed-citation></citation-alternatives></ref><ref id="cit136"><label>136</label><citation-alternatives><mixed-citation xml:lang="ru">Yusuf SW, Daraban N, Abbasi N, Lei X, Durand JB, Daher IN. Treatment and outcomes of acute coronary syndrome in the cancer population. Clin Cardiol. 2012;35(7):443-450. https://doi.org/10.1002/clc.22007</mixed-citation><mixed-citation xml:lang="en">Yusuf SW, Daraban N, Abbasi N, Lei X, Durand JB, Daher IN. Treatment and outcomes of acute coronary syndrome in the cancer population. Clin Cardiol. 2012;35(7):443-450. https://doi.org/10.1002/clc.22007</mixed-citation></citation-alternatives></ref><ref id="cit137"><label>137</label><citation-alternatives><mixed-citation xml:lang="ru">Sara JD, Kaur J, Khodadadi R, et al. 5-ﬂuorouracil and cardiotoxicity: a review. Ther Adv Med Oncol. 2018;10:1758835918780140. Published 2018 Jun 18. https://doi.org/10.1177/1758835918780140</mixed-citation><mixed-citation xml:lang="en">Sara JD, Kaur J, Khodadadi R, et al. 5-ﬂuorouracil and cardiotoxicity: a review. Ther Adv Med Oncol. 2018;10:1758835918780140. Published 2018 Jun 18. https://doi.org/10.1177/1758835918780140</mixed-citation></citation-alternatives></ref><ref id="cit138"><label>138</label><citation-alternatives><mixed-citation xml:lang="ru">Polk A, Vistisen K, Vaage-Nilsen M, Nielsen DL. A systematic review of the pathophysiology of 5-ﬂuorouracil-induced cardiotoxicity. BMC Pharmacol Toxicol. 2014;15:47. Published 2014 Sep 4. https://doi.org/10.1186/2050-6511-15-47</mixed-citation><mixed-citation xml:lang="en">Polk A, Vistisen K, Vaage-Nilsen M, Nielsen DL. A systematic review of the pathophysiology of 5-ﬂuorouracil-induced cardiotoxicity. BMC Pharmacol Toxicol. 2014;15:47. Published 2014 Sep 4. https://doi.org/10.1186/2050-6511-15-47</mixed-citation></citation-alternatives></ref><ref id="cit139"><label>139</label><citation-alternatives><mixed-citation xml:lang="ru">Bohdan M, Kowalczys A, Mickiewicz A, Gruchała M, Lewicka E. Cancer Therapy-Related Cardiovascular Complications in Clinical Practice: Current Perspectives. J Clin Med. 2021;10(8):1647. Published 2021 Apr 13. https://doi.org/10.3390/jcm10081647</mixed-citation><mixed-citation xml:lang="en">Bohdan M, Kowalczys A, Mickiewicz A, Gruchała M, Lewicka E. Cancer Therapy-Related Cardiovascular Complications in Clinical Practice: Current Perspectives. J Clin Med. 2021;10(8):1647. Published 2021 Apr 13. https://doi.org/10.3390/jcm10081647</mixed-citation></citation-alternatives></ref><ref id="cit140"><label>140</label><citation-alternatives><mixed-citation xml:lang="ru">de Forni M, Bugat R, Sorbette F, Delay M, Bachaud JM, Chevreau C. Cardiotoxicité du 5-ﬂuorouracile perfusion intraveineuse continue: étude clinique, prévention, physiopathologie. A propos d’une série de 13 cas [Cardiotoxicity of continuous intravenous infusion of 5-ﬂuorouracil: clinical study, prevention and physiopathology. Apropos of 13 cases]. Bull Cancer. 1990;77(5):429-438.</mixed-citation><mixed-citation xml:lang="en">de Forni M, Bugat R, Sorbette F, Delay M, Bachaud JM, Chevreau C. Cardiotoxicité du 5-ﬂuorouracile perfusion intraveineuse continue: étude clinique, prévention, physiopathologie. A propos d’une série de 13 cas [Cardiotoxicity of continuous intravenous infusion of 5-ﬂuorouracil: clinical study, prevention and physiopathology. Apropos of 13 cases]. Bull Cancer. 1990;77(5):429-438.</mixed-citation></citation-alternatives></ref><ref id="cit141"><label>141</label><citation-alternatives><mixed-citation xml:lang="ru">Südhoff T, Enderle MD, Pahlke M, et al. 5-Fluorouracil induces arterial vasocontractions. Ann Oncol. 2004;15(4):661-664. https://doi.org/10.1093/annonc/mdh150</mixed-citation><mixed-citation xml:lang="en">Südhoff T, Enderle MD, Pahlke M, et al. 5-Fluorouracil induces arterial vasocontractions. Ann Oncol. 2004;15(4):661-664. https://doi.org/10.1093/annonc/mdh150</mixed-citation></citation-alternatives></ref><ref id="cit142"><label>142</label><citation-alternatives><mixed-citation xml:lang="ru">Stewart T, Pavlakis N, Ward M. Cardiotoxicity with 5-ﬂuorouracil and capecitabine: more than just vasospastic angina. Intern Med J. 2010;40(4):303-307. https://doi.org/10.1111/j.1445-5994.2009.02144.x</mixed-citation><mixed-citation xml:lang="en">Stewart T, Pavlakis N, Ward M. Cardiotoxicity with 5-ﬂuorouracil and capecitabine: more than just vasospastic angina. Intern Med J. 2010;40(4):303-307. https://doi.org/10.1111/j.1445-5994.2009.02144.x</mixed-citation></citation-alternatives></ref><ref id="cit143"><label>143</label><citation-alternatives><mixed-citation xml:lang="ru">Grunwald MR, Howie L, Diaz LA Jr. Takotsubo cardiomyopathy and Fluorouracil: case report and review of the literature. J Clin Oncol. 2012;30(2):e11-e14. https://doi.org/10.1200/JCO.2011.38.5278</mixed-citation><mixed-citation xml:lang="en">Grunwald MR, Howie L, Diaz LA Jr. Takotsubo cardiomyopathy and Fluorouracil: case report and review of the literature. J Clin Oncol. 2012;30(2):e11-e14. https://doi.org/10.1200/JCO.2011.38.5278</mixed-citation></citation-alternatives></ref><ref id="cit144"><label>144</label><citation-alternatives><mixed-citation xml:lang="ru">Smith SA, Auseon AJ. Chemotherapy-induced takotsubo cardiomyopathy. Heart Fail Clin. 2013;9(2):233-x. https://doi.org/10.1016/j.hfc.2012.12.009</mixed-citation><mixed-citation xml:lang="en">Smith SA, Auseon AJ. Chemotherapy-induced takotsubo cardiomyopathy. Heart Fail Clin. 2013;9(2):233-x. https://doi.org/10.1016/j.hfc.2012.12.009</mixed-citation></citation-alternatives></ref><ref id="cit145"><label>145</label><citation-alternatives><mixed-citation xml:lang="ru">Cerny J, Hassan A, Smith C, Piperdi B. Coronary vasospasm with myocardial stunning in a patient with colon cancer receiving adjuvant chemotherapy with FOLFOX regimen. Clin Colorectal Cancer. 2009;8(1):55-58. https://doi.org/10.3816/CCC.2009.n.009</mixed-citation><mixed-citation xml:lang="en">Cerny J, Hassan A, Smith C, Piperdi B. Coronary vasospasm with myocardial stunning in a patient with colon cancer receiving adjuvant chemotherapy with FOLFOX regimen. Clin Colorectal Cancer. 2009;8(1):55-58. https://doi.org/10.3816/CCC.2009.n.009</mixed-citation></citation-alternatives></ref><ref id="cit146"><label>146</label><citation-alternatives><mixed-citation xml:lang="ru">Ambrosy AP, Kunz PL, Fisher GA, Witteles RM. Capecitabine-induced chest pain relieved by diltiazem. Am J Cardiol. 2012;110(11):1623-1626. https://doi.org/10.1016/j.amjcard.2012.07.026</mixed-citation><mixed-citation xml:lang="en">Ambrosy AP, Kunz PL, Fisher GA, Witteles RM. Capecitabine-induced chest pain relieved by diltiazem. Am J Cardiol. 2012;110(11):1623-1626. https://doi.org/10.1016/j.amjcard.2012.07.026</mixed-citation></citation-alternatives></ref><ref id="cit147"><label>147</label><citation-alternatives><mixed-citation xml:lang="ru">Boyle JJ, Wilson B, Bicknell R, Harrower S, Weissberg PL, Fan TP. Expression of angiogenic factor thymidine phosphorylase and angiogenesis in human atherosclerosis. J Pathol. 2000;192(2):234-242. https://doi.org/10.1002/1096-9896(2000)9999:9999&lt;::AID-PATH699&gt;3.0.CO;2-9</mixed-citation><mixed-citation xml:lang="en">Boyle JJ, Wilson B, Bicknell R, Harrower S, Weissberg PL, Fan TP. Expression of angiogenic factor thymidine phosphorylase and angiogenesis in human atherosclerosis. J Pathol. 2000;192(2):234-242. https://doi.org/10.1002/1096-9896(2000)9999:9999&lt;::AID-PATH699&gt;3.0.CO;2-9</mixed-citation></citation-alternatives></ref><ref id="cit148"><label>148</label><citation-alternatives><mixed-citation xml:lang="ru">Coward J, Maisey N, Cunningham D. The effects of capecitabine in Raynaud’s disease: a case report. Ann Oncol. 2005;16(5):835-836. https://doi.org/10.1093/annonc/mdi144</mixed-citation><mixed-citation xml:lang="en">Coward J, Maisey N, Cunningham D. The effects of capecitabine in Raynaud’s disease: a case report. Ann Oncol. 2005;16(5):835-836. https://doi.org/10.1093/annonc/mdi144</mixed-citation></citation-alternatives></ref><ref id="cit149"><label>149</label><citation-alternatives><mixed-citation xml:lang="ru">Jensen SA, Sørensen JB. Risk factors and prevention of cardiotoxicity induced by 5-ﬂuorouracil or capecitabine. Cancer Chemother Pharmacol. 2006;58(4):487-493. https://doi.org/10.1007/s00280-005-0178-1</mixed-citation><mixed-citation xml:lang="en">Jensen SA, Sørensen JB. Risk factors and prevention of cardiotoxicity induced by 5-ﬂuorouracil or capecitabine. Cancer Chemother Pharmacol. 2006;58(4):487-493. https://doi.org/10.1007/s00280-005-0178-1</mixed-citation></citation-alternatives></ref><ref id="cit150"><label>150</label><citation-alternatives><mixed-citation xml:lang="ru">Rowinsky EK, McGuire WP, Guarnieri T, Fisherman JS, Christian MC, Donehower RC. Cardiac disturbances during the administration of taxol. J Clin Oncol. 1991;9(9):1704-1712. https://doi.org/10.1200/JCO.1991.9.9.1704</mixed-citation><mixed-citation xml:lang="en">Rowinsky EK, McGuire WP, Guarnieri T, Fisherman JS, Christian MC, Donehower RC. Cardiac disturbances during the administration of taxol. J Clin Oncol. 1991;9(9):1704-1712. https://doi.org/10.1200/JCO.1991.9.9.1704</mixed-citation></citation-alternatives></ref><ref id="cit151"><label>151</label><citation-alternatives><mixed-citation xml:lang="ru">Schrader C, Keussen C, Bewig B, von Freier A, Lins M. Symptoms and signs of an acute myocardial ischemia caused by chemotherapy with Paclitaxel (Taxol) in a patient with metastatic ovarian carcinoma. Eur J Med Res. 2005;10(11):498-501.</mixed-citation><mixed-citation xml:lang="en">Schrader C, Keussen C, Bewig B, von Freier A, Lins M. Symptoms and signs of an acute myocardial ischemia caused by chemotherapy with Paclitaxel (Taxol) in a patient with metastatic ovarian carcinoma. Eur J Med Res. 2005;10(11):498-501.</mixed-citation></citation-alternatives></ref><ref id="cit152"><label>152</label><citation-alternatives><mixed-citation xml:lang="ru">Berliner S, Rahima M, Sidi Y, et al. Acute coronary events following cispl atin-based chemotherapy. Cancer Invest. 1990;8(6):583-586. https://doi.org/10.3109/07357909009018924</mixed-citation><mixed-citation xml:lang="en">Berliner S, Rahima M, Sidi Y, et al. Acute coronary events following cispl atin-based chemotherapy. Cancer Invest. 1990;8(6):583-586. https://doi.org/10.3109/07357909009018924</mixed-citation></citation-alternatives></ref><ref id="cit153"><label>153</label><citation-alternatives><mixed-citation xml:lang="ru">Jafri M, Protheroe A. Cisplatin-associated thrombosis. Anticancer Drugs. 2008;19(9):927-929. https://doi.org/10.1097/CAD.0b013e3283100e9c</mixed-citation><mixed-citation xml:lang="en">Jafri M, Protheroe A. Cisplatin-associated thrombosis. Anticancer Drugs. 2008;19(9):927-929. https://doi.org/10.1097/CAD.0b013e3283100e9c</mixed-citation></citation-alternatives></ref><ref id="cit154"><label>154</label><citation-alternatives><mixed-citation xml:lang="ru">Karabay KO, Yildiz O, Aytekin V. Multiple coronary thrombi with cisplatin. J Invasive Cardiol. 2014;26(2):E18-E20.</mixed-citation><mixed-citation xml:lang="en">Karabay KO, Yildiz O, Aytekin V. Multiple coronary thrombi with cisplatin. J Invasive Cardiol. 2014;26(2):E18-E20.</mixed-citation></citation-alternatives></ref><ref id="cit155"><label>155</label><citation-alternatives><mixed-citation xml:lang="ru">Togna GI, Togna AR, Franconi M, Caprino L. Cisplatin triggers platelet activation. Thromb Res. 2000;99(5):503-509. https://doi.org/10.1016/s0049-3848(00)00294-2</mixed-citation><mixed-citation xml:lang="en">Togna GI, Togna AR, Franconi M, Caprino L. Cisplatin triggers platelet activation. Thromb Res. 2000;99(5):503-509. https://doi.org/10.1016/s0049-3848(00)00294-2</mixed-citation></citation-alternatives></ref><ref id="cit156"><label>156</label><citation-alternatives><mixed-citation xml:lang="ru">Dieckmann KP, Gerl A, Witt J, Hartmann JT; German Testicular Cancer Study Group. Myocardial infarction and other major vascular events during chemotherapy for testicular cancer. Ann Oncol. 2010;21(8):1607-1611. https://doi.org/10.1093/annonc/mdp597</mixed-citation><mixed-citation xml:lang="en">Dieckmann KP, Gerl A, Witt J, Hartmann JT; German Testicular Cancer Study Group. Myocardial infarction and other major vascular events during chemotherapy for testicular cancer. Ann Oncol. 2010;21(8):1607-1611. https://doi.org/10.1093/annonc/mdp597</mixed-citation></citation-alternatives></ref><ref id="cit157"><label>157</label><citation-alternatives><mixed-citation xml:lang="ru">Ito D, Shiraishi J, Nakamura T, et al. Primary percutaneous coronary intervention and intravascular ultrasound imaging for coronary thrombosis after cisplatin-based chemotherapy. Heart Vessels. 2012;27(6):634-638. https://doi.org/10.1007/s00380-011-0222-5</mixed-citation><mixed-citation xml:lang="en">Ito D, Shiraishi J, Nakamura T, et al. Primary percutaneous coronary intervention and intravascular ultrasound imaging for coronary thrombosis after cisplatin-based chemotherapy. Heart Vessels. 2012;27(6):634-638. https://doi.org/10.1007/s00380-011-0222-5</mixed-citation></citation-alternatives></ref><ref id="cit158"><label>158</label><citation-alternatives><mixed-citation xml:lang="ru">Meinardi MT, Gietema JA, van der Graaf WT, et al. Cardiovascular morbidity in long-term survivors of metastatic testicular cancer. J Clin Oncol. 2000;18(8):1725-1732. https://doi.org/10.1200/JCO.2000.18.8.1725</mixed-citation><mixed-citation xml:lang="en">Meinardi MT, Gietema JA, van der Graaf WT, et al. Cardiovascular morbidity in long-term survivors of metastatic testicular cancer. J Clin Oncol. 2000;18(8):1725-1732. https://doi.org/10.1200/JCO.2000.18.8.1725</mixed-citation></citation-alternatives></ref><ref id="cit159"><label>159</label><citation-alternatives><mixed-citation xml:lang="ru">Huddart RA, Norman A, Shahidi M, et al. Cardiovascular disease as a long-term complication of treatment for testicular cancer. J Clin Oncol. 2003;21(8):1513-1523. https://doi.org/10.1200/JCO.2003.04.173</mixed-citation><mixed-citation xml:lang="en">Huddart RA, Norman A, Shahidi M, et al. Cardiovascular disease as a long-term complication of treatment for testicular cancer. J Clin Oncol. 2003;21(8):1513-1523. https://doi.org/10.1200/JCO.2003.04.173</mixed-citation></citation-alternatives></ref><ref id="cit160"><label>160</label><citation-alternatives><mixed-citation xml:lang="ru">Haugnes HS, Wethal T, Aass N, et al. Cardiovascular risk factors and morbidity in long-term survivors of testicular cancer: a 20-year follow-up study. J Clin Oncol. 2010;28(30):4649-4657. https://doi.org/10.1200/JCO.2010.29.9362</mixed-citation><mixed-citation xml:lang="en">Haugnes HS, Wethal T, Aass N, et al. Cardiovascular risk factors and morbidity in long-term survivors of testicular cancer: a 20-year follow-up study. J Clin Oncol. 2010;28(30):4649-4657. https://doi.org/10.1200/JCO.2010.29.9362</mixed-citation></citation-alternatives></ref><ref id="cit161"><label>161</label><citation-alternatives><mixed-citation xml:lang="ru">Feldman DR, Schaffer WL, Steingart RM. Late cardiovascular toxicity following chemotherapy for germ cell tumors. J Natl Compr Canc Netw. 2012;10(4):537-544. https://doi.org/10.6004/jnccn.2012.0051</mixed-citation><mixed-citation xml:lang="en">Feldman DR, Schaffer WL, Steingart RM. Late cardiovascular toxicity following chemotherapy for germ cell tumors. J Natl Compr Canc Netw. 2012;10(4):537-544. https://doi.org/10.6004/jnccn.2012.0051</mixed-citation></citation-alternatives></ref><ref id="cit162"><label>162</label><citation-alternatives><mixed-citation xml:lang="ru">Gietema JA, Meinardi MT, Messerschmidt J, et al. Circulating plasma platinum more than 10 years after cisplatin treatment for testicular cancer. Lancet. 2000;355(9209):1075-1076. https://doi.org/10.1016/s0140-6736(00)02044-4</mixed-citation><mixed-citation xml:lang="en">Gietema JA, Meinardi MT, Messerschmidt J, et al. Circulating plasma platinum more than 10 years after cisplatin treatment for testicular cancer. Lancet. 2000;355(9209):1075-1076. https://doi.org/10.1016/s0140-6736(00)02044-4</mixed-citation></citation-alternatives></ref><ref id="cit163"><label>163</label><citation-alternatives><mixed-citation xml:lang="ru">Nuver J, Smit AJ, Sleijfer DT, et al. Microalbuminuria, decreased fbrinolysis, and inﬂammation as early signs of atherosclerosis in long-term survivors of disseminated testicular cancer. Eur J Cancer. 2004;40(5):701-706. https://doi.org/10.1016/j.ejca.2003.12.012</mixed-citation><mixed-citation xml:lang="en">Nuver J, Smit AJ, Sleijfer DT, et al. Microalbuminuria, decreased fbrinolysis, and inﬂammation as early signs of atherosclerosis in long-term survivors of disseminated testicular cancer. Eur J Cancer. 2004;40(5):701-706. https://doi.org/10.1016/j.ejca.2003.12.012</mixed-citation></citation-alternatives></ref><ref id="cit164"><label>164</label><citation-alternatives><mixed-citation xml:lang="ru">Oh JH, Baum DD, Pham S, et al. Long-term complications of platinum-based chemotherapy in testicular cancer survivors. Med Oncol. 2007;24(2):175-181. https://doi.org/10.1007/BF02698037</mixed-citation><mixed-citation xml:lang="en">Oh JH, Baum DD, Pham S, et al. Long-term complications of platinum-based chemotherapy in testicular cancer survivors. Med Oncol. 2007;24(2):175-181. https://doi.org/10.1007/BF02698037</mixed-citation></citation-alternatives></ref><ref id="cit165"><label>165</label><citation-alternatives><mixed-citation xml:lang="ru">Kachel DL, Martin WJ 2nd. Cyclophosphamide-induced lung toxicity: mechanism of endothelial cell injury. J Pharmacol Exp Ther. 1994;268(1):42-46.</mixed-citation><mixed-citation xml:lang="en">Kachel DL, Martin WJ 2nd. Cyclophosphamide-induced lung toxicity: mechanism of endothelial cell injury. J Pharmacol Exp Ther. 1994;268(1):42-46.</mixed-citation></citation-alternatives></ref><ref id="cit166"><label>166</label><citation-alternatives><mixed-citation xml:lang="ru">Gottdiener JS, Appelbaum FR, Ferrans VJ, Deisseroth A, Ziegler J. Cardiotoxicity associated with high-dose cyclophosphamide therapy. Arch Intern Med. 1981;141(6):758-763.</mixed-citation><mixed-citation xml:lang="en">Gottdiener JS, Appelbaum FR, Ferrans VJ, Deisseroth A, Ziegler J. Cardiotoxicity associated with high-dose cyclophosphamide therapy. Arch Intern Med. 1981;141(6):758-763.</mixed-citation></citation-alternatives></ref><ref id="cit167"><label>167</label><citation-alternatives><mixed-citation xml:lang="ru">Katayama M, Imai Y, Hashimoto H, et al. Fulminant fatal cardiotoxicity following cyclophosphamide therapy. J Cardiol. 2009;54(2):330-334. https://doi.org/10.1016/j.jjcc.2009.01.006</mixed-citation><mixed-citation xml:lang="en">Katayama M, Imai Y, Hashimoto H, et al. Fulminant fatal cardiotoxicity following cyclophosphamide therapy. J Cardiol. 2009;54(2):330-334. https://doi.org/10.1016/j.jjcc.2009.01.006</mixed-citation></citation-alternatives></ref><ref id="cit168"><label>168</label><citation-alternatives><mixed-citation xml:lang="ru">Stefenelli T, Kuzmits R, Ulrich W, Glogar D. Acute vascular toxicity after combination chemotherapy with cisplatin, vinblastine, and bleomycin for testicular cancer. Eur Heart J. 1988;9(5):552-556. https://doi.org/10.1093/oxfordjournals.eurheartj.a062542</mixed-citation><mixed-citation xml:lang="en">Stefenelli T, Kuzmits R, Ulrich W, Glogar D. Acute vascular toxicity after combination chemotherapy with cisplatin, vinblastine, and bleomycin for testicular cancer. Eur Heart J. 1988;9(5):552-556. https://doi.org/10.1093/oxfordjournals.eurheartj.a062542</mixed-citation></citation-alternatives></ref><ref id="cit169"><label>169</label><citation-alternatives><mixed-citation xml:lang="ru">Soultati A, Mountzios G, Avgerinou C, et al. Endothelial vascular toxicity from chemotherapeutic agents: preclinical evidence and clinical implications. Cancer Treat Rev. 2012;38(5):473-483. https://doi.org/10.1016/j.ctrv.2011.09.002</mixed-citation><mixed-citation xml:lang="en">Soultati A, Mountzios G, Avgerinou C, et al. Endothelial vascular toxicity from chemotherapeutic agents: preclinical evidence and clinical implications. Cancer Treat Rev. 2012;38(5):473-483. https://doi.org/10.1016/j.ctrv.2011.09.002</mixed-citation></citation-alternatives></ref><ref id="cit170"><label>170</label><citation-alternatives><mixed-citation xml:lang="ru">Schwarzer S, Eber B, Greinix H, Lind P. Non-Q-wave myocardial infarction associated with bleomycin and etoposide chemotherapy. Eur Heart J. 1991;12(6):748-750.</mixed-citation><mixed-citation xml:lang="en">Schwarzer S, Eber B, Greinix H, Lind P. Non-Q-wave myocardial infarction associated with bleomycin and etoposide chemotherapy. Eur Heart J. 1991;12(6):748-750.</mixed-citation></citation-alternatives></ref><ref id="cit171"><label>171</label><citation-alternatives><mixed-citation xml:lang="ru">Doll DC, List AF, Greco FA, Hainsworth JD, Hande KR, Johnson DH. Acute vascular ischemic events after cisplatin-based combination chemotherapy for germ-cell tumors of the testis. Ann Intern Med. 1986;105(1):48-51. https://doi.org/10.7326/0003-4819-105-1-48</mixed-citation><mixed-citation xml:lang="en">Doll DC, List AF, Greco FA, Hainsworth JD, Hande KR, Johnson DH. Acute vascular ischemic events after cisplatin-based combination chemotherapy for germ-cell tumors of the testis. Ann Intern Med. 1986;105(1):48-51. https://doi.org/10.7326/0003-4819-105-1-48</mixed-citation></citation-alternatives></ref><ref id="cit172"><label>172</label><citation-alternatives><mixed-citation xml:lang="ru">Samuels BL, Vogelzang NJ, Kennedy BJ. Severe vascular toxicity associated with vinblastine, bleomycin, and cisplatin chemotherapy. Cancer Chemother Pharmacol. 1987;19(3):253-256. https://doi.org/10.1007/BF00252982</mixed-citation><mixed-citation xml:lang="en">Samuels BL, Vogelzang NJ, Kennedy BJ. Severe vascular toxicity associated with vinblastine, bleomycin, and cisplatin chemotherapy. Cancer Chemother Pharmacol. 1987;19(3):253-256. https://doi.org/10.1007/BF00252982</mixed-citation></citation-alternatives></ref><ref id="cit173"><label>173</label><citation-alternatives><mixed-citation xml:lang="ru">Panella M, Ross JE, Garvin K, Martin A. Cardiac sudden death as a result of acute coronary artery thrombosis during chemotherapy for testicular carcinoma. J Forensic Sci. 2010;55(5):1384-1388. https://doi.org/10.1111/j.1556-4029.2010.01437.x</mixed-citation><mixed-citation xml:lang="en">Panella M, Ross JE, Garvin K, Martin A. Cardiac sudden death as a result of acute coronary artery thrombosis during chemotherapy for testicular carcinoma. J Forensic Sci. 2010;55(5):1384-1388. https://doi.org/10.1111/j.1556-4029.2010.01437.x</mixed-citation></citation-alternatives></ref><ref id="cit174"><label>174</label><citation-alternatives><mixed-citation xml:lang="ru">Gallagher H, Carroll WM, Dowd M, Rochev Y. The effects of vinblastine on endothelial cells. Endothelium. 2008;15(1):9-15. https://doi.org/10.1080/10623320802092161</mixed-citation><mixed-citation xml:lang="en">Gallagher H, Carroll WM, Dowd M, Rochev Y. The effects of vinblastine on endothelial cells. Endothelium. 2008;15(1):9-15. https://doi.org/10.1080/10623320802092161</mixed-citation></citation-alternatives></ref><ref id="cit175"><label>175</label><citation-alternatives><mixed-citation xml:lang="ru">Schutz FAB, Je Y, Azzi GR, Nguyen PL, Choueiri TK. Bevacizumab increases the risk of arterial ischemia: a large study in cancer patients with a focus on different subgroup outcomes. Ann Oncol. 2011;22(6):1404-1412. https://doi.org/10.1093/annonc/mdq587</mixed-citation><mixed-citation xml:lang="en">Schutz FAB, Je Y, Azzi GR, Nguyen PL, Choueiri TK. Bevacizumab increases the risk of arterial ischemia: a large study in cancer patients with a focus on different subgroup outcomes. Ann Oncol. 2011;22(6):1404-1412. https://doi.org/10.1093/annonc/mdq587</mixed-citation></citation-alternatives></ref><ref id="cit176"><label>176</label><citation-alternatives><mixed-citation xml:lang="ru">Ranpura V, Hapani S, Chuang J, Wu S. Risk of cardiac ischemia and arterial thromboembolic events with the angiogenesis inhibitor bevacizumab in cancer patients: a meta-analysis of randomized controlled trials. Acta Oncol. 2010;49(3):287-297. https://doi.org/10.3109/02841860903524396</mixed-citation><mixed-citation xml:lang="en">Ranpura V, Hapani S, Chuang J, Wu S. Risk of cardiac ischemia and arterial thromboembolic events with the angiogenesis inhibitor bevacizumab in cancer patients: a meta-analysis of randomized controlled trials. Acta Oncol. 2010;49(3):287-297. https://doi.org/10.3109/02841860903524396</mixed-citation></citation-alternatives></ref><ref id="cit177"><label>177</label><citation-alternatives><mixed-citation xml:lang="ru">Qi WX, Shen Z, Tang LN, Yao Y. Risk of arterial thromboembolic events with vascular endothelial growth factor receptor tyrosine kinase inhibitors: an upto-date meta-analysis. Crit Rev Oncol Hematol. 2014;92(2):71-82. https://doi.org/10.1016/j.critrevonc.2014.04.004</mixed-citation><mixed-citation xml:lang="en">Qi WX, Shen Z, Tang LN, Yao Y. Risk of arterial thromboembolic events with vascular endothelial growth factor receptor tyrosine kinase inhibitors: an upto-date meta-analysis. Crit Rev Oncol Hematol. 2014;92(2):71-82. https://doi.org/10.1016/j.critrevonc.2014.04.004</mixed-citation></citation-alternatives></ref><ref id="cit178"><label>178</label><citation-alternatives><mixed-citation xml:lang="ru">Kappers MH, van Esch JH, Sluiter W, Sleijfer S, Danser AH, van den Meiracker AH. Hypertension induced by the tyrosine kinase inhibitor sunitinib is associated with increased circulating endothelin-1 levels. Hypertension. 2010;56(4):675-681. https://doi.org/10.1161/HYPERTENSIONAHA.109.149690</mixed-citation><mixed-citation xml:lang="en">Kappers MH, van Esch JH, Sluiter W, Sleijfer S, Danser AH, van den Meiracker AH. Hypertension induced by the tyrosine kinase inhibitor sunitinib is associated with increased circulating endothelin-1 levels. Hypertension. 2010;56(4):675-681. https://doi.org/10.1161/HYPERTENSIONAHA.109.149690</mixed-citation></citation-alternatives></ref><ref id="cit179"><label>179</label><citation-alternatives><mixed-citation xml:lang="ru">Winnik S, Lohmann C, Siciliani G, et al. Systemic VEGF inhibition accelerates experimental atherosclerosis and disrupts endothelial homeostasis--implications for cardiovascular safety. Int J Cardiol. 2013;168(3):2453-2461.https://doi.org/10.1016/j.ijcard.2013.03.010</mixed-citation><mixed-citation xml:lang="en">Winnik S, Lohmann C, Siciliani G, et al. Systemic VEGF inhibition accelerates experimental atherosclerosis and disrupts endothelial homeostasis--implications for cardiovascular safety. Int J Cardiol. 2013;168(3):2453-2461.https://doi.org/10.1016/j.ijcard.2013.03.010</mixed-citation></citation-alternatives></ref><ref id="cit180"><label>180</label><citation-alternatives><mixed-citation xml:lang="ru">Arima Y, Oshima S, Noda K, et al. Sorafenib-induced acute myocardial infarction due to coronary artery spasm. J Cardiol. 2009;54(3):512-515. https://doi.org/10.1016/j.jjcc.2009.03.009</mixed-citation><mixed-citation xml:lang="en">Arima Y, Oshima S, Noda K, et al. Sorafenib-induced acute myocardial infarction due to coronary artery spasm. J Cardiol. 2009;54(3):512-515. https://doi.org/10.1016/j.jjcc.2009.03.009</mixed-citation></citation-alternatives></ref><ref id="cit181"><label>181</label><citation-alternatives><mixed-citation xml:lang="ru">Porto I, Leo A, Miele L, Pompili M, Landolf R, Crea F. A case of variant angina in a patient under chronic treatment with sorafenib. Nat Rev Clin Oncol. 2010;7(8):476-480. https://doi.org/10.1038/nrclinonc.2010.67</mixed-citation><mixed-citation xml:lang="en">Porto I, Leo A, Miele L, Pompili M, Landolf R, Crea F. A case of variant angina in a patient under chronic treatment with sorafenib. Nat Rev Clin Oncol. 2010;7(8):476-480. https://doi.org/10.1038/nrclinonc.2010.67</mixed-citation></citation-alternatives></ref><ref id="cit182"><label>182</label><citation-alternatives><mixed-citation xml:lang="ru">Naib T, Steingart RM, Chen CL. Sorafenib-associated multivessel coronary artery vasospasm. Herz. 2011;36(4):348-351. https://doi.org/10.1007/s00059-011-3444-5</mixed-citation><mixed-citation xml:lang="en">Naib T, Steingart RM, Chen CL. Sorafenib-associated multivessel coronary artery vasospasm. Herz. 2011;36(4):348-351. https://doi.org/10.1007/s00059-011-3444-5</mixed-citation></citation-alternatives></ref><ref id="cit183"><label>183</label><citation-alternatives><mixed-citation xml:lang="ru">Franco TH, Khan A, Joshi V, Thomas B. Takotsubo cardiomyopathy in two men receiving bevacizumab for metastatic cancer. Ther Clin Risk Manag. 2008;4(6):1367-1370. https://doi.org/10.2147/tcrm.s3960</mixed-citation><mixed-citation xml:lang="en">Franco TH, Khan A, Joshi V, Thomas B. Takotsubo cardiomyopathy in two men receiving bevacizumab for metastatic cancer. Ther Clin Risk Manag. 2008;4(6):1367-1370. https://doi.org/10.2147/tcrm.s3960</mixed-citation></citation-alternatives></ref><ref id="cit184"><label>184</label><citation-alternatives><mixed-citation xml:lang="ru">Numico G, Sicuro M, Silvestris N, et al. Takotsubo syndrome in a patient treated with sunitinib for renal cancer. J Clin Oncol. 2012;30(24):e218-e220. https://doi.org/10.1200/JCO.2012.42.4911</mixed-citation><mixed-citation xml:lang="en">Numico G, Sicuro M, Silvestris N, et al. Takotsubo syndrome in a patient treated with sunitinib for renal cancer. J Clin Oncol. 2012;30(24):e218-e220. https://doi.org/10.1200/JCO.2012.42.4911</mixed-citation></citation-alternatives></ref><ref id="cit185"><label>185</label><citation-alternatives><mixed-citation xml:lang="ru">Sen F, Yildiz I, Basaran M, et al. Impaired coronary ﬂow reserve in metastatic cancer patients treated with sunitinib. J BUON. 2013;18(3):775-781.</mixed-citation><mixed-citation xml:lang="en">Sen F, Yildiz I, Basaran M, et al. Impaired coronary ﬂow reserve in metastatic cancer patients treated with sunitinib. J BUON. 2013;18(3):775-781.</mixed-citation></citation-alternatives></ref><ref id="cit186"><label>186</label><citation-alternatives><mixed-citation xml:lang="ru">Chintalgattu V, Rees ML, Culver JC, et al. Coronary microvascular pericytes are the cellular target of sunitinib malate-induced cardiotoxicity. Sci Transl Med. 2013;5(187):187ra69. https://doi.org/10.1126/scitranslmed.3005066</mixed-citation><mixed-citation xml:lang="en">Chintalgattu V, Rees ML, Culver JC, et al. Coronary microvascular pericytes are the cellular target of sunitinib malate-induced cardiotoxicity. Sci Transl Med. 2013;5(187):187ra69. https://doi.org/10.1126/scitranslmed.3005066</mixed-citation></citation-alternatives></ref><ref id="cit187"><label>187</label><citation-alternatives><mixed-citation xml:lang="ru">van der Veldt AA, de Boer MP, Boven E, et al. Reduction in skin microvascular density and changes in vessel morphology in patients treated with sunitinib. Anticancer Drugs. 2010;21(4):439-446. https://doi.org/10.1097/CAD.0b013e3283359c79</mixed-citation><mixed-citation xml:lang="en">van der Veldt AA, de Boer MP, Boven E, et al. Reduction in skin microvascular density and changes in vessel morphology in patients treated with sunitinib. Anticancer Drugs. 2010;21(4):439-446. https://doi.org/10.1097/CAD.0b013e3283359c79</mixed-citation></citation-alternatives></ref><ref id="cit188"><label>188</label><citation-alternatives><mixed-citation xml:lang="ru">Pantaleo MA, Mandrioli A, Saponara M, et al. Development of coronary artery stenosis in a patient with metastatic renal cell carcinoma treated with sorafenib. BMC Cancer. 2012;12:231. Published 2012 Jun 11. https://doi.org/10.1186/1471-2407-12-231</mixed-citation><mixed-citation xml:lang="en">Pantaleo MA, Mandrioli A, Saponara M, et al. Development of coronary artery stenosis in a patient with metastatic renal cell carcinoma treated with sorafenib. BMC Cancer. 2012;12:231. Published 2012 Jun 11. https://doi.org/10.1186/1471-2407-12-231</mixed-citation></citation-alternatives></ref><ref id="cit189"><label>189</label><citation-alternatives><mixed-citation xml:lang="ru">Meyer T, Robles-Carrillo L, Robson T, et al. Bevacizumab immune complexes activate platelets and induce thrombosis in FCGR2A transgenic mice. J Thromb Haemost. 2009;7(1):171-181. https://doi.org/10.1111/j.1538-7836.2008.03212.x</mixed-citation><mixed-citation xml:lang="en">Meyer T, Robles-Carrillo L, Robson T, et al. Bevacizumab immune complexes activate platelets and induce thrombosis in FCGR2A transgenic mice. J Thromb Haemost. 2009;7(1):171-181. https://doi.org/10.1111/j.1538-7836.2008.03212.x</mixed-citation></citation-alternatives></ref><ref id="cit190"><label>190</label><citation-alternatives><mixed-citation xml:lang="ru">Aichberger KJ, Herndlhofer S, Schernthaner GH, et al. Progressive peripheral arterial occlusive disease and other vascular events during nilotinib therapy in CML. Am J Hematol. 2011;86(7):533-539. https://doi.org/10.1002/ajh.22037</mixed-citation><mixed-citation xml:lang="en">Aichberger KJ, Herndlhofer S, Schernthaner GH, et al. Progressive peripheral arterial occlusive disease and other vascular events during nilotinib therapy in CML. Am J Hematol. 2011;86(7):533-539. https://doi.org/10.1002/ajh.22037</mixed-citation></citation-alternatives></ref><ref id="cit191"><label>191</label><citation-alternatives><mixed-citation xml:lang="ru">Quintás-Cardama A, Kantarjian H, Cortes J. Nilotinib-associated vascular events. Clin Lymphoma Myeloma Leuk. 2012;12(5):337-340. https://doi.org/10.1016/j.clml.2012.04.005</mixed-citation><mixed-citation xml:lang="en">Quintás-Cardama A, Kantarjian H, Cortes J. Nilotinib-associated vascular events. Clin Lymphoma Myeloma Leuk. 2012;12(5):337-340. https://doi.org/10.1016/j.clml.2012.04.005</mixed-citation></citation-alternatives></ref><ref id="cit192"><label>192</label><citation-alternatives><mixed-citation xml:lang="ru">Levato L, Cantaffa R, Kropp MG, Magro D, Piro E, Molica S. Progressive peripheral arterial occlusive disease and other vascular events during nilotinib therapy in chronic myeloid leukemia: a single institution study. Eur J Haematol. 2013;90(6):531-532. https://doi.org/10.1111/ejh.12096</mixed-citation><mixed-citation xml:lang="en">Levato L, Cantaffa R, Kropp MG, Magro D, Piro E, Molica S. Progressive peripheral arterial occlusive disease and other vascular events during nilotinib therapy in chronic myeloid leukemia: a single institution study. Eur J Haematol. 2013;90(6):531-532. https://doi.org/10.1111/ejh.12096</mixed-citation></citation-alternatives></ref><ref id="cit193"><label>193</label><citation-alternatives><mixed-citation xml:lang="ru">Cortes JE, Kantarjian H, Shah NP, et al. Ponatinib in refractory Philadelphia chromosome-positive leukemias. N Engl J Med. 2012;367(22):2075-2088. https://doi.org/10.1056/NEJMoa1205127</mixed-citation><mixed-citation xml:lang="en">Cortes JE, Kantarjian H, Shah NP, et al. Ponatinib in refractory Philadelphia chromosome-positive leukemias. N Engl J Med. 2012;367(22):2075-2088. https://doi.org/10.1056/NEJMoa1205127</mixed-citation></citation-alternatives></ref><ref id="cit194"><label>194</label><citation-alternatives><mixed-citation xml:lang="ru">Tefferi A. Nilotinib treatment-associated accelerated atherosclerosis: when is the risk justifed?. Leukemia. 2013;27(9):1939-1940. https://doi.org/10.1038/leu.2013.112</mixed-citation><mixed-citation xml:lang="en">Tefferi A. Nilotinib treatment-associated accelerated atherosclerosis: when is the risk justifed?. Leukemia. 2013;27(9):1939-1940. https://doi.org/10.1038/leu.2013.112</mixed-citation></citation-alternatives></ref><ref id="cit195"><label>195</label><citation-alternatives><mixed-citation xml:lang="ru">Tefferi A, Letendre L. Nilotinib treatment-associated peripheral artery disease and sudden death: yet another reason to stick to imatinib as front-line therapy for chronic myelogenous leukemia. Am J Hematol. 2011;86(7):610-611. https://doi.org/10.1002/ajh.22051</mixed-citation><mixed-citation xml:lang="en">Tefferi A, Letendre L. Nilotinib treatment-associated peripheral artery disease and sudden death: yet another reason to stick to imatinib as front-line therapy for chronic myelogenous leukemia. Am J Hematol. 2011;86(7):610-611. https://doi.org/10.1002/ajh.22051</mixed-citation></citation-alternatives></ref><ref id="cit196"><label>196</label><citation-alternatives><mixed-citation xml:lang="ru">Coon EA, Zalewski NL, Hoffman EM, Tefferi A, Flemming KD. Nilotinib treatment-associated cerebrovascular disease and stroke. Am J Hematol. 2013;88(6):534-535. https://doi.org/10.1002/ajh.23442</mixed-citation><mixed-citation xml:lang="en">Coon EA, Zalewski NL, Hoffman EM, Tefferi A, Flemming KD. Nilotinib treatment-associated cerebrovascular disease and stroke. Am J Hematol. 2013;88(6):534-535. https://doi.org/10.1002/ajh.23442</mixed-citation></citation-alternatives></ref><ref id="cit197"><label>197</label><citation-alternatives><mixed-citation xml:lang="ru">Breccia M, Colafgli G, Molica M, Alimena G. Cardiovascular risk assessments in chronic myeloid leukemia allow identifcation of patients at high risk of cardiovascular events during treatment with nilotinib. Am J Hematol. 2015;90(5):E100-E101. https://doi.org/10.1002/ajh.23976</mixed-citation><mixed-citation xml:lang="en">Breccia M, Colafgli G, Molica M, Alimena G. Cardiovascular risk assessments in chronic myeloid leukemia allow identifcation of patients at high risk of cardiovascular events during treatment with nilotinib. Am J Hematol. 2015;90(5):E100-E101. https://doi.org/10.1002/ajh.23976</mixed-citation></citation-alternatives></ref><ref id="cit198"><label>198</label><citation-alternatives><mixed-citation xml:lang="ru">Chislock EM, Ring C, Pendergast AM. Abl kinases are required for vascular function, Tie2 expression, and angiopoietin-1-mediated survival. Proc Natl Acad Sci U S A. 2013;110(30):12432-12437. https://doi.org/10.1073/pnas.1304188110</mixed-citation><mixed-citation xml:lang="en">Chislock EM, Ring C, Pendergast AM. Abl kinases are required for vascular function, Tie2 expression, and angiopoietin-1-mediated survival. Proc Natl Acad Sci U S A. 2013;110(30):12432-12437. https://doi.org/10.1073/pnas.1304188110</mixed-citation></citation-alternatives></ref><ref id="cit199"><label>199</label><citation-alternatives><mixed-citation xml:lang="ru">Teragawa H, Hondo T, Amano H, Hino F, Ohbayashi M. Adverse effects of interferon on the cardiovascular system in patients with chronic hepatitis C. Jpn Heart J. 1996;37(6):905-915. https://doi.org/10.1536/ihj.37.905</mixed-citation><mixed-citation xml:lang="en">Teragawa H, Hondo T, Amano H, Hino F, Ohbayashi M. Adverse effects of interferon on the cardiovascular system in patients with chronic hepatitis C. Jpn Heart J. 1996;37(6):905-915. https://doi.org/10.1536/ihj.37.905</mixed-citation></citation-alternatives></ref><ref id="cit200"><label>200</label><citation-alternatives><mixed-citation xml:lang="ru">Senkus E, Jassem J. Cardiovascular effects of systemic cancer treatment. Cancer Treat Rev. 2011;37(4):300-311. https://doi.org/10.1016/j.ctrv.2010.11.001</mixed-citation><mixed-citation xml:lang="en">Senkus E, Jassem J. Cardiovascular effects of systemic cancer treatment. Cancer Treat Rev. 2011;37(4):300-311. https://doi.org/10.1016/j.ctrv.2010.11.001</mixed-citation></citation-alternatives></ref><ref id="cit201"><label>201</label><citation-alternatives><mixed-citation xml:lang="ru">Kruit WH, Eggermont AM, Stoter G. Interferon-alpha induced Raynaud’s syndrome. Ann Oncol. 2000;11(11):1501-1502. https://doi.org/10.1023/a:1026586629166</mixed-citation><mixed-citation xml:lang="en">Kruit WH, Eggermont AM, Stoter G. Interferon-alpha induced Raynaud’s syndrome. Ann Oncol. 2000;11(11):1501-1502. https://doi.org/10.1023/a:1026586629166</mixed-citation></citation-alternatives></ref><ref id="cit202"><label>202</label><citation-alternatives><mixed-citation xml:lang="ru">Al-Zahrani H, Gupta V, Minden MD, Messner HA, Lipton JH. Vascular events associated with alpha interferon therapy. Leuk Lymphoma. 2003;44(3):471-475. https://doi.org/10.1080/1042819021000055066</mixed-citation><mixed-citation xml:lang="en">Al-Zahrani H, Gupta V, Minden MD, Messner HA, Lipton JH. Vascular events associated with alpha interferon therapy. Leuk Lymphoma. 2003;44(3):471-475. https://doi.org/10.1080/1042819021000055066</mixed-citation></citation-alternatives></ref><ref id="cit203"><label>203</label><citation-alternatives><mixed-citation xml:lang="ru">Thacker SG, Zhao W, Smith CK, et al. Type I interferons modulate vascular function, repair, thrombosis, and plaque progression in murine models of lupus and atherosclerosis. Arthritis Rheum. 2012;64(9):2975-2985. https://doi.org/10.1002/art.34504</mixed-citation><mixed-citation xml:lang="en">Thacker SG, Zhao W, Smith CK, et al. Type I interferons modulate vascular function, repair, thrombosis, and plaque progression in murine models of lupus and atherosclerosis. Arthritis Rheum. 2012;64(9):2975-2985. https://doi.org/10.1002/art.34504</mixed-citation></citation-alternatives></ref><ref id="cit204"><label>204</label><citation-alternatives><mixed-citation xml:lang="ru">Liang Z, Zhu J, Chen L, et al. Is androgen deprivation therapy for prostate cancer associated with cardiovascular disease? A meta-analysis and systematic review. Andrology. 2020;8(3):559-574. https://doi.org/10.1111/andr.12731</mixed-citation><mixed-citation xml:lang="en">Liang Z, Zhu J, Chen L, et al. Is androgen deprivation therapy for prostate cancer associated with cardiovascular disease? A meta-analysis and systematic review. Andrology. 2020;8(3):559-574. https://doi.org/10.1111/andr.12731</mixed-citation></citation-alternatives></ref><ref id="cit205"><label>205</label><citation-alternatives><mixed-citation xml:lang="ru">Lancellotti P, Nkomo VT, Badano LP, et al. Expert consensus for multi-modality imaging evaluation of cardiovascular complications of radiotherapy in adults: a report from the European Association of Cardiovascular Imaging and the American Society of Echocardiography [published correction appears in Eur Heart J Cardiovasc Imaging. 2013 Dec;14(12):1217]. Eur Heart J Cardiovasc Imaging. 2013;14(8):721-740. https://doi.org/10.1093/ehjci/jet123</mixed-citation><mixed-citation xml:lang="en">Lancellotti P, Nkomo VT, Badano LP, et al. Expert consensus for multi-modality imaging evaluation of cardiovascular complications of radiotherapy in adults: a report from the European Association of Cardiovascular Imaging and the American Society of Echocardiography [published correction appears in Eur Heart J Cardiovasc Imaging. 2013 Dec;14(12):1217]. Eur Heart J Cardiovasc Imaging. 2013;14(8):721-740. https://doi.org/10.1093/ehjci/jet123</mixed-citation></citation-alternatives></ref><ref id="cit206"><label>206</label><citation-alternatives><mixed-citation xml:lang="ru">Visseren FLJ, Mach F, Smulders YM, et al. 2021 ESC Guidelines on cardiovascular disease prevention in clinical practice. Eur Heart J. 2021;42(34):3227-3337. https://doi.org/10.1093/eurheartj/ehab484</mixed-citation><mixed-citation xml:lang="en">Visseren FLJ, Mach F, Smulders YM, et al. 2021 ESC Guidelines on cardiovascular disease prevention in clinical practice. Eur Heart J. 2021;42(34):3227-3337. https://doi.org/10.1093/eurheartj/ehab484</mixed-citation></citation-alternatives></ref><ref id="cit207"><label>207</label><citation-alternatives><mixed-citation xml:lang="ru">Clasen SC, Ky B, O’Quinn R, Giantonio B, Teitelbaum U, Carver JR. Fluoropyrimidine-induced cardiac toxicity: challenging the current paradigm. J Gastrointest Oncol. 2017;8(6):970-979. https://doi.org/10.21037/jgo.2017.09.07</mixed-citation><mixed-citation xml:lang="en">Clasen SC, Ky B, O’Quinn R, Giantonio B, Teitelbaum U, Carver JR. Fluoropyrimidine-induced cardiac toxicity: challenging the current paradigm. J Gastrointest Oncol. 2017;8(6):970-979. https://doi.org/10.21037/jgo.2017.09.07</mixed-citation></citation-alternatives></ref><ref id="cit208"><label>208</label><citation-alternatives><mixed-citation xml:lang="ru">РЕКОМЕНДАЦИИ ЕОК ПО ВЕДЕНИЮ ПАЦИЕНТОВ С ОСТРЫМ ИНФАРКТОМ МИОКАРДА С ПОДЪЕМОМ СЕГМЕНТА ST 2017. Российский кардиологический журнал. 2018;(5):103-158. https://doi.org/10.15829/1560-4071-2018-5-103-158</mixed-citation><mixed-citation xml:lang="en">РЕКОМЕНДАЦИИ ЕОК ПО ВЕДЕНИЮ ПАЦИЕНТОВ С ОСТРЫМ ИНФАРКТОМ МИОКАРДА С ПОДЪЕМОМ СЕГМЕНТА ST 2017. Российский кардиологический журнал. 2018;(5):103-158. https://doi.org/10.15829/1560-4071-2018-5-103-158</mixed-citation></citation-alternatives></ref><ref id="cit209"><label>209</label><citation-alternatives><mixed-citation xml:lang="ru">Iliescu C, Grines CL, Herrmann J, et al. SCAI expert consensus statement: Evaluation, management, and special considerations of cardio-oncology patients in the cardiac catheterization laboratory (Endorsed by the Cardiological Society of India, and Sociedad Latino Americana de Cardiologıa Intervencionista). Catheter Cardiovasc Interv. 2016;87(5):895-899. https://doi.org/10.1002/ccd.26375</mixed-citation><mixed-citation xml:lang="en">Iliescu C, Grines CL, Herrmann J, et al. SCAI expert consensus statement: Evaluation, management, and special considerations of cardio-oncology patients in the cardiac catheterization laboratory (Endorsed by the Cardiological Society of India, and Sociedad Latino Americana de Cardiologıa Intervencionista). Catheter Cardiovasc Interv. 2016;87(5):895-899. https://doi.org/10.1002/ccd.26375</mixed-citation></citation-alternatives></ref><ref id="cit210"><label>210</label><citation-alternatives><mixed-citation xml:lang="ru">Knuuti J, Wijns W, Saraste A, Capodanno D, et al. 2019 ESC Guidelines for the diagnosis and management of chronic coronary syndromes. ESC Scientifc Document Group.Eur Heart J. 2020 Jan 14;41(3):407-477. https://doi.org/10.1093/eurheartj/ehz425</mixed-citation><mixed-citation xml:lang="en">Knuuti J, Wijns W, Saraste A, Capodanno D, et al. 2019 ESC Guidelines for the diagnosis and management of chronic coronary syndromes. ESC Scientifc Document Group.Eur Heart J. 2020 Jan 14;41(3):407-477. https://doi.org/10.1093/eurheartj/ehz425</mixed-citation></citation-alternatives></ref><ref id="cit211"><label>211</label><citation-alternatives><mixed-citation xml:lang="ru">NCD Risk Factor Collaboration (NCD-RisC). Worldwide trends in blood pressure from 1975 to 2015: a pooled analysis of 1479 populationbased measurement studies with 19·1 million participants [published correction appears in Lancet. 2020 Sep 26;396(10255):886]. Lancet. 2017;389(10064):37-55. https://doi.org/10.1016/S0140-6736(16)31919-5</mixed-citation><mixed-citation xml:lang="en">NCD Risk Factor Collaboration (NCD-RisC). Worldwide trends in blood pressure from 1975 to 2015: a pooled analysis of 1479 populationbased measurement studies with 19·1 million participants [published correction appears in Lancet. 2020 Sep 26;396(10255):886]. Lancet. 2017;389(10064):37-55. https://doi.org/10.1016/S0140-6736(16)31919-5</mixed-citation></citation-alternatives></ref><ref id="cit212"><label>212</label><citation-alternatives><mixed-citation xml:lang="ru">Arima H, Barzi F, Chalmers J. Mortality patterns in hypertension. J Hypertens. 2011;29 Suppl 1:S3-S7. https://doi.org/10.1097/01.hjh.0000410246.59221.b1</mixed-citation><mixed-citation xml:lang="en">Arima H, Barzi F, Chalmers J. Mortality patterns in hypertension. J Hypertens. 2011;29 Suppl 1:S3-S7. https://doi.org/10.1097/01.hjh.0000410246.59221.b1</mixed-citation></citation-alternatives></ref><ref id="cit213"><label>213</label><citation-alternatives><mixed-citation xml:lang="ru">Hidayat K, Du X, Zou SY, Shi BM. Blood pressure and kidney cancer risk: meta-analysis of prospective studies. J Hypertens. 2017;35(7):1333-1344. https://doi.org/10.1097/HJH.0000000000001286</mixed-citation><mixed-citation xml:lang="en">Hidayat K, Du X, Zou SY, Shi BM. Blood pressure and kidney cancer risk: meta-analysis of prospective studies. J Hypertens. 2017;35(7):1333-1344. https://doi.org/10.1097/HJH.0000000000001286</mixed-citation></citation-alternatives></ref><ref id="cit214"><label>214</label><citation-alternatives><mixed-citation xml:lang="ru">Christakoudi S, Kakourou A, Markozannes G, et al. Blood pressure and risk of cancer in the European Prospective Investigation into Cancer and Nutrition. Int J Cancer. 2020;146(10):2680-2693. https://doi.org/10.1002/ijc.32576</mixed-citation><mixed-citation xml:lang="en">Christakoudi S, Kakourou A, Markozannes G, et al. Blood pressure and risk of cancer in the European Prospective Investigation into Cancer and Nutrition. Int J Cancer. 2020;146(10):2680-2693. https://doi.org/10.1002/ijc.32576</mixed-citation></citation-alternatives></ref><ref id="cit215"><label>215</label><citation-alternatives><mixed-citation xml:lang="ru">Petrelli F, Ghidini A, Cabiddu M, et al. Effects of hypertension on cancer survival: A meta-analysis. Eur J Clin Invest. 2021;51(6):e13493. https://doi.org/10.1111/eci.13493</mixed-citation><mixed-citation xml:lang="en">Petrelli F, Ghidini A, Cabiddu M, et al. Effects of hypertension on cancer survival: A meta-analysis. Eur J Clin Invest. 2021;51(6):e13493. https://doi.org/10.1111/eci.13493</mixed-citation></citation-alternatives></ref><ref id="cit216"><label>216</label><citation-alternatives><mixed-citation xml:lang="ru">Piccirillo JF, Tierney RM, Costas I, Grove L, Spitznagel EL Jr. Prognostic importance of comorbidity in a hospital-based cancer registry. JAMA. 2004;291(20):2441-2447. https://doi.org/10.1001/jama.291.20.2441</mixed-citation><mixed-citation xml:lang="en">Piccirillo JF, Tierney RM, Costas I, Grove L, Spitznagel EL Jr. Prognostic importance of comorbidity in a hospital-based cancer registry. JAMA. 2004;291(20):2441-2447. https://doi.org/10.1001/jama.291.20.2441</mixed-citation></citation-alternatives></ref><ref id="cit217"><label>217</label><citation-alternatives><mixed-citation xml:lang="ru">Kidoguchi S, Sugano N, Tokudome G, et al. New Concept of OncoHypertension and Future Perspectives. Hypertension. 2021;77(1):16-27. https://doi.org/10.1161/HYPERTENSIONAHA.120.16044</mixed-citation><mixed-citation xml:lang="en">Kidoguchi S, Sugano N, Tokudome G, et al. New Concept of OncoHypertension and Future Perspectives. Hypertension. 2021;77(1):16-27. https://doi.org/10.1161/HYPERTENSIONAHA.120.16044</mixed-citation></citation-alternatives></ref><ref id="cit218"><label>218</label><citation-alternatives><mixed-citation xml:lang="ru">Cai J, Ma H, Huang F, et al. Correlation of bevacizumab-induced hypertension and outcomes of metastatic colorectal cancer patients treated with bevacizumab: a systematic review and meta-analysis. World J Surg Oncol. 2013;11:306. Published 2013 Nov 28. https://doi.org/10.1186/1477-7819-11-306</mixed-citation><mixed-citation xml:lang="en">Cai J, Ma H, Huang F, et al. Correlation of bevacizumab-induced hypertension and outcomes of metastatic colorectal cancer patients treated with bevacizumab: a systematic review and meta-analysis. World J Surg Oncol. 2013;11:306. Published 2013 Nov 28. https://doi.org/10.1186/1477-7819-11-306</mixed-citation></citation-alternatives></ref><ref id="cit219"><label>219</label><citation-alternatives><mixed-citation xml:lang="ru">Liu Y, Zhou L, Chen Y, et al. Hypertension as a prognostic factor in metastatic renal cell carcinoma treated with tyrosine kinase inhibitors: a systematic review and meta-analysis. BMC Urol. 2019;19(1):49. Published 2019 Jun 7. https://doi.org/10.1186/s12894-019-0481-5</mixed-citation><mixed-citation xml:lang="en">Liu Y, Zhou L, Chen Y, et al. Hypertension as a prognostic factor in metastatic renal cell carcinoma treated with tyrosine kinase inhibitors: a systematic review and meta-analysis. BMC Urol. 2019;19(1):49. Published 2019 Jun 7. https://doi.org/10.1186/s12894-019-0481-5</mixed-citation></citation-alternatives></ref><ref id="cit220"><label>220</label><citation-alternatives><mixed-citation xml:lang="ru">Чазова И.Е., Жернакова Ю.В. от имени экспертов. Клинические рекомендации. Диагностика и лечение артериальной гипертонии. Системные гипертензии. 2019; 16(1):6–31. https://doi.org/10.26442/2075082X.2019.1.190179.</mixed-citation><mixed-citation xml:lang="en">Chazova I.E., Zhernakova Yu.V. on behalf of the experts. Clinical guidelines. Diagnosis and treatment of arterial hypertension. Systemic Hypertension. 2019; 16 (1): 6–31. https://doi.org/10.26442/2075082X.2019.1.190179</mixed-citation></citation-alternatives></ref><ref id="cit221"><label>221</label><citation-alternatives><mixed-citation xml:lang="ru">Mir O, Coriat R, Ropert S, et al. Treatment of bevacizumab-induced hypertension by amlodipine. Invest New Drugs. 2012;30(2):702-707. https://doi.org/10.1007/s10637-010-9549-5</mixed-citation><mixed-citation xml:lang="en">Mir O, Coriat R, Ropert S, et al. Treatment of bevacizumab-induced hypertension by amlodipine. Invest New Drugs. 2012;30(2):702-707. https://doi.org/10.1007/s10637-010-9549-5</mixed-citation></citation-alternatives></ref><ref id="cit222"><label>222</label><citation-alternatives><mixed-citation xml:lang="ru">Nazer B, Humphreys BD, Moslehi J. Effects of novel angiogenesis inhibitors for the treatment of cancer on the cardiovascular system: focus on hypertension. Circulation. 2011;124(15):1687-1691. https://doi.org/10.1161/CIRCULATIONAHA.110.992230</mixed-citation><mixed-citation xml:lang="en">Nazer B, Humphreys BD, Moslehi J. Effects of novel angiogenesis inhibitors for the treatment of cancer on the cardiovascular system: focus on hypertension. Circulation. 2011;124(15):1687-1691. https://doi.org/10.1161/CIRCULATIONAHA.110.992230</mixed-citation></citation-alternatives></ref><ref id="cit223"><label>223</label><citation-alternatives><mixed-citation xml:lang="ru">McKay RR, Rodriguez GE, Lin X, et al. Angiotensin system inhibitors and survival outcomes in patients with metastatic renal cell carcinoma. Clin Cancer Res. 2015;21(11):2471-2479. https://doi.org/10.1158/1078-0432.CCR-14-2332</mixed-citation><mixed-citation xml:lang="en">McKay RR, Rodriguez GE, Lin X, et al. Angiotensin system inhibitors and survival outcomes in patients with metastatic renal cell carcinoma. Clin Cancer Res. 2015;21(11):2471-2479. https://doi.org/10.1158/1078-0432.CCR-14-2332</mixed-citation></citation-alternatives></ref><ref id="cit224"><label>224</label><citation-alternatives><mixed-citation xml:lang="ru">Araújo WF, Naves MA, Ravanini JN, Schor N, Teixeira VP. Renin-angiotensin system (RAS) blockade attenuates growth and metastatic potential of renal cell carcinoma in mice. Urol Oncol. 2015;33(9):389.e1-389.e3897. https://doi.org/10.1016/j.urolonc.2014.11.022</mixed-citation><mixed-citation xml:lang="en">Araújo WF, Naves MA, Ravanini JN, Schor N, Teixeira VP. Renin-angiotensin system (RAS) blockade attenuates growth and metastatic potential of renal cell carcinoma in mice. Urol Oncol. 2015;33(9):389.e1-389.e3897. https://doi.org/10.1016/j.urolonc.2014.11.022</mixed-citation></citation-alternatives></ref><ref id="cit225"><label>225</label><citation-alternatives><mixed-citation xml:lang="ru">Romitan DM, Rădulescu D, Berindan-Neagoe I, et al. Cardiomyopathies and Arrhythmias Induced by Cancer Therapies. Biomedicines. 2020;8(11):496. Published 2020 Nov 12. https://doi.org/10.3390/biomedicines8110496</mixed-citation><mixed-citation xml:lang="en">Romitan DM, Rădulescu D, Berindan-Neagoe I, et al. Cardiomyopathies and Arrhythmias Induced by Cancer Therapies. Biomedicines. 2020;8(11):496. Published 2020 Nov 12. https://doi.org/10.3390/biomedicines8110496</mixed-citation></citation-alternatives></ref><ref id="cit226"><label>226</label><citation-alternatives><mixed-citation xml:lang="ru">Asteggiano R., Norbiato C., Marengo S., Parrini I. Cancer and arrhythmias. e-Journal of Cardiology Practice. 2021 May 05;19(21).</mixed-citation><mixed-citation xml:lang="en">Asteggiano R., Norbiato C., Marengo S., Parrini I. Cancer and arrhythmias. e-Journal of Cardiology Practice. 2021 May 05;19(21).</mixed-citation></citation-alternatives></ref><ref id="cit227"><label>227</label><citation-alternatives><mixed-citation xml:lang="ru">Yeh ET, Bickford CL. Cardiovascular complications of cancer therapy: incidence, pathogenesis, diagnosis, and management. J Am Coll Cardiol. 2009;53(24):2231-2247. https://doi.org/10.1016/j.jacc.2009.02.050</mixed-citation><mixed-citation xml:lang="en">Yeh ET, Bickford CL. Cardiovascular complications of cancer therapy: incidence, pathogenesis, diagnosis, and management. J Am Coll Cardiol. 2009;53(24):2231-2247. https://doi.org/10.1016/j.jacc.2009.02.050</mixed-citation></citation-alternatives></ref><ref id="cit228"><label>228</label><citation-alternatives><mixed-citation xml:lang="ru">Tamargo J, Caballero R, Delpón E. Cancer chemotherapy and cardiac arrhythmias: a review. Drug Saf. 2015 Feb;38(2):129-52. https://doi.org/10.1007/s40264-014-0258-4 PMID: 25577497.</mixed-citation><mixed-citation xml:lang="en">Tamargo J, Caballero R, Delpón E. Cancer chemotherapy and cardiac arrhythmias: a review. Drug Saf. 2015 Feb;38(2):129-52. https://doi.org/10.1007/s40264-014-0258-4 PMID: 25577497.</mixed-citation></citation-alternatives></ref><ref id="cit229"><label>229</label><citation-alternatives><mixed-citation xml:lang="ru">Rautaharju PM, Surawicz B, Gettes LS, et al. AHA/ACCF/HRS recommendations for the standardization and interpretation of the electrocardiogram: part IV: the ST segment, T and U waves, and the QT interval: a scientifc statement from the American Heart Association Electrocardiography and Arrhythmias Committee, Council on Clinical Cardiology; the American College of Cardiology Foundation; and the Heart Rhythm Society. Endorsed by the International Society for Computerized Electrocardiology. J Am Coll Cardiol. 2009;53(11):982-991. https://doi.org/10.1016/j.jacc.2008.12.014</mixed-citation><mixed-citation xml:lang="en">Rautaharju PM, Surawicz B, Gettes LS, et al. AHA/ACCF/HRS recommendations for the standardization and interpretation of the electrocardiogram: part IV: the ST segment, T and U waves, and the QT interval: a scientifc statement from the American Heart Association Electrocardiography and Arrhythmias Committee, Council on Clinical Cardiology; the American College of Cardiology Foundation; and the Heart Rhythm Society. Endorsed by the International Society for Computerized Electrocardiology. J Am Coll Cardiol. 2009;53(11):982-991. https://doi.org/10.1016/j.jacc.2008.12.014</mixed-citation></citation-alternatives></ref><ref id="cit230"><label>230</label><citation-alternatives><mixed-citation xml:lang="ru">Infante JR, Cassier PA, Gerecitano JF, et al. A Phase I Study of the CyclinDependent Kinase 4/6 Inhibitor Ribociclib (LEE011) in Patients with Advanced Solid Tumors and Lymphomas. Clin Cancer Res. 2016;22(23):5696-5705. https://doi.org/10.1158/1078-0432.CCR-16-1248</mixed-citation><mixed-citation xml:lang="en">Infante JR, Cassier PA, Gerecitano JF, et al. A Phase I Study of the CyclinDependent Kinase 4/6 Inhibitor Ribociclib (LEE011) in Patients with Advanced Solid Tumors and Lymphomas. Clin Cancer Res. 2016;22(23):5696-5705. https://doi.org/10.1158/1078-0432.CCR-16-1248</mixed-citation></citation-alternatives></ref><ref id="cit231"><label>231</label><citation-alternatives><mixed-citation xml:lang="ru">Al-Khatib SM, Stevenson WG, Ackerman MJ, et al. 2017 AHA/ACC/HRS guideline for management of patients with ventricular arrhythmias and the prevention of sudden cardiac death: Executive summary: A Report of the American College of Cardiology/American Heart Association Task Force on Clinical Practice Guidelines and the Heart Rhythm Society [published correction appears in Heart Rhythm. 2018 Sep 26;:]. Heart Rhythm. 2018;15(10):e190-e252. https://doi.org/10.1016/j.hrthm.2017.10.035</mixed-citation><mixed-citation xml:lang="en">Al-Khatib SM, Stevenson WG, Ackerman MJ, et al. 2017 AHA/ACC/HRS guideline for management of patients with ventricular arrhythmias and the prevention of sudden cardiac death: Executive summary: A Report of the American College of Cardiology/American Heart Association Task Force on Clinical Practice Guidelines and the Heart Rhythm Society [published correction appears in Heart Rhythm. 2018 Sep 26;:]. Heart Rhythm. 2018;15(10):e190-e252. https://doi.org/10.1016/j.hrthm.2017.10.035</mixed-citation></citation-alternatives></ref><ref id="cit232"><label>232</label><citation-alternatives><mixed-citation xml:lang="ru">Mazur M, Wang F, Hodge DO, et al. Burden of Cardiac Arrhythmias in Patients With Anthracycline-Related Cardiomyopathy. JACC Clin Electrophysiol. 2017;3(2):139-150. https://doi.org/10.1016/j.jacep.2016.08.009</mixed-citation><mixed-citation xml:lang="en">Mazur M, Wang F, Hodge DO, et al. Burden of Cardiac Arrhythmias in Patients With Anthracycline-Related Cardiomyopathy. JACC Clin Electrophysiol. 2017;3(2):139-150. https://doi.org/10.1016/j.jacep.2016.08.009</mixed-citation></citation-alternatives></ref><ref id="cit233"><label>233</label><citation-alternatives><mixed-citation xml:lang="ru">Abdel-Rahman O. Toxicity patterns associated with chemotherapy/immune checkpoint inhibitor combinations: a meta-analysis. Immunotherapy. 2019;11(6):543-554. https://doi.org/10.2217/imt-2018-0186</mixed-citation><mixed-citation xml:lang="en">Abdel-Rahman O. Toxicity patterns associated with chemotherapy/immune checkpoint inhibitor combinations: a meta-analysis. Immunotherapy. 2019;11(6):543-554. https://doi.org/10.2217/imt-2018-0186</mixed-citation></citation-alternatives></ref><ref id="cit234"><label>234</label><citation-alternatives><mixed-citation xml:lang="ru">Guha A, Derbala MH, Zhao Q, et al. Ventricular Arrhythmias Following Ibrutinib Initiation for Lymphoid Malignancies. J Am Coll Cardiol. 2018;72(6):697-698. https://doi.org/10.1016/j.jacc.2018.06.002</mixed-citation><mixed-citation xml:lang="en">Guha A, Derbala MH, Zhao Q, et al. Ventricular Arrhythmias Following Ibrutinib Initiation for Lymphoid Malignancies. J Am Coll Cardiol. 2018;72(6):697-698. https://doi.org/10.1016/j.jacc.2018.06.002</mixed-citation></citation-alternatives></ref><ref id="cit235"><label>235</label><citation-alternatives><mixed-citation xml:lang="ru">Lip GY, Nieuwlaat R, Pisters R, Lane DA, Crijns HJ. Refning clinical risk stratifcation for predicting stroke and thromboembolism in atrial fbrillation using a novel risk factor-based approach: the euro heart survey on atrial fbrillation. Chest. 2010;137(2):263-272. https://doi.org/10.1378/chest.09-1584</mixed-citation><mixed-citation xml:lang="en">Lip GY, Nieuwlaat R, Pisters R, Lane DA, Crijns HJ. Refning clinical risk stratifcation for predicting stroke and thromboembolism in atrial fbrillation using a novel risk factor-based approach: the euro heart survey on atrial fbrillation. Chest. 2010;137(2):263-272. https://doi.org/10.1378/chest.09-1584</mixed-citation></citation-alternatives></ref><ref id="cit236"><label>236</label><citation-alternatives><mixed-citation xml:lang="ru">Hindricks G, Potpara T, Dagres N, et al. 2020 ESC Guidelines for the diagnosis and management of atrial fbrillation developed in collaboration with the European Association for Cardio-Thoracic Surgery (EACTS): The Task Force for the diagnosis and management of atrial fbrillation of the European Society of Cardiology (ESC) Developed with the special contribution of the European Heart Rhythm Association (EHRA) of the ESC [published correction appears in Eur Heart J. 2021 Feb 1;42(5):507] [published correction appears in Eur Heart J. 2021 Feb 1;42(5):546-547] [published correction appears in Eur Heart J. 2021 Feb 1;42(5):541-543]. Eur Heart J. 2021;42(5):373-498. https://doi.org/10.1093/eurheartj/ehaa612</mixed-citation><mixed-citation xml:lang="en">Hindricks G, Potpara T, Dagres N, et al. 2020 ESC Guidelines for the diagnosis and management of atrial fbrillation developed in collaboration with the European Association for Cardio-Thoracic Surgery (EACTS): The Task Force for the diagnosis and management of atrial fbrillation of the European Society of Cardiology (ESC) Developed with the special contribution of the European Heart Rhythm Association (EHRA) of the ESC [published correction appears in Eur Heart J. 2021 Feb 1;42(5):507] [published correction appears in Eur Heart J. 2021 Feb 1;42(5):546-547] [published correction appears in Eur Heart J. 2021 Feb 1;42(5):541-543]. Eur Heart J. 2021;42(5):373-498. https://doi.org/10.1093/eurheartj/ehaa612</mixed-citation></citation-alternatives></ref><ref id="cit237"><label>237</label><citation-alternatives><mixed-citation xml:lang="ru">Friberg L, Rosenqvist M, Lip GY. Evaluation of risk stratifcation schemes for ischaemic stroke and bleeding in 182 678 patients with atrial fbrillation: the Swedish Atrial Fibrillation cohort study. Eur Heart J. 2012;33(12):1500-1510. https://doi.org/10.1093/eurheartj/ehr488</mixed-citation><mixed-citation xml:lang="en">Friberg L, Rosenqvist M, Lip GY. Evaluation of risk stratifcation schemes for ischaemic stroke and bleeding in 182 678 patients with atrial fbrillation: the Swedish Atrial Fibrillation cohort study. Eur Heart J. 2012;33(12):1500-1510. https://doi.org/10.1093/eurheartj/ehr488</mixed-citation></citation-alternatives></ref><ref id="cit238"><label>238</label><citation-alternatives><mixed-citation xml:lang="ru">Hart RG, Pearce LA, Aguilar MI. Meta-analysis: antithrombotic therapy to prevent stroke in patients who have nonvalvular atrial fbrillation. Ann Intern Med. 2007;146(12):857-867. https://doi.org/10.7326/0003-4819-146-12-200706190-00007</mixed-citation><mixed-citation xml:lang="en">Hart RG, Pearce LA, Aguilar MI. Meta-analysis: antithrombotic therapy to prevent stroke in patients who have nonvalvular atrial fbrillation. Ann Intern Med. 2007;146(12):857-867. https://doi.org/10.7326/0003-4819-146-12-200706190-00007</mixed-citation></citation-alternatives></ref><ref id="cit239"><label>239</label><citation-alternatives><mixed-citation xml:lang="ru">López-López JA, Sterne JAC, Thom HHZ, et al. Oral anticoagulants for prevention of stroke in atrial fbrillation: systematic review, network metaanalysis, and cost effectiveness analysis [published correction appears in BMJ. 2017 Dec 4;359:j5631] [published correction appears in BMJ. 2018 May 23;361:k2295]. BMJ. 2017;359:j5058. Published 2017 Nov 28. https://doi.org/10.1136/bmj.j5058</mixed-citation><mixed-citation xml:lang="en">López-López JA, Sterne JAC, Thom HHZ, et al. Oral anticoagulants for prevention of stroke in atrial fbrillation: systematic review, network metaanalysis, and cost effectiveness analysis [published correction appears in BMJ. 2017 Dec 4;359:j5631] [published correction appears in BMJ. 2018 May 23;361:k2295]. BMJ. 2017;359:j5058. Published 2017 Nov 28. https://doi.org/10.1136/bmj.j5058</mixed-citation></citation-alternatives></ref><ref id="cit240"><label>240</label><citation-alternatives><mixed-citation xml:lang="ru">Lee DH, Chandrashekhar S, Fradley MG. Electrophysiologic Complications in Cancer Patients. Methodist Debakey Cardiovasc J. 2019;15(4):282-288. https://doi.org/10.14797/mdcj-15-4-282</mixed-citation><mixed-citation xml:lang="en">Lee DH, Chandrashekhar S, Fradley MG. Electrophysiologic Complications in Cancer Patients. Methodist Debakey Cardiovasc J. 2019;15(4):282-288. https://doi.org/10.14797/mdcj-15-4-282</mixed-citation></citation-alternatives></ref><ref id="cit241"><label>241</label><citation-alternatives><mixed-citation xml:lang="ru">Limsuwan A, Pakakasama S, Rochanawutanon M, Hong-eng S. Pulmonary arterial hypertension after childhood cancer therapy and bone marrow transplantation. Cardiology. 2006;105(3):188-194. https://doi.org/10.1159/000091638</mixed-citation><mixed-citation xml:lang="en">Limsuwan A, Pakakasama S, Rochanawutanon M, Hong-eng S. Pulmonary arterial hypertension after childhood cancer therapy and bone marrow transplantation. Cardiology. 2006;105(3):188-194. https://doi.org/10.1159/000091638</mixed-citation></citation-alternatives></ref><ref id="cit242"><label>242</label><citation-alternatives><mixed-citation xml:lang="ru">Hoeper MM, Barst RJ, Bourge RC, et al. Imatinib mesylate as add-on therapy for pulmonary arterial hypertension: results of the randomized IMPRES study. Circulation. 2013;127(10):1128-1138. https://doi.org/10.1161/CIRCULATIONAHA.112.000765</mixed-citation><mixed-citation xml:lang="en">Hoeper MM, Barst RJ, Bourge RC, et al. Imatinib mesylate as add-on therapy for pulmonary arterial hypertension: results of the randomized IMPRES study. Circulation. 2013;127(10):1128-1138. https://doi.org/10.1161/CIRCULATIONAHA.112.000765</mixed-citation></citation-alternatives></ref><ref id="cit243"><label>243</label><citation-alternatives><mixed-citation xml:lang="ru">Чазова И.Е., Мартынюк Т.В. Легочная гипертензия. — М: Практика. 2015. — 928 с.</mixed-citation><mixed-citation xml:lang="en">Чазова И.Е., Мартынюк Т.В. Легочная гипертензия. — М: Практика. 2015. — 928 с.</mixed-citation></citation-alternatives></ref><ref id="cit244"><label>244</label><citation-alternatives><mixed-citation xml:lang="ru">Montani D, Bergot E, Günther S, et al. Pulmonary arterial hypertension in patients treated by dasatinib. Circulation. 2012;125(17):2128-2137. https://doi.org/10.1161/CIRCULATIONAHA.111.079921</mixed-citation><mixed-citation xml:lang="en">Montani D, Bergot E, Günther S, et al. Pulmonary arterial hypertension in patients treated by dasatinib. Circulation. 2012;125(17):2128-2137. https://doi.org/10.1161/CIRCULATIONAHA.111.079921</mixed-citation></citation-alternatives></ref><ref id="cit245"><label>245</label><citation-alternatives><mixed-citation xml:lang="ru">Dumitrescu D, Seck C, ten Freyhaus H, Gerhardt F, Erdmann E, Rosenkranz S. Fully reversible pulmonary arterial hypertension associated with dasatinib treatment for chronic myeloid leukaemia. Eur Respir J. 2011;38(1):218-220. https://doi.org/10.1183/09031936.00154210</mixed-citation><mixed-citation xml:lang="en">Dumitrescu D, Seck C, ten Freyhaus H, Gerhardt F, Erdmann E, Rosenkranz S. Fully reversible pulmonary arterial hypertension associated with dasatinib treatment for chronic myeloid leukaemia. Eur Respir J. 2011;38(1):218-220. https://doi.org/10.1183/09031936.00154210</mixed-citation></citation-alternatives></ref><ref id="cit246"><label>246</label><citation-alternatives><mixed-citation xml:lang="ru">Guignabert C, Montani D. Key roles of Src family tyrosine kinases in the integrity of the pulmonary vascular bed. Eur Respir J. 2013;41(1):3-4. https://doi.org/10.1183/09031936.00091912</mixed-citation><mixed-citation xml:lang="en">Guignabert C, Montani D. Key roles of Src family tyrosine kinases in the integrity of the pulmonary vascular bed. Eur Respir J. 2013;41(1):3-4. https://doi.org/10.1183/09031936.00091912</mixed-citation></citation-alternatives></ref><ref id="cit247"><label>247</label><citation-alternatives><mixed-citation xml:lang="ru">Simonneau G, Montani D, Celermajer DS, et al. Haemodynamic defnitions and updated clinical classifcation of pulmonary hypertension. Eur Respir J. 2019;53(1):1801913. Published 2019 Jan 24. https://doi.org/10.1183/13993003.01913-2018</mixed-citation><mixed-citation xml:lang="en">Simonneau G, Montani D, Celermajer DS, et al. Haemodynamic defnitions and updated clinical classifcation of pulmonary hypertension. Eur Respir J. 2019;53(1):1801913. Published 2019 Jan 24. https://doi.org/10.1183/13993003.01913-2018</mixed-citation></citation-alternatives></ref><ref id="cit248"><label>248</label><citation-alternatives><mixed-citation xml:lang="ru">Чазова И.Е., Мартынюк Т.В., Валиева З.С., Азизов В.А., Барбараш О.Л., Веселова Т.Н., Галявич А.С., Горбачевский С.В., Зелвеян П.А., Лазарева И.В., Мукаров М.А., Наконечников С.Н., Саидова М.А., Сарыбаев А.Ш., Стукалова О.В., Шалаев С.В., Шмальц А.А. ЕВРАЗИЙСКИЕ КЛИНИЧЕСКИЕ РЕКОМЕНДАЦИИ ПО ДИАГНОСТИКЕ И ЛЕЧЕНИЮ ЛЕГОЧНОЙ ГИПЕРТЕНЗИИ. Евразийский кардиологический журнал. 2020;(1):78-122. https://doi.org/10.38109/2225-1685-2020-1-78-122.</mixed-citation><mixed-citation xml:lang="en">Chazova I.E., Martynyuk T.V., Valieva Z.S., Azizov V.A., Barbarash O.L., Veselova T.N., Galyavich A.S., Gorbachevsky S.V., Zelveian P.A., Lazareva I.V., Mukarov M.A., Nakonetchnikov S.N., Saidova M.A., Sarybaev A.S., Stukalova O.V., Shalaev S.V., Shmalts A.A. EURASIAN CLINICAL GUIDELINES ON DIAGNOSIS AND TREATMENT OF PULMONARY HYPERTENSION. Eurasian heart journal. 2020;(1):78-122. (In Russ.) https://doi.org/10.38109/2225-1685-2020-1-78-122</mixed-citation></citation-alternatives></ref><ref id="cit249"><label>249</label><citation-alternatives><mixed-citation xml:lang="ru">Weatherald J, Chaumais MC, Savale L, et al. Long-term outcomes of dasatinib-induced pulmonary arterial hypertension: a population-based study. Eur Respir J. 2017;50(1):1700217. Published 2017 Jul 27. https://doi.org/10.1183/13993003.00217-2017</mixed-citation><mixed-citation xml:lang="en">Weatherald J, Chaumais MC, Savale L, et al. Long-term outcomes of dasatinib-induced pulmonary arterial hypertension: a population-based study. Eur Respir J. 2017;50(1):1700217. Published 2017 Jul 27. https://doi.org/10.1183/13993003.00217-2017</mixed-citation></citation-alternatives></ref><ref id="cit250"><label>250</label><citation-alternatives><mixed-citation xml:lang="ru">Ranchoux B, Günther S, Quarck R, et al. Chemotherapy-induced pulmonary hypertension: role of alkylating agents. Am J Pathol. 2015;185(2):356-371. https://doi.org/10.1016/j.ajpath.2014.10.021</mixed-citation><mixed-citation xml:lang="en">Ranchoux B, Günther S, Quarck R, et al. Chemotherapy-induced pulmonary hypertension: role of alkylating agents. Am J Pathol. 2015;185(2):356-371. https://doi.org/10.1016/j.ajpath.2014.10.021</mixed-citation></citation-alternatives></ref><ref id="cit251"><label>251</label><citation-alternatives><mixed-citation xml:lang="ru">Riou M, Seferian A, Savale L, et al. Deterioration of pulmonary hypertension and pleural effusion with bosutinib following dasatinib lung toxicity. Eur Respir J. 2016;48(5):1517-1519. https://doi.org/10.1183/13993003.01410-2016</mixed-citation><mixed-citation xml:lang="en">Riou M, Seferian A, Savale L, et al. Deterioration of pulmonary hypertension and pleural effusion with bosutinib following dasatinib lung toxicity. Eur Respir J. 2016;48(5):1517-1519. https://doi.org/10.1183/13993003.01410-2016</mixed-citation></citation-alternatives></ref><ref id="cit252"><label>252</label><citation-alternatives><mixed-citation xml:lang="ru">Hickey PM, Thompson AA, Charalampopoulos A, et al. Bosutinib therapy resulting in severe deterioration of pre-existing pulmonary arterial hypertension. Eur Respir J. 2016;48(5):1514-1516. https://doi.org/10.1183/13993003.01004-2016</mixed-citation><mixed-citation xml:lang="en">Hickey PM, Thompson AA, Charalampopoulos A, et al. Bosutinib therapy resulting in severe deterioration of pre-existing pulmonary arterial hypertension. Eur Respir J. 2016;48(5):1514-1516. https://doi.org/10.1183/13993003.01004-2016</mixed-citation></citation-alternatives></ref><ref id="cit253"><label>253</label><citation-alternatives><mixed-citation xml:lang="ru">Nishio M, Hirooka K, Dоі Y. Chinese herbal drug natural indigo may cause pulmonary artery hypertension. Eur Heart J. 2016;37(25):1992. https://doi.org/10.1093/eurheartj/ehw090</mixed-citation><mixed-citation xml:lang="en">Nishio M, Hirooka K, Dоі Y. Chinese herbal drug natural indigo may cause pulmonary artery hypertension. Eur Heart J. 2016;37(25):1992. https://doi.org/10.1093/eurheartj/ehw090</mixed-citation></citation-alternatives></ref><ref id="cit254"><label>254</label><citation-alternatives><mixed-citation xml:lang="ru">Galiè N, Humbert M, Vachiery JL, et al. 2015 ESC/ERS Guidelines for the diagnosis and treatment of pulmonary hypertension: The Joint Task Force for the Diagnosis and Treatment of Pulmonary Hypertension of the European Society of Cardiology (ESC) and the European Respiratory Society (ERS): Endorsed by: Association for European Paediatric and Congenital Cardiology (AEPC), International Society for Heart and Lung Transplantation (ISHLT) [published correction appears in Eur Respir J. 2015 Dec;46(6):1855-6]. Eur Respir J. 2015;46(4):903-975. https://doi.org/10.1183/13993003.01032-2015</mixed-citation><mixed-citation xml:lang="en">Galiè N, Humbert M, Vachiery JL, et al. 2015 ESC/ERS Guidelines for the diagnosis and treatment of pulmonary hypertension: The Joint Task Force for the Diagnosis and Treatment of Pulmonary Hypertension of the European Society of Cardiology (ESC) and the European Respiratory Society (ERS): Endorsed by: Association for European Paediatric and Congenital Cardiology (AEPC), International Society for Heart and Lung Transplantation (ISHLT) [published correction appears in Eur Respir J. 2015 Dec;46(6):1855-6]. Eur Respir J. 2015;46(4):903-975. https://doi.org/10.1183/13993003.01032-2015</mixed-citation></citation-alternatives></ref><ref id="cit255"><label>255</label><citation-alternatives><mixed-citation xml:lang="ru">Karimi M, Cohan N. Cancer-associated thrombosis. Open Cardiovasc Med J. 2010;4:78-82. Published 2010 Feb 23. https://doi.org/10.2174/1874192401004020078</mixed-citation><mixed-citation xml:lang="en">Karimi M, Cohan N. Cancer-associated thrombosis. Open Cardiovasc Med J. 2010;4:78-82. Published 2010 Feb 23. https://doi.org/10.2174/1874192401004020078</mixed-citation></citation-alternatives></ref><ref id="cit256"><label>256</label><citation-alternatives><mixed-citation xml:lang="ru">Rickles FR. Mechanisms of cancer-induced thrombosis in cancer. Pathophysiol Haemost Thromb. 2006;35(1-2):103-110. https://doi.org/10.1159/000093551</mixed-citation><mixed-citation xml:lang="en">Rickles FR. Mechanisms of cancer-induced thrombosis in cancer. Pathophysiol Haemost Thromb. 2006;35(1-2):103-110. https://doi.org/10.1159/000093551</mixed-citation></citation-alternatives></ref><ref id="cit257"><label>257</label><citation-alternatives><mixed-citation xml:lang="ru">Green KB, Silverstein RL. Hypercoagulability in cancer. Hematol Oncol Clin North Am. 1996;10(2):499-530. https://doi.org/10.1016/s0889-8588(05)70349-x</mixed-citation><mixed-citation xml:lang="en">Green KB, Silverstein RL. Hypercoagulability in cancer. Hematol Oncol Clin North Am. 1996;10(2):499-530. https://doi.org/10.1016/s0889-8588(05)70349-x</mixed-citation></citation-alternatives></ref><ref id="cit258"><label>258</label><citation-alternatives><mixed-citation xml:lang="ru">Hillen HF. Thrombosis in cancer patients. Ann Oncol. 2000;11 Suppl 3:273-276. https://doi.org/10.1093/annonc/11.suppl_3.273</mixed-citation><mixed-citation xml:lang="en">Hillen HF. Thrombosis in cancer patients. Ann Oncol. 2000;11 Suppl 3:273-276. https://doi.org/10.1093/annonc/11.suppl_3.273</mixed-citation></citation-alternatives></ref><ref id="cit259"><label>259</label><citation-alternatives><mixed-citation xml:lang="ru">Levine M, Kakkar AK. Catheter-associated thrombosis: thromboprophylaxis or not?. J Clin Oncol. 2005;23(18):4006-4008. https://doi.org/10.1200/JCO.2005.12.901</mixed-citation><mixed-citation xml:lang="en">Levine M, Kakkar AK. Catheter-associated thrombosis: thromboprophylaxis or not?. J Clin Oncol. 2005;23(18):4006-4008. https://doi.org/10.1200/JCO.2005.12.901</mixed-citation></citation-alternatives></ref><ref id="cit260"><label>260</label><citation-alternatives><mixed-citation xml:lang="ru">Falanga A, Rickles FR. Pathophysiology of the thrombophilic state in the cancer patient. Semin Thromb Hemost. 1999;25(2):173-182. https://doi.org/10.1055/s-2007-994919</mixed-citation><mixed-citation xml:lang="en">Falanga A, Rickles FR. Pathophysiology of the thrombophilic state in the cancer patient. Semin Thromb Hemost. 1999;25(2):173-182. https://doi.org/10.1055/s-2007-994919</mixed-citation></citation-alternatives></ref><ref id="cit261"><label>261</label><citation-alternatives><mixed-citation xml:lang="ru">Moore RA, Adel N, Riedel E, et al. High incidence of thromboembolic events in patients treated with cisplatin-based chemotherapy: a large retrospective analysis. J Clin Oncol. 2011;29(25):3466-3473. https://doi.org/10.1200/JCO.2011.35.5669</mixed-citation><mixed-citation xml:lang="en">Moore RA, Adel N, Riedel E, et al. High incidence of thromboembolic events in patients treated with cisplatin-based chemotherapy: a large retrospective analysis. J Clin Oncol. 2011;29(25):3466-3473. https://doi.org/10.1200/JCO.2011.35.5669</mixed-citation></citation-alternatives></ref><ref id="cit262"><label>262</label><citation-alternatives><mixed-citation xml:lang="ru">Authors/Task Force members, Windecker S, Kolh P, et al. 2014 ESC/EACTS Guidelines on myocardial revascularization: The Task Force on Myocardial Revascularization of the European Society of Cardiology (ESC) and the European Association for Cardio-Thoracic Surgery (EACTS)Developed with the special contribution of the European Association of Percutaneous Cardiovascular Interventions (EAPCI). Eur Heart J. 2014;35(37):2541-2619. https://doi.org/10.1093/eurheartj/ehu278</mixed-citation><mixed-citation xml:lang="en">Authors/Task Force members, Windecker S, Kolh P, et al. 2014 ESC/EACTS Guidelines on myocardial revascularization: The Task Force on Myocardial Revascularization of the European Society of Cardiology (ESC) and the European Association for Cardio-Thoracic Surgery (EACTS)Developed with the special contribution of the European Association of Percutaneous Cardiovascular Interventions (EAPCI). Eur Heart J. 2014;35(37):2541-2619. https://doi.org/10.1093/eurheartj/ehu278</mixed-citation></citation-alternatives></ref><ref id="cit263"><label>263</label><citation-alternatives><mixed-citation xml:lang="ru">Roff M, Patrono C, Collet JP, et al. 2015 ESC Guidelines for the management of acute coronary syndromes in patients presenting without persistent STsegment elevation: Task Force for the Management of Acute Coronary Syndromes in Patients Presenting without Persistent ST-Segment Elevation of the European Society of Cardiology (ESC). Eur Heart J. 2016;37(3):267-315. https://doi.org/10.1093/eurheartj/ehv320</mixed-citation><mixed-citation xml:lang="en">Roff M, Patrono C, Collet JP, et al. 2015 ESC Guidelines for the management of acute coronary syndromes in patients presenting without persistent STsegment elevation: Task Force for the Management of Acute Coronary Syndromes in Patients Presenting without Persistent ST-Segment Elevation of the European Society of Cardiology (ESC). Eur Heart J. 2016;37(3):267-315. https://doi.org/10.1093/eurheartj/ehv320</mixed-citation></citation-alternatives></ref><ref id="cit264"><label>264</label><citation-alternatives><mixed-citation xml:lang="ru">Levine GN, Bates ER, Bittl JA, et al. 2016 ACC/AHA Guideline Focused Update on Duration of Dual Antiplatelet Therapy in Patients With Coronary Artery Disease: A Report of the American College of Cardiology/American Heart Association Task Force on Clinical Practice Guidelines: An Update of the 2011 ACCF/AHA/SCAI Guideline for Percutaneous Coronary Intervention, 2011 ACCF/AHA Guideline for Coronary Artery Bypass Graft Surgery, 2012 ACC/AHA/ACP/AATS/PCNA/SCAI/STS Guideline for the Diagnosis and Management of Patients With Stable Ischemic Heart Disease, 2013 ACCF/AHA Guideline for the Management of ST-Elevation Myocardial Infarction, 2014 AHA/ACC Guideline for the Management of Patients With Non-STElevation Acute Coronary Syndromes, and 2014 ACC/AHA Guideline on Perioperative Cardiovascular Evaluation and Management of Patients Undergoing Noncardiac Surgery [published correction appears in Circulation. 2016 Sep 6;134(10):e192-4]. Circulation. 2016;134(10):e123-e155. https://doi.org/10.1161/CIR.0000000000000404</mixed-citation><mixed-citation xml:lang="en">Levine GN, Bates ER, Bittl JA, et al. 2016 ACC/AHA Guideline Focused Update on Duration of Dual Antiplatelet Therapy in Patients With Coronary Artery Disease: A Report of the American College of Cardiology/American Heart Association Task Force on Clinical Practice Guidelines: An Update of the 2011 ACCF/AHA/SCAI Guideline for Percutaneous Coronary Intervention, 2011 ACCF/AHA Guideline for Coronary Artery Bypass Graft Surgery, 2012 ACC/AHA/ACP/AATS/PCNA/SCAI/STS Guideline for the Diagnosis and Management of Patients With Stable Ischemic Heart Disease, 2013 ACCF/AHA Guideline for the Management of ST-Elevation Myocardial Infarction, 2014 AHA/ACC Guideline for the Management of Patients With Non-STElevation Acute Coronary Syndromes, and 2014 ACC/AHA Guideline on Perioperative Cardiovascular Evaluation and Management of Patients Undergoing Noncardiac Surgery [published correction appears in Circulation. 2016 Sep 6;134(10):e192-4]. Circulation. 2016;134(10):e123-e155. https://doi.org/10.1161/CIR.0000000000000404</mixed-citation></citation-alternatives></ref><ref id="cit265"><label>265</label><citation-alternatives><mixed-citation xml:lang="ru">Levitan N, Dowlati A, Remick SC, et al. Rates of initial and recurrent thromboembolic disease among patients with malignancy versus those without malignancy. Risk analysis using Medicare claims data. Medicine (Baltimore). 1999;78(5):285-291. https://doi.org/10.1097/00005792-199909000-00001</mixed-citation><mixed-citation xml:lang="en">Levitan N, Dowlati A, Remick SC, et al. Rates of initial and recurrent thromboembolic disease among patients with malignancy versus those without malignancy. Risk analysis using Medicare claims data. Medicine (Baltimore). 1999;78(5):285-291. https://doi.org/10.1097/00005792-199909000-00001</mixed-citation></citation-alternatives></ref><ref id="cit266"><label>266</label><citation-alternatives><mixed-citation xml:lang="ru">Chew HK, Wun T, Harvey D, Zhou H, White RH. Incidence of venous thromboembolism and its effect on survival among patients with common cancers. Arch Intern Med. 2006;166(4):458-464. https://doi.org/10.1001/archinte.166.4.458</mixed-citation><mixed-citation xml:lang="en">Chew HK, Wun T, Harvey D, Zhou H, White RH. Incidence of venous thromboembolism and its effect on survival among patients with common cancers. Arch Intern Med. 2006;166(4):458-464. https://doi.org/10.1001/archinte.166.4.458</mixed-citation></citation-alternatives></ref><ref id="cit267"><label>267</label><citation-alternatives><mixed-citation xml:lang="ru">Khorana AA, Francis CW, Culakova E, Kuderer NM, Lyman GH. Thromboembolism is a leading cause of death in cancer patients receiving outpatient chemotherapy. J Thromb Haemost. 2007;5(3):632-634. https://doi.org/10.1111/j.1538-7836.2007.02374.x</mixed-citation><mixed-citation xml:lang="en">Khorana AA, Francis CW, Culakova E, Kuderer NM, Lyman GH. Thromboembolism is a leading cause of death in cancer patients receiving outpatient chemotherapy. J Thromb Haemost. 2007;5(3):632-634. https://doi.org/10.1111/j.1538-7836.2007.02374.x</mixed-citation></citation-alternatives></ref><ref id="cit268"><label>268</label><citation-alternatives><mixed-citation xml:lang="ru">Heit JA, Spencer FA, White RH. The epidemiology of venous thromboembolism. J Thromb Thrombolysis. 2016;41(1):3-14. https://doi.org/10.1007/s11239-015-1311-6</mixed-citation><mixed-citation xml:lang="en">Heit JA, Spencer FA, White RH. The epidemiology of venous thromboembolism. J Thromb Thrombolysis. 2016;41(1):3-14. https://doi.org/10.1007/s11239-015-1311-6</mixed-citation></citation-alternatives></ref><ref id="cit269"><label>269</label><citation-alternatives><mixed-citation xml:lang="ru">Панченко Е.П., Балахонова Т.В., Данилов Н.М., Комаров А.Л., Кропачёва Е.С., Саидова М.А., Шахматова О.О., Явелов И.С. ДИАГНОСТИКА И ЛЕЧЕНИЕ ТРОМБОЭМБОЛИИ ЛЁГОЧНОЙ АРТЕРИИ: КЛИНИЧЕСКИЕ РЕКОМЕНДАЦИИ ЕВРАЗИЙСКОЙ АССОЦИАЦИИ КАРДИОЛОГОВ ДЛЯ ПРАКТИЧЕСКИХ ВРАЧЕЙ (2021). Евразийский кардиологический журнал. 2021;(1):44-77. https://doi.org/10.38109/2225-1685-2021-1-44-77.</mixed-citation><mixed-citation xml:lang="en">Panchenko E.P., Balahonova T.V., Danilov N.M., Komarov A.L., Kropachyova E.S., Saidova M.A., Shahmatova O.O., Yavelov I.S. DIAGNOSIS AND MANAGEMENT OF PULMONARY EMBOLISM EURASIAN ASSOCIATION OF CARDIOLOGY (EAC) CLINICAL PRACTICE GUIDELINES (2021). Eurasian heart journal. 2021;(1):44-77. (In Russ.) https://doi.org/10.38109/2225-1685-2021-1-44-77</mixed-citation></citation-alternatives></ref><ref id="cit270"><label>270</label><citation-alternatives><mixed-citation xml:lang="ru">Timp JF, Braekkan SK, Versteeg HH, Cannegieter SC. Epidemiology of cancer-associated venous thrombosis. Blood. 2013;122(10):1712-1723. https://doi.org/10.1182/blood-2013-04-460121</mixed-citation><mixed-citation xml:lang="en">Timp JF, Braekkan SK, Versteeg HH, Cannegieter SC. Epidemiology of cancer-associated venous thrombosis. Blood. 2013;122(10):1712-1723. https://doi.org/10.1182/blood-2013-04-460121</mixed-citation></citation-alternatives></ref><ref id="cit271"><label>271</label><citation-alternatives><mixed-citation xml:lang="ru">Ahlbrecht J, Dickmann B, Ay C et al. Tumor Grade Is Associated With Venous Thromboembolism in Patients With 55555Cancer: Results From the Vienna Cancer and Thrombosis Study. Journal of Clinical Oncology. 2012;30(31):3870-3875. https://doi.org/10.1200/jco.2011.40.1810</mixed-citation><mixed-citation xml:lang="en">Ahlbrecht J, Dickmann B, Ay C et al. Tumor Grade Is Associated With Venous Thromboembolism in Patients With 55555Cancer: Results From the Vienna Cancer and Thrombosis Study. Journal of Clinical Oncology. 2012;30(31):3870-3875. https://doi.org/10.1200/jco.2011.40.1810</mixed-citation></citation-alternatives></ref><ref id="cit272"><label>272</label><citation-alternatives><mixed-citation xml:lang="ru">Trinh VQ, Karakiewicz PI, Sammon J, et al. Venous thromboembolism after major cancer surgery: temporal trends and patterns of care. JAMA Surg. 2014;149(1):43-49. https://doi.org/10.1001/jamasurg.2013.3172</mixed-citation><mixed-citation xml:lang="en">Trinh VQ, Karakiewicz PI, Sammon J, et al. Venous thromboembolism after major cancer surgery: temporal trends and patterns of care. JAMA Surg. 2014;149(1):43-49. https://doi.org/10.1001/jamasurg.2013.3172</mixed-citation></citation-alternatives></ref><ref id="cit273"><label>273</label><citation-alternatives><mixed-citation xml:lang="ru">van Es N, Franke VF, Middeldorp S, Wilmink JW, Büller HR. The Khorana score for the prediction of venous thromboembolism in patients with pancreatic cancer. Thromb Res. 2017;150:30-32. https://doi.org/10.1016/j.thromres.2016.12.013</mixed-citation><mixed-citation xml:lang="en">van Es N, Franke VF, Middeldorp S, Wilmink JW, Büller HR. The Khorana score for the prediction of venous thromboembolism in patients with pancreatic cancer. Thromb Res. 2017;150:30-32. https://doi.org/10.1016/j.thromres.2016.12.013</mixed-citation></citation-alternatives></ref><ref id="cit274"><label>274</label><citation-alternatives><mixed-citation xml:lang="ru">Ay C, Dunkler D, Marosi C et al. Prediction of venous thromboembolism in cancer patients. Blood. 2010;116(24):5377-5382. https://doi.org/10.1182/blood-2010-02-270116</mixed-citation><mixed-citation xml:lang="en">Ay C, Dunkler D, Marosi C et al. Prediction of venous thromboembolism in cancer patients. Blood. 2010;116(24):5377-5382. https://doi.org/10.1182/blood-2010-02-270116</mixed-citation></citation-alternatives></ref><ref id="cit275"><label>275</label><citation-alternatives><mixed-citation xml:lang="ru">Verso M, Agnelli G, Barni S, Gasparini G, LaBianca R. A modifed Khorana risk assessment score for venous thromboembolism in cancer patients receiving chemotherapy: the Protecht score. Intern Emerg Med. 2012;7(3):291-292. https://doi.org/10.1007/s11739-012-0784-y</mixed-citation><mixed-citation xml:lang="en">Verso M, Agnelli G, Barni S, Gasparini G, LaBianca R. A modifed Khorana risk assessment score for venous thromboembolism in cancer patients receiving chemotherapy: the Protecht score. Intern Emerg Med. 2012;7(3):291-292. https://doi.org/10.1007/s11739-012-0784-y</mixed-citation></citation-alternatives></ref><ref id="cit276"><label>276</label><citation-alternatives><mixed-citation xml:lang="ru">Pelzer U, Sinn M, Stieler J, Riess H. Primäre medikamentöse Thromboembolieprophylaxe bei ambulanten Patienten mit fortgeschrittenem Pankreaskarzinom unter Chemotherapie? [Primary pharmacological prevention of thromboembolic events in ambulatory patients with advanced pancreatic cancer treated with chemotherapy?]. Dtsch Med Wochenschr. 2013;138(41):2084-2088. https://doi.org/10.1055/s-0033-1349608</mixed-citation><mixed-citation xml:lang="en">Pelzer U, Sinn M, Stieler J, Riess H. Primäre medikamentöse Thromboembolieprophylaxe bei ambulanten Patienten mit fortgeschrittenem Pankreaskarzinom unter Chemotherapie? [Primary pharmacological prevention of thromboembolic events in ambulatory patients with advanced pancreatic cancer treated with chemotherapy?]. Dtsch Med Wochenschr. 2013;138(41):2084-2088. https://doi.org/10.1055/s-0033-1349608</mixed-citation></citation-alternatives></ref><ref id="cit277"><label>277</label><citation-alternatives><mixed-citation xml:lang="ru">van Es N, Di Nisio M, Cesarman G, et al. Comparison of risk prediction scores for venous thromboembolism in cancer patients: a prospective cohort study. Haematologica. 2017;102(9):1494-1501. https://doi.org/10.3324/haematol.2017.169060</mixed-citation><mixed-citation xml:lang="en">van Es N, Di Nisio M, Cesarman G, et al. Comparison of risk prediction scores for venous thromboembolism in cancer patients: a prospective cohort study. Haematologica. 2017;102(9):1494-1501. https://doi.org/10.3324/haematol.2017.169060</mixed-citation></citation-alternatives></ref><ref id="cit278"><label>278</label><citation-alternatives><mixed-citation xml:lang="ru">Farge D, Frere C, Connors JM, et al. 2019 international clinical practice guidelines for the treatment and prophylaxis of venous thromboembolism in patients with cancer. Lancet Oncol. 2019;20(10):e566-e581. https://doi.org/10.1016/S1470-2045(19)30336-5</mixed-citation><mixed-citation xml:lang="en">Farge D, Frere C, Connors JM, et al. 2019 international clinical practice guidelines for the treatment and prophylaxis of venous thromboembolism in patients with cancer. Lancet Oncol. 2019;20(10):e566-e581. https://doi.org/10.1016/S1470-2045(19)30336-5</mixed-citation></citation-alternatives></ref><ref id="cit279"><label>279</label><citation-alternatives><mixed-citation xml:lang="ru">Kucher N, Koo S, Quiroz R, et al. Electronic alerts to prevent venous thromboembolism among hospitalized patients. N Engl J Med. 2005;352(10):969-977. https://doi.org/10.1056/NEJMoa041533</mixed-citation><mixed-citation xml:lang="en">Kucher N, Koo S, Quiroz R, et al. Electronic alerts to prevent venous thromboembolism among hospitalized patients. N Engl J Med. 2005;352(10):969-977. https://doi.org/10.1056/NEJMoa041533</mixed-citation></citation-alternatives></ref><ref id="cit280"><label>280</label><citation-alternatives><mixed-citation xml:lang="ru">Khorana AA, Kuderer NM, Culakova E, Lyman GH, Francis CW. Development and validation of a predictive model for chemotherapy-associated thrombosis. Blood. 2008;111(10):4902-4907. https://doi.org/10.1182/blood-2007-10-116327</mixed-citation><mixed-citation xml:lang="en">Khorana AA, Kuderer NM, Culakova E, Lyman GH, Francis CW. Development and validation of a predictive model for chemotherapy-associated thrombosis. Blood. 2008;111(10):4902-4907. https://doi.org/10.1182/blood-2007-10-116327</mixed-citation></citation-alternatives></ref><ref id="cit281"><label>281</label><citation-alternatives><mixed-citation xml:lang="ru">Lyman GH, Carrier M, Ay C, et al. American Society of Hematology 2021 guidelines for management of venous thromboembolism: prevention and treatment in patients with cancer [published correction appears in Blood Adv. 2021 Apr 13;5(7):1953]. Blood Adv. 2021;5(4):927-974. https://doi.org/10.1182/bloodadvances.2020003442</mixed-citation><mixed-citation xml:lang="en">Lyman GH, Carrier M, Ay C, et al. American Society of Hematology 2021 guidelines for management of venous thromboembolism: prevention and treatment in patients with cancer [published correction appears in Blood Adv. 2021 Apr 13;5(7):1953]. Blood Adv. 2021;5(4):927-974. https://doi.org/10.1182/bloodadvances.2020003442</mixed-citation></citation-alternatives></ref><ref id="cit282"><label>282</label><citation-alternatives><mixed-citation xml:lang="ru">Lyman GH, Khorana AA, Kuderer NM, et al. Venous thromboembolism prophylaxis and treatment in patients with cancer: American Society of Clinical Oncology clinical practice guideline update. J Clin Oncol. 2013;31(17):2189-2204. https://doi.org/10.1200/JCO.2013.49.1118</mixed-citation><mixed-citation xml:lang="en">Lyman GH, Khorana AA, Kuderer NM, et al. Venous thromboembolism prophylaxis and treatment in patients with cancer: American Society of Clinical Oncology clinical practice guideline update. J Clin Oncol. 2013;31(17):2189-2204. https://doi.org/10.1200/JCO.2013.49.1118</mixed-citation></citation-alternatives></ref><ref id="cit283"><label>283</label><citation-alternatives><mixed-citation xml:lang="ru">Aleman BM, van den Belt-Dusebout AW, Klokman WJ, Van’t Veer MB, Bartelink H, van Leeuwen FE. Long-term cause-specifc mortality of patients treated for Hodgkin’s disease. J Clin Oncol. 2003;21(18):3431-3439. https://doi.org/10.1200/JCO.2003.07.131</mixed-citation><mixed-citation xml:lang="en">Aleman BM, van den Belt-Dusebout AW, Klokman WJ, Van’t Veer MB, Bartelink H, van Leeuwen FE. Long-term cause-specifc mortality of patients treated for Hodgkin’s disease. J Clin Oncol. 2003;21(18):3431-3439. https://doi.org/10.1200/JCO.2003.07.131</mixed-citation></citation-alternatives></ref><ref id="cit284"><label>284</label><citation-alternatives><mixed-citation xml:lang="ru">Darby SC, Cutter DJ, Boerma M, et al. Radiation-related heart disease: current knowledge and future prospects. Int J Radiat Oncol Biol Phys. 2010;76(3):656-665. https://doi.org/10.1016/j.ijrobp.2009.09.064</mixed-citation><mixed-citation xml:lang="en">Darby SC, Cutter DJ, Boerma M, et al. Radiation-related heart disease: current knowledge and future prospects. Int J Radiat Oncol Biol Phys. 2010;76(3):656-665. https://doi.org/10.1016/j.ijrobp.2009.09.064</mixed-citation></citation-alternatives></ref><ref id="cit285"><label>285</label><citation-alternatives><mixed-citation xml:lang="ru">Wei X, Liu HH, Tucker SL, et al. Risk factors for pericardial effusion in inoperable esophageal cancer patients treated with defnitive chemoradiation therapy. Int J Radiat Oncol Biol Phys. 2008;70(3):707-714. https://doi.org/10.1016/j.ijrobp.2007.10.056</mixed-citation><mixed-citation xml:lang="en">Wei X, Liu HH, Tucker SL, et al. Risk factors for pericardial effusion in inoperable esophageal cancer patients treated with defnitive chemoradiation therapy. Int J Radiat Oncol Biol Phys. 2008;70(3):707-714. https://doi.org/10.1016/j.ijrobp.2007.10.056</mixed-citation></citation-alternatives></ref><ref id="cit286"><label>286</label><citation-alternatives><mixed-citation xml:lang="ru">Jaworski C, Mariani JA, Wheeler G, Kaye DM. Cardiac complications of thoracic irradiation. J Am Coll Cardiol. 2013;61(23):2319-2328. https://doi.org/10.1016/j.jacc.2013.01.090</mixed-citation><mixed-citation xml:lang="en">Jaworski C, Mariani JA, Wheeler G, Kaye DM. Cardiac complications of thoracic irradiation. J Am Coll Cardiol. 2013;61(23):2319-2328. https://doi.org/10.1016/j.jacc.2013.01.090</mixed-citation></citation-alternatives></ref><ref id="cit287"><label>287</label><citation-alternatives><mixed-citation xml:lang="ru">Aleman BM, van den Belt-Dusebout AW, De Bruin ML, et al. Late cardiotoxicity after treatment for Hodgkin lymphoma. Blood. 2007;109(5):1878-1886. https://doi.org/10.1182/blood-2006-07-034405</mixed-citation><mixed-citation xml:lang="en">Aleman BM, van den Belt-Dusebout AW, De Bruin ML, et al. Late cardiotoxicity after treatment for Hodgkin lymphoma. Blood. 2007;109(5):1878-1886. https://doi.org/10.1182/blood-2006-07-034405</mixed-citation></citation-alternatives></ref><ref id="cit288"><label>288</label><citation-alternatives><mixed-citation xml:lang="ru">Taylor CW, Nisbet A, McGale P, Darby SC. Cardiac exposures in breast cancer radiotherapy: 1950s-1990s. Int J Radiat Oncol Biol Phys. 2007;69(5):1484-1495. https://doi.org/10.1016/j.ijrobp.2007.05.034</mixed-citation><mixed-citation xml:lang="en">Taylor CW, Nisbet A, McGale P, Darby SC. Cardiac exposures in breast cancer radiotherapy: 1950s-1990s. Int J Radiat Oncol Biol Phys. 2007;69(5):1484-1495. https://doi.org/10.1016/j.ijrobp.2007.05.034</mixed-citation></citation-alternatives></ref><ref id="cit289"><label>289</label><citation-alternatives><mixed-citation xml:lang="ru">Cuzick J, Stewart H, Peto R, et al. Overview of randomized trials of postoperative adjuvant radiotherapy in breast cancer. Cancer Treat Rep. 1987;71(1):15-29</mixed-citation><mixed-citation xml:lang="en">Cuzick J, Stewart H, Peto R, et al. Overview of randomized trials of postoperative adjuvant radiotherapy in breast cancer. Cancer Treat Rep. 1987;71(1):15-29</mixed-citation></citation-alternatives></ref><ref id="cit290"><label>290</label><citation-alternatives><mixed-citation xml:lang="ru">Paszat LF, Mackillop WJ, Groome PA, Boyd C, Schulze K, Holowaty E. Mortality from myocardial infarction after adjuvant radiotherapy for breast cancer in the surveillance, epidemiology, and end-results cancer registries [published correction appears in J Clin Oncol 1999 Feb;17(2):740]. J Clin Oncol. 1998;16(8):2625-2631. https://doi.org/10.1200/JCO.1998.16.8.2625</mixed-citation><mixed-citation xml:lang="en">Paszat LF, Mackillop WJ, Groome PA, Boyd C, Schulze K, Holowaty E. Mortality from myocardial infarction after adjuvant radiotherapy for breast cancer in the surveillance, epidemiology, and end-results cancer registries [published correction appears in J Clin Oncol 1999 Feb;17(2):740]. J Clin Oncol. 1998;16(8):2625-2631. https://doi.org/10.1200/JCO.1998.16.8.2625</mixed-citation></citation-alternatives></ref><ref id="cit291"><label>291</label><citation-alternatives><mixed-citation xml:lang="ru">Clarke M, Collins R, Darby S, et al. Effects of radiotherapy and of differences in the extent of surgery for early breast cancer on local recurrence and 15-year survival: an overview of the randomised trials. Lancet. 2005;366(9503):2087-2106. https://doi.org/10.1016/S0140-6736(05)67887-7</mixed-citation><mixed-citation xml:lang="en">Clarke M, Collins R, Darby S, et al. Effects of radiotherapy and of differences in the extent of surgery for early breast cancer on local recurrence and 15-year survival: an overview of the randomised trials. Lancet. 2005;366(9503):2087-2106. https://doi.org/10.1016/S0140-6736(05)67887-7</mixed-citation></citation-alternatives></ref><ref id="cit292"><label>292</label><citation-alternatives><mixed-citation xml:lang="ru">Giordano SH, Kuo YF, Freeman JL, Buchholz TA, Hortobagyi GN, Goodwin JS. Risk of cardiac death after adjuvant radiotherapy for breast cancer. J Natl Cancer Inst. 2005;97(6):419-424. https://doi.org/10.1093/jnci/dji067</mixed-citation><mixed-citation xml:lang="en">Giordano SH, Kuo YF, Freeman JL, Buchholz TA, Hortobagyi GN, Goodwin JS. Risk of cardiac death after adjuvant radiotherapy for breast cancer. J Natl Cancer Inst. 2005;97(6):419-424. https://doi.org/10.1093/jnci/dji067</mixed-citation></citation-alternatives></ref><ref id="cit293"><label>293</label><citation-alternatives><mixed-citation xml:lang="ru">Hooning MJ, Botma A, Aleman BM, et al. Long-term risk of cardiovascular disease in 10-year survivors of breast cancer. J Natl Cancer Inst. 2007;99(5):365-375. https://doi.org/10.1093/jnci/djk064</mixed-citation><mixed-citation xml:lang="en">Hooning MJ, Botma A, Aleman BM, et al. Long-term risk of cardiovascular disease in 10-year survivors of breast cancer. J Natl Cancer Inst. 2007;99(5):365-375. https://doi.org/10.1093/jnci/djk064</mixed-citation></citation-alternatives></ref><ref id="cit294"><label>294</label><citation-alternatives><mixed-citation xml:lang="ru">Borger JH, Hooning MJ, Boersma LJ, et al. Cardiotoxic effects of tangential breast irradiation in early breast cancer patients: the role of irradiated heart volume. Int J Radiat Oncol Biol Phys. 2007;69(4):1131-1138. https://doi.org/10.1016/j.ijrobp.2007.04.042</mixed-citation><mixed-citation xml:lang="en">Borger JH, Hooning MJ, Boersma LJ, et al. Cardiotoxic effects of tangential breast irradiation in early breast cancer patients: the role of irradiated heart volume. Int J Radiat Oncol Biol Phys. 2007;69(4):1131-1138. https://doi.org/10.1016/j.ijrobp.2007.04.042</mixed-citation></citation-alternatives></ref><ref id="cit295"><label>295</label><citation-alternatives><mixed-citation xml:lang="ru">Darby SC, McGale P, Taylor CW, Peto R. Long-term mortality from heart disease and lung cancer after radiotherapy for early breast cancer: prospective cohort study of about 300,000 women in US SEER cancer registries. Lancet Oncol. 2005;6(8):557-565. https://doi.org/10.1016/S1470-2045(05)70251-5</mixed-citation><mixed-citation xml:lang="en">Darby SC, McGale P, Taylor CW, Peto R. Long-term mortality from heart disease and lung cancer after radiotherapy for early breast cancer: prospective cohort study of about 300,000 women in US SEER cancer registries. Lancet Oncol. 2005;6(8):557-565. https://doi.org/10.1016/S1470-2045(05)70251-5</mixed-citation></citation-alternatives></ref><ref id="cit296"><label>296</label><citation-alternatives><mixed-citation xml:lang="ru">Early Breast Cancer Trialists’ Collaborative Group (EBCTCG), Darby S, McGale P, et al. Effect of radiotherapy after breast-conserving surgery on 10-year recurrence and 15-year breast cancer death: meta-analysis of individual patient data for 10,801 women in 17 randomised trials. Lancet. 2011;378(9804):1707-1716. https://doi.org/10.1016/S0140-6736(11)61629-2</mixed-citation><mixed-citation xml:lang="en">Early Breast Cancer Trialists’ Collaborative Group (EBCTCG), Darby S, McGale P, et al. Effect of radiotherapy after breast-conserving surgery on 10-year recurrence and 15-year breast cancer death: meta-analysis of individual patient data for 10,801 women in 17 randomised trials. Lancet. 2011;378(9804):1707-1716. https://doi.org/10.1016/S0140-6736(11)61629-2</mixed-citation></citation-alternatives></ref><ref id="cit297"><label>297</label><citation-alternatives><mixed-citation xml:lang="ru">Patt DA, Goodwin JS, Kuo YF, et al. Cardiac morbidity of adjuvant radiotherapy for breast cancer. J Clin Oncol. 2005;23(30):7475-7482. https://doi.org/10.1200/JCO.2005.13.755</mixed-citation><mixed-citation xml:lang="en">Patt DA, Goodwin JS, Kuo YF, et al. Cardiac morbidity of adjuvant radiotherapy for breast cancer. J Clin Oncol. 2005;23(30):7475-7482. https://doi.org/10.1200/JCO.2005.13.755</mixed-citation></citation-alternatives></ref><ref id="cit298"><label>298</label><citation-alternatives><mixed-citation xml:lang="ru">Paul Wright G, Drinane JJ, Sobel HL, Chung MH. Left-Sided Breast Irradiation does not Result in Increased Long-Term Cardiac-Related Mortality Among Women Treated with Breast-Conserving Surgery. Ann Surg Oncol. 2016;23(4):1117-1122. https://doi.org/10.1245/s10434-015-4949-6</mixed-citation><mixed-citation xml:lang="en">Paul Wright G, Drinane JJ, Sobel HL, Chung MH. Left-Sided Breast Irradiation does not Result in Increased Long-Term Cardiac-Related Mortality Among Women Treated with Breast-Conserving Surgery. Ann Surg Oncol. 2016;23(4):1117-1122. https://doi.org/10.1245/s10434-015-4949-6</mixed-citation></citation-alternatives></ref><ref id="cit299"><label>299</label><citation-alternatives><mixed-citation xml:lang="ru">Schultz-Hector S, Trott KR. Radiation-induced cardiovascular diseases: is the epidemiologic evidence compatible with the radiobiologic data?. Int J Radiat Oncol Biol Phys. 2007;67(1):10-18. https://doi.org/10.1016/j.ijrobp.2006.08.071</mixed-citation><mixed-citation xml:lang="en">Schultz-Hector S, Trott KR. Radiation-induced cardiovascular diseases: is the epidemiologic evidence compatible with the radiobiologic data?. Int J Radiat Oncol Biol Phys. 2007;67(1):10-18. https://doi.org/10.1016/j.ijrobp.2006.08.071</mixed-citation></citation-alternatives></ref><ref id="cit300"><label>300</label><citation-alternatives><mixed-citation xml:lang="ru">Wu W, Masri A, Popovic ZB, et al. Long-term survival of patients with radiation heart disease undergoing cardiac surgery: a cohort study. Circulation. 2013;127(14):1476-1485. https://doi.org/10.1161/CIRCULATIONAHA.113.001435</mixed-citation><mixed-citation xml:lang="en">Wu W, Masri A, Popovic ZB, et al. Long-term survival of patients with radiation heart disease undergoing cardiac surgery: a cohort study. Circulation. 2013;127(14):1476-1485. https://doi.org/10.1161/CIRCULATIONAHA.113.001435</mixed-citation></citation-alternatives></ref><ref id="cit301"><label>301</label><citation-alternatives><mixed-citation xml:lang="ru">Heidenreich PA, SL, Lee BK, Mariscal CS, Schnittger I. Asymptomatic cardiac disease following mediastinal irradiation. J Am Coll Cardiol. 2003;42(4):743-749. https://doi.org/10.1016/s0735-1097(03)00759-9</mixed-citation><mixed-citation xml:lang="en">Heidenreich PA, SL, Lee BK, Mariscal CS, Schnittger I. Asymptomatic cardiac disease following mediastinal irradiation. J Am Coll Cardiol. 2003;42(4):743-749. https://doi.org/10.1016/s0735-1097(03)00759-9</mixed-citation></citation-alternatives></ref><ref id="cit302"><label>302</label><citation-alternatives><mixed-citation xml:lang="ru">Carver JR, Shapiro CL, Ng A, et al. American Society of Clinical Oncology clinical evidence review on the ongoing care of adult cancer survivors: cardiac and pulmonary late effects. J Clin Oncol. 2007;25(25):3991-4008. https://doi.org/10.1200/JCO.2007.10.9777</mixed-citation><mixed-citation xml:lang="en">Carver JR, Shapiro CL, Ng A, et al. American Society of Clinical Oncology clinical evidence review on the ongoing care of adult cancer survivors: cardiac and pulmonary late effects. J Clin Oncol. 2007;25(25):3991-4008. https://doi.org/10.1200/JCO.2007.10.9777</mixed-citation></citation-alternatives></ref><ref id="cit303"><label>303</label><citation-alternatives><mixed-citation xml:lang="ru">Meyer RM, Gospodarowicz MK, Connors JM, et al. ABVD alone versus radiation-based therapy in limited-stage Hodgkin’s lymphoma. N Engl J Med. 2012;366(5):399-408. https://doi.org/10.1056/NEJMoa1111961</mixed-citation><mixed-citation xml:lang="en">Meyer RM, Gospodarowicz MK, Connors JM, et al. ABVD alone versus radiation-based therapy in limited-stage Hodgkin’s lymphoma. N Engl J Med. 2012;366(5):399-408. https://doi.org/10.1056/NEJMoa1111961</mixed-citation></citation-alternatives></ref><ref id="cit304"><label>304</label><citation-alternatives><mixed-citation xml:lang="ru">Lee CK, Aeppli D, Nierengarten ME. The need for long-term surveillance for patients treated with curative radiotherapy for Hodgkin’s disease: University of Minnesota experience. Int J Radiat Oncol Biol Phys. 2000;48(1):169-179. https://doi.org/10.1016/s0360-3016(00)00647-7</mixed-citation><mixed-citation xml:lang="en">Lee CK, Aeppli D, Nierengarten ME. The need for long-term surveillance for patients treated with curative radiotherapy for Hodgkin’s disease: University of Minnesota experience. Int J Radiat Oncol Biol Phys. 2000;48(1):169-179. https://doi.org/10.1016/s0360-3016(00)00647-7</mixed-citation></citation-alternatives></ref><ref id="cit305"><label>305</label><citation-alternatives><mixed-citation xml:lang="ru">Ridker PM, Buring JE, Rifai N, Cook NR. Development and validation of improved algorithms for the assessment of global cardiovascular risk in women: the Reynolds Risk Score [published correction appears in JAMA. 2007 Apr 4;297(13):1433]. JAMA. 2007;297(6):611-619. https://doi.org/10.1001/jama.297.6.611</mixed-citation><mixed-citation xml:lang="en">Ridker PM, Buring JE, Rifai N, Cook NR. Development and validation of improved algorithms for the assessment of global cardiovascular risk in women: the Reynolds Risk Score [published correction appears in JAMA. 2007 Apr 4;297(13):1433]. JAMA. 2007;297(6):611-619. https://doi.org/10.1001/jama.297.6.611</mixed-citation></citation-alternatives></ref><ref id="cit306"><label>306</label><citation-alternatives><mixed-citation xml:lang="ru">Darby SC, Ewertz M, McGale P, et al. Risk of ischemic heart disease in women after radiotherapy for breast cancer. N Engl J Med. 2013;368(11):987-998. https://doi.org/10.1056/NEJMoa1209825</mixed-citation><mixed-citation xml:lang="en">Darby SC, Ewertz M, McGale P, et al. Risk of ischemic heart disease in women after radiotherapy for breast cancer. N Engl J Med. 2013;368(11):987-998. https://doi.org/10.1056/NEJMoa1209825</mixed-citation></citation-alternatives></ref><ref id="cit307"><label>307</label><citation-alternatives><mixed-citation xml:lang="ru">Marhin W, Wai E, Tyldesley S. Impact of fraction size on cardiac mortality in women treated with tangential radiotherapy for localized breast cancer. Int J Radiat Oncol Biol Phys. 2007;69(2):483-489. https://doi.org/10.1016/j.ijrobp.2007.03.033</mixed-citation><mixed-citation xml:lang="en">Marhin W, Wai E, Tyldesley S. Impact of fraction size on cardiac mortality in women treated with tangential radiotherapy for localized breast cancer. Int J Radiat Oncol Biol Phys. 2007;69(2):483-489. https://doi.org/10.1016/j.ijrobp.2007.03.033</mixed-citation></citation-alternatives></ref><ref id="cit308"><label>308</label><citation-alternatives><mixed-citation xml:lang="ru">Shapiro CL, Hardenbergh PH, Gelman R, et al. Cardiac effects of adjuvant doxorubicin and radiation therapy in breast cancer patients. J Clin Oncol. 1998;16(11):3493-3501. https://doi.org/10.1200/JCO.1998.16.11.3493</mixed-citation><mixed-citation xml:lang="en">Shapiro CL, Hardenbergh PH, Gelman R, et al. Cardiac effects of adjuvant doxorubicin and radiation therapy in breast cancer patients. J Clin Oncol. 1998;16(11):3493-3501. https://doi.org/10.1200/JCO.1998.16.11.3493</mixed-citation></citation-alternatives></ref><ref id="cit309"><label>309</label><citation-alternatives><mixed-citation xml:lang="ru">Hull MC et al. JAMA. 2003;290:2831–2837, Brown ML J Thorac Cardiovasc Surg. 2008;136:1167–1171.</mixed-citation><mixed-citation xml:lang="en">Hull MC et al. JAMA. 2003;290:2831–2837, Brown ML J Thorac Cardiovasc Surg. 2008;136:1167–1171.</mixed-citation></citation-alternatives></ref><ref id="cit310"><label>310</label><citation-alternatives><mixed-citation xml:lang="ru">Marks LB, Yu X, Prosnitz RG et al. The incidence functional consequences of RT-associated cardiac perfusion defects. Int J Radiat Oncol Biol Phys. 2005,63, No 1, P.214-223</mixed-citation><mixed-citation xml:lang="en">Marks LB, Yu X, Prosnitz RG et al. The incidence functional consequences of RT-associated cardiac perfusion defects. Int J Radiat Oncol Biol Phys. 2005,63, No 1, P.214-223</mixed-citation></citation-alternatives></ref><ref id="cit311"><label>311</label><citation-alternatives><mixed-citation xml:lang="ru">Gagliardi G, Constine LS, Moiseenko V, et al. Radiation dose-volume effects in the heart. Int J Radiat Oncol Biol Phys. 2010;76(3 Suppl):S77-S85. https://doi.org/10.1016/j.ijrobp.2009.04.093</mixed-citation><mixed-citation xml:lang="en">Gagliardi G, Constine LS, Moiseenko V, et al. Radiation dose-volume effects in the heart. Int J Radiat Oncol Biol Phys. 2010;76(3 Suppl):S77-S85. https://doi.org/10.1016/j.ijrobp.2009.04.093</mixed-citation></citation-alternatives></ref><ref id="cit312"><label>312</label><citation-alternatives><mixed-citation xml:lang="ru">King V, Constine LS, Clark D, et al. Symptomatic coronary artery disease after mantle irradiation for Hodgkin’s disease. Int J Radiat Oncol Biol Phys. 1996;36 (4):881-889. https://doi.org/10.1016/s0360-3016(96)00295-7</mixed-citation><mixed-citation xml:lang="en">King V, Constine LS, Clark D, et al. Symptomatic coronary artery disease after mantle irradiation for Hodgkin’s disease. Int J Radiat Oncol Biol Phys. 1996;36 (4):881-889. https://doi.org/10.1016/s0360-3016(96)00295-7</mixed-citation></citation-alternatives></ref><ref id="cit313"><label>313</label><citation-alternatives><mixed-citation xml:lang="ru">Heidenreich PA, Kapoor JR. Radiation induced heart disease: systemic disorders in heart disease. Heart. 2009;95(3):252-258. https://doi.org/10.1136/hrt.2008.149088</mixed-citation><mixed-citation xml:lang="en">Heidenreich PA, Kapoor JR. Radiation induced heart disease: systemic disorders in heart disease. Heart. 2009;95(3):252-258. https://doi.org/10.1136/hrt.2008.149088</mixed-citation></citation-alternatives></ref><ref id="cit314"><label>314</label><citation-alternatives><mixed-citation xml:lang="ru">Harris EE, Correa C, Hwang WT, et al. Late cardiac mortality and morbidity in early-stage breast cancer patients after breast-conservation treatment. J Clin Oncol. 2006;24(25):4100-4106. https://doi.org/10.1200/JCO.2005.05.1037</mixed-citation><mixed-citation xml:lang="en">Harris EE, Correa C, Hwang WT, et al. Late cardiac mortality and morbidity in early-stage breast cancer patients after breast-conservation treatment. J Clin Oncol. 2006;24(25):4100-4106. https://doi.org/10.1200/JCO.2005.05.1037</mixed-citation></citation-alternatives></ref><ref id="cit315"><label>315</label><citation-alternatives><mixed-citation xml:lang="ru">Baker JE, Moulder JE, Hopewell JW. Radiation as a risk factor for cardiovascular disease. Antioxid Redox Signal. 2011;15(7):1945-1956. https://doi.org/10.1089/ars.2010.3742</mixed-citation><mixed-citation xml:lang="en">Baker JE, Moulder JE, Hopewell JW. Radiation as a risk factor for cardiovascular disease. Antioxid Redox Signal. 2011;15(7):1945-1956. https://doi.org/10.1089/ars.2010.3742</mixed-citation></citation-alternatives></ref><ref id="cit316"><label>316</label><citation-alternatives><mixed-citation xml:lang="ru">Cuomo JR, Sharma GK, Conger PD, Weintraub NL. Novel concepts in radiation-induced cardiovascular disease. World J Cardiol. 2016;8(9):504-519. https://doi.org/10.4330/wjc.v8.i9.504</mixed-citation><mixed-citation xml:lang="en">Cuomo JR, Sharma GK, Conger PD, Weintraub NL. Novel concepts in radiation-induced cardiovascular disease. World J Cardiol. 2016;8(9):504-519. https://doi.org/10.4330/wjc.v8.i9.504</mixed-citation></citation-alternatives></ref><ref id="cit317"><label>317</label><citation-alternatives><mixed-citation xml:lang="ru">Sárközy M, Varga Z, Gáspár R, et al. Pathomechanisms and therapeutic opportunities in radiation-induced heart disease: from bench to bedside. Clin Res Cardiol. 2021;110(4):507-531. https://doi.org/10.1007/s00392-021-01809-y</mixed-citation><mixed-citation xml:lang="en">Sárközy M, Varga Z, Gáspár R, et al. Pathomechanisms and therapeutic opportunities in radiation-induced heart disease: from bench to bedside. Clin Res Cardiol. 2021;110(4):507-531. https://doi.org/10.1007/s00392-021-01809-y</mixed-citation></citation-alternatives></ref><ref id="cit318"><label>318</label><citation-alternatives><mixed-citation xml:lang="ru">Taunk NK, Haffty BG, Kostis JB, Goyal S. Radiation-induced heart disease: pathologic abnormalities and putative mechanisms. Front Oncol. 2015;5:39. Published 2015 Feb 18. https://doi.org/10.3389/fonc.2015.00039</mixed-citation><mixed-citation xml:lang="en">Taunk NK, Haffty BG, Kostis JB, Goyal S. Radiation-induced heart disease: pathologic abnormalities and putative mechanisms. Front Oncol. 2015;5:39. Published 2015 Feb 18. https://doi.org/10.3389/fonc.2015.00039</mixed-citation></citation-alternatives></ref><ref id="cit319"><label>319</label><citation-alternatives><mixed-citation xml:lang="ru">Boerma M, Hauer-Jensen M. Preclinical research into basic mechanisms of radiation-induced heart disease. Cardiol Res Pract. 2010;2011:858262. Published 2010 Oct 4. https://doi.org/10.4061/2011/858262</mixed-citation><mixed-citation xml:lang="en">Boerma M, Hauer-Jensen M. Preclinical research into basic mechanisms of radiation-induced heart disease. Cardiol Res Pract. 2010;2011:858262. Published 2010 Oct 4. https://doi.org/10.4061/2011/858262</mixed-citation></citation-alternatives></ref><ref id="cit320"><label>320</label><citation-alternatives><mixed-citation xml:lang="ru">Stewart FA, Hoving S, Russell NS. Vascular damage as an underlying mechanism of cardiac and cerebral toxicity in irradiated cancer patients. Radiat Res. 2010;174(6):865-869. https://doi.org/10.1667/RR1862.1</mixed-citation><mixed-citation xml:lang="en">Stewart FA, Hoving S, Russell NS. Vascular damage as an underlying mechanism of cardiac and cerebral toxicity in irradiated cancer patients. Radiat Res. 2010;174(6):865-869. https://doi.org/10.1667/RR1862.1</mixed-citation></citation-alternatives></ref><ref id="cit321"><label>321</label><citation-alternatives><mixed-citation xml:lang="ru">Yusuf SW, Sami S, Daher IN. Radiation-induced heart disease: a clinical update. Cardiol Res Pract. 2011;2011:317659. Published 2011 Feb 27. https://doi.org/10.4061/2011/317659</mixed-citation><mixed-citation xml:lang="en">Yusuf SW, Sami S, Daher IN. Radiation-induced heart disease: a clinical update. Cardiol Res Pract. 2011;2011:317659. Published 2011 Feb 27. https://doi.org/10.4061/2011/317659</mixed-citation></citation-alternatives></ref><ref id="cit322"><label>322</label><citation-alternatives><mixed-citation xml:lang="ru">Stewart FA, Heeneman S, Te Poele J, et al. Ionizing radiation accelerates the development of atherosclerotic lesions in ApoE-/- mice and predisposes to an inﬂammatory plaque phenotype prone to hemorrhage. Am J Pathol. 2006;168(2):649-658. https://doi.org/10.2353/ajpath.2006.050409</mixed-citation><mixed-citation xml:lang="en">Stewart FA, Heeneman S, Te Poele J, et al. Ionizing radiation accelerates the development of atherosclerotic lesions in ApoE-/- mice and predisposes to an inﬂammatory plaque phenotype prone to hemorrhage. Am J Pathol. 2006;168(2):649-658. https://doi.org/10.2353/ajpath.2006.050409</mixed-citation></citation-alternatives></ref><ref id="cit323"><label>323</label><citation-alternatives><mixed-citation xml:lang="ru">Armstrong GT, Joshi VM, Ness KK, et al. Comprehensive Echocardiographic Detection of Treatment-Related Cardiac Dysfunction in Adult Survivors of Childhood Cancer: Results From the St. Jude Lifetime Cohort Study. J Am Coll Cardiol. 2015;65(23):2511-2522. https://doi.org/10.1016/j.jacc.2015.04.013</mixed-citation><mixed-citation xml:lang="en">Armstrong GT, Joshi VM, Ness KK, et al. Comprehensive Echocardiographic Detection of Treatment-Related Cardiac Dysfunction in Adult Survivors of Childhood Cancer: Results From the St. Jude Lifetime Cohort Study. J Am Coll Cardiol. 2015;65(23):2511-2522. https://doi.org/10.1016/j.jacc.2015.04.013</mixed-citation></citation-alternatives></ref><ref id="cit324"><label>324</label><citation-alternatives><mixed-citation xml:lang="ru">Hardenbergh PH, Munley MT, Bentel GC, et al. Cardiac perfusion changes in patients treated for breast cancer with radiation therapy and doxorubicin: preliminary results. Int J Radiat Oncol Biol Phys. 2001;49(4):1023-1028. https://doi.org/10.1016/s0360-3016(00)01531-5</mixed-citation><mixed-citation xml:lang="en">Hardenbergh PH, Munley MT, Bentel GC, et al. Cardiac perfusion changes in patients treated for breast cancer with radiation therapy and doxorubicin: preliminary results. Int J Radiat Oncol Biol Phys. 2001;49(4):1023-1028. https://doi.org/10.1016/s0360-3016(00)01531-5</mixed-citation></citation-alternatives></ref><ref id="cit325"><label>325</label><citation-alternatives><mixed-citation xml:lang="ru">Gomez DR, Yusuf SW, Munsell MF, et al. Prospective exploratory analysis of cardiac biomarkers and electrocardiogram abnormalities in patients receiving thoracic radiation therapy with high-dose heart exposure. J Thorac Oncol. 2014;9(10):1554-1560. https://doi.org/10.1097/JTO.0000000000000306</mixed-citation><mixed-citation xml:lang="en">Gomez DR, Yusuf SW, Munsell MF, et al. Prospective exploratory analysis of cardiac biomarkers and electrocardiogram abnormalities in patients receiving thoracic radiation therapy with high-dose heart exposure. J Thorac Oncol. 2014;9(10):1554-1560. https://doi.org/10.1097/JTO.0000000000000306</mixed-citation></citation-alternatives></ref><ref id="cit326"><label>326</label><citation-alternatives><mixed-citation xml:lang="ru">Erven K, Florian A, Slagmolen P, et al. Subclinical cardiotoxicity detected by strain rate imaging up to 14 months after breast radiation therapy. Int J Radiat Oncol Biol Phys. 2013;85(5):1172-1178. https://doi.org/10.1016/j.ijrobp.2012.09.022</mixed-citation><mixed-citation xml:lang="en">Erven K, Florian A, Slagmolen P, et al. Subclinical cardiotoxicity detected by strain rate imaging up to 14 months after breast radiation therapy. Int J Radiat Oncol Biol Phys. 2013;85(5):1172-1178. https://doi.org/10.1016/j.ijrobp.2012.09.022</mixed-citation></citation-alternatives></ref><ref id="cit327"><label>327</label><citation-alternatives><mixed-citation xml:lang="ru">Walker V, Lairez O, Fondard O, et al. Myocardial deformation after radiotherapy: a layer-specifc and territorial longitudinal strain analysis in a cohort of left-sided breast cancer patients (BACCARAT study). Radiat Oncol. 2020;15(1):201. Published 2020 Aug 20. https://doi.org/10.1186/s13014-020-01635-y</mixed-citation><mixed-citation xml:lang="en">Walker V, Lairez O, Fondard O, et al. Myocardial deformation after radiotherapy: a layer-specifc and territorial longitudinal strain analysis in a cohort of left-sided breast cancer patients (BACCARAT study). Radiat Oncol. 2020;15(1):201. Published 2020 Aug 20. https://doi.org/10.1186/s13014-020-01635-y</mixed-citation></citation-alternatives></ref><ref id="cit328"><label>328</label><citation-alternatives><mixed-citation xml:lang="ru">Desai MY, Windecker S, Lancellotti P, et al. Prevention, Diagnosis, and Management of Radiation-Associated Cardiac Disease: JACC Scientifc Expert Panel. J Am Coll Cardiol. 2019;74(7):905-927. https://doi.org/10.1016/j.jacc.2019.07.006</mixed-citation><mixed-citation xml:lang="en">Desai MY, Windecker S, Lancellotti P, et al. Prevention, Diagnosis, and Management of Radiation-Associated Cardiac Disease: JACC Scientifc Expert Panel. J Am Coll Cardiol. 2019;74(7):905-927. https://doi.org/10.1016/j.jacc.2019.07.006</mixed-citation></citation-alternatives></ref><ref id="cit329"><label>329</label><citation-alternatives><mixed-citation xml:lang="ru">van Nimwegen FA, Ntentas G, Darby SC, et al. Risk of heart failure in survivors of Hodgkin lymphoma: effects of cardiac exposure to radiation and anthracyclines. Blood. 2017;129(16):2257-2265. https://doi.org/10.1182/blood-2016-09-740332</mixed-citation><mixed-citation xml:lang="en">van Nimwegen FA, Ntentas G, Darby SC, et al. Risk of heart failure in survivors of Hodgkin lymphoma: effects of cardiac exposure to radiation and anthracyclines. Blood. 2017;129(16):2257-2265. https://doi.org/10.1182/blood-2016-09-740332</mixed-citation></citation-alternatives></ref><ref id="cit330"><label>330</label><citation-alternatives><mixed-citation xml:lang="ru">Saiki H, Petersen IA, Scott CG, et al. Risk of Heart Failure With Preserved Ejection Fraction in Older Women After Contemporary Radiotherapy for Breast Cancer. Circulation. 2017;135(15):1388-1396. https://doi.org/10.1161/CIRCULATIONAHA.116.025434</mixed-citation><mixed-citation xml:lang="en">Saiki H, Petersen IA, Scott CG, et al. Risk of Heart Failure With Preserved Ejection Fraction in Older Women After Contemporary Radiotherapy for Breast Cancer. Circulation. 2017;135(15):1388-1396. https://doi.org/10.1161/CIRCULATIONAHA.116.025434</mixed-citation></citation-alternatives></ref><ref id="cit331"><label>331</label><citation-alternatives><mixed-citation xml:lang="ru">Poltavskaya MG, Emelina EI, Avdeev YV, Gendlin GE, Paramonova GN. Heart valve injury due to radiation therapy. Kardiologiia. 2019;59(2S):56-68. Published 2019 Mar 7. https://doi.org/10.18087/cardio.2656 / in Russ Полтавская М.Г., Емелина Е.И., Авдеев Ю.В., Гендлин Г.Е., Парамонова Г.Н. Поражения клапанов сердца вследствие лучевой терапии злокачественных новообразований. Кардиология. 2019;59(2S):56-68. https://doi.org/10.18087/cardio.2656</mixed-citation><mixed-citation xml:lang="en">Poltavskaya MG, Emelina EI, Avdeev YV, Gendlin GE, Paramonova GN. Heart valve injury due to radiation therapy. Kardiologiia. 2019;59(2S):56-68. Published 2019 Mar 7. https://doi.org/10.18087/cardio.2656 / in Russ Полтавская М.Г., Емелина Е.И., Авдеев Ю.В., Гендлин Г.Е., Парамонова Г.Н. Поражения клапанов сердца вследствие лучевой терапии злокачественных новообразований. Кардиология. 2019;59(2S):56-68. https://doi.org/10.18087/cardio.2656</mixed-citation></citation-alternatives></ref><ref id="cit332"><label>332</label><citation-alternatives><mixed-citation xml:lang="ru">Armenian SH, Hudson MM, Mulder RL, et al. Recommendations for cardiomyopathy surveillance for survivors of childhood cancer: a report from the International Late Effects of Childhood Cancer Guideline Harmonization Group. Lancet Oncol. 2015;16(3):e123-e136. https://doi.org/10.1016/S1470-2045(14)70409-7</mixed-citation><mixed-citation xml:lang="en">Armenian SH, Hudson MM, Mulder RL, et al. Recommendations for cardiomyopathy surveillance for survivors of childhood cancer: a report from the International Late Effects of Childhood Cancer Guideline Harmonization Group. Lancet Oncol. 2015;16(3):e123-e136. https://doi.org/10.1016/S1470-2045(14)70409-7</mixed-citation></citation-alternatives></ref><ref id="cit333"><label>333</label><citation-alternatives><mixed-citation xml:lang="ru">Rehammar JC, Jensen MB, McGale P, et al. Risk of heart disease in relation to radiotherapy and chemotherapy with anthracyclines among 19,464 breast cancer patients in Denmark, 1977-2005. Radiother Oncol. 2017;123(2):299-305. https://doi.org/10.1016/j.radonc.2017.03.012</mixed-citation><mixed-citation xml:lang="en">Rehammar JC, Jensen MB, McGale P, et al. Risk of heart disease in relation to radiotherapy and chemotherapy with anthracyclines among 19,464 breast cancer patients in Denmark, 1977-2005. Radiother Oncol. 2017;123(2):299-305. https://doi.org/10.1016/j.radonc.2017.03.012</mixed-citation></citation-alternatives></ref><ref id="cit334"><label>334</label><citation-alternatives><mixed-citation xml:lang="ru">Yavas G, Gultekin M, Yildiz O, et al. Assessment of concomitant versus sequential trastuzumab on radiation-induced cardiovascular toxicity. Hum Exp Toxicol. 2017;36(11):1121-1130. https://doi.org/10.1177/0960327116680276</mixed-citation><mixed-citation xml:lang="en">Yavas G, Gultekin M, Yildiz O, et al. Assessment of concomitant versus sequential trastuzumab on radiation-induced cardiovascular toxicity. Hum Exp Toxicol. 2017;36(11):1121-1130. https://doi.org/10.1177/0960327116680276</mixed-citation></citation-alternatives></ref><ref id="cit335"><label>335</label><citation-alternatives><mixed-citation xml:lang="ru">Nagueh SF, Appleton CP, Gillebert TC, et al. Recommendations for the evaluation of left ventricular diastolic function by echocardiography. Eur J Echocardiogr. 2009;10(2):165-193. https://doi.org/10.1093/ejechocard/jep007</mixed-citation><mixed-citation xml:lang="en">Nagueh SF, Appleton CP, Gillebert TC, et al. Recommendations for the evaluation of left ventricular diastolic function by echocardiography. Eur J Echocardiogr. 2009;10(2):165-193. https://doi.org/10.1093/ejechocard/jep007</mixed-citation></citation-alternatives></ref><ref id="cit336"><label>336</label><citation-alternatives><mixed-citation xml:lang="ru">Trivedi SJ, Choudhary P, Lo Q, et al. Persistent reduction in global longitudinal strain in the longer term after radiation therapy in patients with breast cancer. Radiother Oncol. 2019;132:148-154. https://doi.org/10.1016/j.radonc.2018.10.023</mixed-citation><mixed-citation xml:lang="en">Trivedi SJ, Choudhary P, Lo Q, et al. Persistent reduction in global longitudinal strain in the longer term after radiation therapy in patients with breast cancer. Radiother Oncol. 2019;132:148-154. https://doi.org/10.1016/j.radonc.2018.10.023</mixed-citation></citation-alternatives></ref><ref id="cit337"><label>337</label><citation-alternatives><mixed-citation xml:lang="ru">Constine LS, Schwartz RG, Savage DE, King V, Muhs A. Cardiac function, perfusion, and morbidity in irradiated long-term survivors of Hodgkin’s disease. Int J Radiat Oncol Biol Phys. 1997;39(4):897-906. https://doi.org/10.1016/s0360-3016(97)00467-7</mixed-citation><mixed-citation xml:lang="en">Constine LS, Schwartz RG, Savage DE, King V, Muhs A. Cardiac function, perfusion, and morbidity in irradiated long-term survivors of Hodgkin’s disease. Int J Radiat Oncol Biol Phys. 1997;39(4):897-906. https://doi.org/10.1016/s0360-3016(97)00467-7</mixed-citation></citation-alternatives></ref><ref id="cit338"><label>338</label><citation-alternatives><mixed-citation xml:lang="ru">Plana JC, Thavendiranathan P, Bucciarelli-Ducci C, Lancellotti P. MultiModality Imaging in the Assessment of Cardiovascular Toxicity in the Cancer Patient [published correction appears in JACC Cardiovasc Imaging. 2019 Jan;12(1):224]. JACC Cardiovasc Imaging. 2018;11(8):1173-1186. https://doi.org/10.1016/j.jcmg.2018.06.003</mixed-citation><mixed-citation xml:lang="en">Plana JC, Thavendiranathan P, Bucciarelli-Ducci C, Lancellotti P. MultiModality Imaging in the Assessment of Cardiovascular Toxicity in the Cancer Patient [published correction appears in JACC Cardiovasc Imaging. 2019 Jan;12(1):224]. JACC Cardiovasc Imaging. 2018;11(8):1173-1186. https://doi.org/10.1016/j.jcmg.2018.06.003</mixed-citation></citation-alternatives></ref><ref id="cit339"><label>339</label><citation-alternatives><mixed-citation xml:lang="ru">M Sárközy, Z Varga, R Gáspár Pathomechanisms and therapeutic opportunities in radiation-induced heart disease: from bench to bedside. Clinical Research in Cardiology. Clin Res Cardiol . 2021 Apr;110(4):507-531. https://doi.org/10.1007/s00392-021-01809-y</mixed-citation><mixed-citation xml:lang="en">M Sárközy, Z Varga, R Gáspár Pathomechanisms and therapeutic opportunities in radiation-induced heart disease: from bench to bedside. Clinical Research in Cardiology. Clin Res Cardiol . 2021 Apr;110(4):507-531. https://doi.org/10.1007/s00392-021-01809-y</mixed-citation></citation-alternatives></ref><ref id="cit340"><label>340</label><citation-alternatives><mixed-citation xml:lang="ru">DePasquale EC, Nasir K, Jacoby DL. Outcomes of adults with restrictive cardiomyopathy after heart transplantation. J Heart Lung Transplant. 2012;31(12):1269-1275. https://doi.org/10.1016/j.healun.2012.09.018</mixed-citation><mixed-citation xml:lang="en">DePasquale EC, Nasir K, Jacoby DL. Outcomes of adults with restrictive cardiomyopathy after heart transplantation. J Heart Lung Transplant. 2012;31(12):1269-1275. https://doi.org/10.1016/j.healun.2012.09.018</mixed-citation></citation-alternatives></ref><ref id="cit341"><label>341</label><citation-alternatives><mixed-citation xml:lang="ru">McGale P, Darby SC, Hall P, et al. Incidence of heart disease in 35,000 women treated with radiotherapy for breast cancer in Denmark and Sweden. Radiother Oncol. 2011;100(2):167-175. https://doi.org/10.1016/j.radonc.2011.06.016</mixed-citation><mixed-citation xml:lang="en">McGale P, Darby SC, Hall P, et al. Incidence of heart disease in 35,000 women treated with radiotherapy for breast cancer in Denmark and Sweden. Radiother Oncol. 2011;100(2):167-175. https://doi.org/10.1016/j.radonc.2011.06.016</mixed-citation></citation-alternatives></ref><ref id="cit342"><label>342</label><citation-alternatives><mixed-citation xml:lang="ru">Virmani R, Farb A, Carter AJ, Jones RM. Comparative pathology: radiationinduced coronary artery disease in man and animals. Semin Interv Cardiol. 1998;3(3-4):163-172</mixed-citation><mixed-citation xml:lang="en">Virmani R, Farb A, Carter AJ, Jones RM. Comparative pathology: radiationinduced coronary artery disease in man and animals. Semin Interv Cardiol. 1998;3(3-4):163-172</mixed-citation></citation-alternatives></ref><ref id="cit343"><label>343</label><citation-alternatives><mixed-citation xml:lang="ru">Brosius FC 3rd, Waller BF, Roberts WC. Radiation heart disease. Analysis of 16 young (aged 15 to 33 years) necropsy patients who received over 3,500 rads to the heart. Am J Med. 1981;70(3):519-530. https://doi.org/10.1016/0002-9343(81)90574-x</mixed-citation><mixed-citation xml:lang="en">Brosius FC 3rd, Waller BF, Roberts WC. Radiation heart disease. Analysis of 16 young (aged 15 to 33 years) necropsy patients who received over 3,500 rads to the heart. Am J Med. 1981;70(3):519-530. https://doi.org/10.1016/0002-9343(81)90574-x</mixed-citation></citation-alternatives></ref><ref id="cit344"><label>344</label><citation-alternatives><mixed-citation xml:lang="ru">Veinot JP, Edwards WD. Pathology of radiation-induced heart disease: a surgical and autopsy study of 27 cases. Hum Pathol. 1996;27(8):766-773. https://doi.org/10.1016/s0046-8177(96)90447-5</mixed-citation><mixed-citation xml:lang="en">Veinot JP, Edwards WD. Pathology of radiation-induced heart disease: a surgical and autopsy study of 27 cases. Hum Pathol. 1996;27(8):766-773. https://doi.org/10.1016/s0046-8177(96)90447-5</mixed-citation></citation-alternatives></ref><ref id="cit345"><label>345</label><citation-alternatives><mixed-citation xml:lang="ru">McEniery PT, Dorosti K, Schiavone WA, Pedrick TJ, Sheldon WC. Clinical and angiographic features of coronary artery disease after chest irradiation. Am J Cardiol. 1987;60(13):1020-1024. https://doi.org/10.1016/0002-9149(87)90345-6</mixed-citation><mixed-citation xml:lang="en">McEniery PT, Dorosti K, Schiavone WA, Pedrick TJ, Sheldon WC. Clinical and angiographic features of coronary artery disease after chest irradiation. Am J Cardiol. 1987;60(13):1020-1024. https://doi.org/10.1016/0002-9149(87)90345-6</mixed-citation></citation-alternatives></ref><ref id="cit346"><label>346</label><citation-alternatives><mixed-citation xml:lang="ru">Jacobse JN, Duane FK, Boekel NB, et al. Radiation Dose-Response for Risk of Myocardial Infarction in Breast Cancer Survivors. Int J Radiat Oncol Biol Phys. 2019;103(3):595-604. https://doi.org/10.1016/j.ijrobp.2018.10.025</mixed-citation><mixed-citation xml:lang="en">Jacobse JN, Duane FK, Boekel NB, et al. Radiation Dose-Response for Risk of Myocardial Infarction in Breast Cancer Survivors. Int J Radiat Oncol Biol Phys. 2019;103(3):595-604. https://doi.org/10.1016/j.ijrobp.2018.10.025</mixed-citation></citation-alternatives></ref><ref id="cit347"><label>347</label><citation-alternatives><mixed-citation xml:lang="ru">Hering D, Faber L, Horstkotte D. Echocardiographic features of radiationassociated valvular disease. Am J Cardiol. 2003;92(2):226-230. https://doi.org/10.1016/s0002-9149(03)00546-0</mixed-citation><mixed-citation xml:lang="en">Hering D, Faber L, Horstkotte D. Echocardiographic features of radiationassociated valvular disease. Am J Cardiol. 2003;92(2):226-230. https://doi.org/10.1016/s0002-9149(03)00546-0</mixed-citation></citation-alternatives></ref><ref id="cit348"><label>348</label><citation-alternatives><mixed-citation xml:lang="ru">Brouwer CA, Postma A, Hooimeijer HL, et al. Endothelial damage in long-term survivors of childhood cancer. J Clin Oncol. 2013;31(31):3906-3913. https://doi.org/10.1200/JCO.2012.46.6086</mixed-citation><mixed-citation xml:lang="en">Brouwer CA, Postma A, Hooimeijer HL, et al. Endothelial damage in long-term survivors of childhood cancer. J Clin Oncol. 2013;31(31):3906-3913. https://doi.org/10.1200/JCO.2012.46.6086</mixed-citation></citation-alternatives></ref><ref id="cit349"><label>349</label><citation-alternatives><mixed-citation xml:lang="ru">Correa CR, Litt HI, Hwang WT, Ferrari VA, Solin LJ, Harris EE. Coronary artery fndings after left-sided compared with right-sided radiation treatment for early-stage breast cancer. J Clin Oncol. 2007;25(21):3031-3037. https://doi.org/10.1200/JCO.2006.08.6595</mixed-citation><mixed-citation xml:lang="en">Correa CR, Litt HI, Hwang WT, Ferrari VA, Solin LJ, Harris EE. Coronary artery fndings after left-sided compared with right-sided radiation treatment for early-stage breast cancer. J Clin Oncol. 2007;25(21):3031-3037. https://doi.org/10.1200/JCO.2006.08.6595</mixed-citation></citation-alternatives></ref><ref id="cit350"><label>350</label><citation-alternatives><mixed-citation xml:lang="ru">Storey MR, Munden R, Strom EA, McNeese MD, Buchholz TA. Coronary artery dosimetry in intact left breast irradiation. Cancer J. 2001;7(6):492-497</mixed-citation><mixed-citation xml:lang="en">Storey MR, Munden R, Strom EA, McNeese MD, Buchholz TA. Coronary artery dosimetry in intact left breast irradiation. Cancer J. 2001;7(6):492-497</mixed-citation></citation-alternatives></ref><ref id="cit351"><label>351</label><citation-alternatives><mixed-citation xml:lang="ru">Taylor C, McGale P, Brønnum D, et al. Cardiac Structure Injury After Radiotherapy for Breast Cancer: Cross-Sectional Study With Individual Patient Data. J Clin Oncol. 2018;36(22):2288-2296. https://doi.org/10.1200/JCO.2017.77.6351</mixed-citation><mixed-citation xml:lang="en">Taylor C, McGale P, Brønnum D, et al. Cardiac Structure Injury After Radiotherapy for Breast Cancer: Cross-Sectional Study With Individual Patient Data. J Clin Oncol. 2018;36(22):2288-2296. https://doi.org/10.1200/JCO.2017.77.6351</mixed-citation></citation-alternatives></ref><ref id="cit352"><label>352</label><citation-alternatives><mixed-citation xml:lang="ru">Hull MC, Morris CG, Pepine CJ, Mendenhall NP. Valvular dysfunction and carotid, subclavian, and coronary artery disease in survivors of hodgkin lymphoma treated with radiation therapy. JAMA. 2003;290(21):2831-2837.https://doi.org/10.1001/jama.290.21.2831</mixed-citation><mixed-citation xml:lang="en">Hull MC, Morris CG, Pepine CJ, Mendenhall NP. Valvular dysfunction and carotid, subclavian, and coronary artery disease in survivors of hodgkin lymphoma treated with radiation therapy. JAMA. 2003;290(21):2831-2837.https://doi.org/10.1001/jama.290.21.2831</mixed-citation></citation-alternatives></ref><ref id="cit353"><label>353</label><citation-alternatives><mixed-citation xml:lang="ru">Oeffnger KC, Mertens AC, Sklar CA, et al. Chronic health conditions in adult survivors of childhood cancer. N Engl J Med. 2006;355(15):1572-1582. https://doi.org/10.1056/NEJMsa060185</mixed-citation><mixed-citation xml:lang="en">Oeffnger KC, Mertens AC, Sklar CA, et al. Chronic health conditions in adult survivors of childhood cancer. N Engl J Med. 2006;355(15):1572-1582. https://doi.org/10.1056/NEJMsa060185</mixed-citation></citation-alternatives></ref><ref id="cit354"><label>354</label><citation-alternatives><mixed-citation xml:lang="ru">Orzan F, Brusca A, Conte MR, Presbitero P, Figliomeni MC. Severe coronary artery disease after radiation therapy of the chest and mediastinum: clinical presentation and treatment. Br Heart J. 1993;69(6):496-500. https://doi.org/10.1136/hrt.69.6.496</mixed-citation><mixed-citation xml:lang="en">Orzan F, Brusca A, Conte MR, Presbitero P, Figliomeni MC. Severe coronary artery disease after radiation therapy of the chest and mediastinum: clinical presentation and treatment. Br Heart J. 1993;69(6):496-500. https://doi.org/10.1136/hrt.69.6.496</mixed-citation></citation-alternatives></ref><ref id="cit355"><label>355</label><citation-alternatives><mixed-citation xml:lang="ru">Vijayakumar S, Rosenberg I, Spelbring D, Brandt T. Estimation of doses to heart, coronary arteries, and spinal cord in mediastinal irradiation for Hodgkin’s disease. Med Dosim. 1991;16(4):237-241. https://doi.org/10.1016/0958-3947(91)90089-k</mixed-citation><mixed-citation xml:lang="en">Vijayakumar S, Rosenberg I, Spelbring D, Brandt T. Estimation of doses to heart, coronary arteries, and spinal cord in mediastinal irradiation for Hodgkin’s disease. Med Dosim. 1991;16(4):237-241. https://doi.org/10.1016/0958-3947(91)90089-k</mixed-citation></citation-alternatives></ref><ref id="cit356"><label>356</label><citation-alternatives><mixed-citation xml:lang="ru">Prosnitz RG, Hubbs JL, Evans ES, et al. Prospective assessment of radiotherapy-associated cardiac toxicity in breast cancer patients: analysis of data 3 to 6 years after treatment. Cancer. 2007;110(8):1840-1850. https://doi.org/10.1002/cncr.22965</mixed-citation><mixed-citation xml:lang="en">Prosnitz RG, Hubbs JL, Evans ES, et al. Prospective assessment of radiotherapy-associated cardiac toxicity in breast cancer patients: analysis of data 3 to 6 years after treatment. Cancer. 2007;110(8):1840-1850. https://doi.org/10.1002/cncr.22965</mixed-citation></citation-alternatives></ref><ref id="cit357"><label>357</label><citation-alternatives><mixed-citation xml:lang="ru">Gyenes G, Fornander T, Carlens P, Glas U, Rutqvist LE. Detection of radiationinduced myocardial damage by technetium-99m sestamibi scintigraphy. Eur J Nucl Med. 1997;24(3):286-292. https://doi.org/10.1007/BF01728765</mixed-citation><mixed-citation xml:lang="en">Gyenes G, Fornander T, Carlens P, Glas U, Rutqvist LE. Detection of radiationinduced myocardial damage by technetium-99m sestamibi scintigraphy. Eur J Nucl Med. 1997;24(3):286-292. https://doi.org/10.1007/BF01728765</mixed-citation></citation-alternatives></ref><ref id="cit358"><label>358</label><citation-alternatives><mixed-citation xml:lang="ru">de Haas EC, Oosting SF, Lefrandt JD, Wolffenbuttel BH, Sleijfer DT, Gietema JA. The metabolic syndrome in cancer survivors. Lancet Oncol. 2010;11(2):193-203. https://doi.org/10.1016/S1470-2045(09)70287-6</mixed-citation><mixed-citation xml:lang="en">de Haas EC, Oosting SF, Lefrandt JD, Wolffenbuttel BH, Sleijfer DT, Gietema JA. The metabolic syndrome in cancer survivors. Lancet Oncol. 2010;11(2):193-203. https://doi.org/10.1016/S1470-2045(09)70287-6</mixed-citation></citation-alternatives></ref><ref id="cit359"><label>359</label><citation-alternatives><mixed-citation xml:lang="ru">Reed GW, Masri A, Griffn BP, Kapadia SR, Ellis SG, Desai MY. Long-Term Mortality in Patients With Radiation-Associated Coronary Artery Disease Treated With Percutaneous Coronary Intervention. Circ Cardiovasc Interv. 2016;9(6):e003483. https://doi.org/10.1161/CIRCINTERVENTIONS.115.003483</mixed-citation><mixed-citation xml:lang="en">Reed GW, Masri A, Griffn BP, Kapadia SR, Ellis SG, Desai MY. Long-Term Mortality in Patients With Radiation-Associated Coronary Artery Disease Treated With Percutaneous Coronary Intervention. Circ Cardiovasc Interv. 2016;9(6):e003483. https://doi.org/10.1161/CIRCINTERVENTIONS.115.003483</mixed-citation></citation-alternatives></ref><ref id="cit360"><label>360</label><citation-alternatives><mixed-citation xml:lang="ru">Fender EA, Liang JJ, Sio TT, et al. Percutaneous revascularization in patients treated with thoracic radiation for cancer. Am Heart J. 2017;187:98-103. https://doi.org/10.1016/j.ahj.2017.02.014</mixed-citation><mixed-citation xml:lang="en">Fender EA, Liang JJ, Sio TT, et al. Percutaneous revascularization in patients treated with thoracic radiation for cancer. Am Heart J. 2017;187:98-103. https://doi.org/10.1016/j.ahj.2017.02.014</mixed-citation></citation-alternatives></ref><ref id="cit361"><label>361</label><citation-alternatives><mixed-citation xml:lang="ru">Bijl JM, Roos MM, van Leeuwen-Segarceanu EM, et al. Assessment of Valvular Disorders in Survivors of Hodgkin’s Lymphoma Treated by Mediastinal Radiotherapy ± Chemotherapy. Am J Cardiol. 2016;117(4):691-696. https://doi.org/10.1016/j.amjcard.2015.11.027</mixed-citation><mixed-citation xml:lang="en">Bijl JM, Roos MM, van Leeuwen-Segarceanu EM, et al. Assessment of Valvular Disorders in Survivors of Hodgkin’s Lymphoma Treated by Mediastinal Radiotherapy ± Chemotherapy. Am J Cardiol. 2016;117(4):691-696. https://doi.org/10.1016/j.amjcard.2015.11.027</mixed-citation></citation-alternatives></ref><ref id="cit362"><label>362</label><citation-alternatives><mixed-citation xml:lang="ru">Brand MD, Abadi CA, Aurigemma GP, Dauerman HL, Meyer TE. Radiationassociated valvular heart disease in Hodgkin’s disease is associated with characteristic thickening and fbrosis of the aortic-mitral curtain. J Heart Valve Dis. 2001;10(5):681-685</mixed-citation><mixed-citation xml:lang="en">Brand MD, Abadi CA, Aurigemma GP, Dauerman HL, Meyer TE. Radiationassociated valvular heart disease in Hodgkin’s disease is associated with characteristic thickening and fbrosis of the aortic-mitral curtain. J Heart Valve Dis. 2001;10(5):681-685</mixed-citation></citation-alternatives></ref><ref id="cit363"><label>363</label><citation-alternatives><mixed-citation xml:lang="ru">Katz NM, Hall AW, Cerqueira MD. Radiation induced valvulitis with late leaﬂet rupture. Heart. 2001;86(6):E20. https://doi.org/10.1136/heart.86.6.e20</mixed-citation><mixed-citation xml:lang="en">Katz NM, Hall AW, Cerqueira MD. Radiation induced valvulitis with late leaﬂet rupture. Heart. 2001;86(6):E20. https://doi.org/10.1136/heart.86.6.e20</mixed-citation></citation-alternatives></ref><ref id="cit364"><label>364</label><citation-alternatives><mixed-citation xml:lang="ru">Pohjola-Sintonen S, Tötterman KJ, Salmo M, Siltanen P. Late cardiac effects of mediastinal radiotherapy in patients with Hodgkin’s disease. Cancer. 1987;60(1):31-37. https://doi.org/10.1002/1097-0142(19870701)60:1&lt;31::aid-cncr2820600107&gt;3.0.co;2-d</mixed-citation><mixed-citation xml:lang="en">Pohjola-Sintonen S, Tötterman KJ, Salmo M, Siltanen P. Late cardiac effects of mediastinal radiotherapy in patients with Hodgkin’s disease. Cancer. 1987;60(1):31-37. https://doi.org/10.1002/1097-0142(19870701)60:1&lt;31::aid-cncr2820600107&gt;3.0.co;2-d</mixed-citation></citation-alternatives></ref><ref id="cit365"><label>365</label><citation-alternatives><mixed-citation xml:lang="ru">Donnellan E, Griffn BP, Johnston DR, et al. Rate of Progression of Aortic Stenosis and its Impact on Outcomes in Patients With Radiation-Associated Cardiac Disease: A Matched Cohort Study. JACC Cardiovasc Imaging. 2018;11(8):1072-1080. https://doi.org/10.1016/j.jcmg.2018.04.019</mixed-citation><mixed-citation xml:lang="en">Donnellan E, Griffn BP, Johnston DR, et al. Rate of Progression of Aortic Stenosis and its Impact on Outcomes in Patients With Radiation-Associated Cardiac Disease: A Matched Cohort Study. JACC Cardiovasc Imaging. 2018;11(8):1072-1080. https://doi.org/10.1016/j.jcmg.2018.04.019</mixed-citation></citation-alternatives></ref><ref id="cit366"><label>366</label><citation-alternatives><mixed-citation xml:lang="ru">Cutter DJ, Schaapveld M, Darby SC, et al. Risk of valvular heart disease after treatment for Hodgkin lymphoma. J Natl Cancer Inst. 2015;107(4):djv008. Published 2015 Feb 23. https://doi.org/10.1093/jnci/djv008</mixed-citation><mixed-citation xml:lang="en">Cutter DJ, Schaapveld M, Darby SC, et al. Risk of valvular heart disease after treatment for Hodgkin lymphoma. J Natl Cancer Inst. 2015;107(4):djv008. Published 2015 Feb 23. https://doi.org/10.1093/jnci/djv008</mixed-citation></citation-alternatives></ref><ref id="cit367"><label>367</label><citation-alternatives><mixed-citation xml:lang="ru">Groarke JD, Nguyen PL, Nohria A, Ferrari R, Cheng S, Moslehi J. Cardiovascular complications of radiation therapy for thoracic malignancies: the role for non-invasive imaging for detection of cardiovascular disease. Eur Heart J. 2014;35(10):612-623. https://doi.org/10.1093/eurheartj/eht114</mixed-citation><mixed-citation xml:lang="en">Groarke JD, Nguyen PL, Nohria A, Ferrari R, Cheng S, Moslehi J. Cardiovascular complications of radiation therapy for thoracic malignancies: the role for non-invasive imaging for detection of cardiovascular disease. Eur Heart J. 2014;35(10):612-623. https://doi.org/10.1093/eurheartj/eht114</mixed-citation></citation-alternatives></ref><ref id="cit368"><label>368</label><citation-alternatives><mixed-citation xml:lang="ru">Donnellan E, Masri A, Johnston DR, et al. Long-Term Outcomes of Patients With Mediastinal Radiation -Associated Severe Aortic Stenosis and Subsequent Surgical Aortic Valve Replacement: A Matched Cohort Study. J Am Heart Assoc. 2017;6(5):e005396. Published 2017 May 5. https://doi.org/10.1161/JAHA.116.005396</mixed-citation><mixed-citation xml:lang="en">Donnellan E, Masri A, Johnston DR, et al. Long-Term Outcomes of Patients With Mediastinal Radiation -Associated Severe Aortic Stenosis and Subsequent Surgical Aortic Valve Replacement: A Matched Cohort Study. J Am Heart Assoc. 2017;6(5):e005396. Published 2017 May 5. https://doi.org/10.1161/JAHA.116.005396</mixed-citation></citation-alternatives></ref><ref id="cit369"><label>369</label><citation-alternatives><mixed-citation xml:lang="ru">Desai MY, Cremer PC, Schoenhagen P. Thoracic Aortic Calcifcation: Diagnostic, Prognostic, and Management Considerations. JACC Cardiovasc Imaging. 2018;11(7):1012-1026. https://doi.org/10.1016/j.jcmg.2018.03.023</mixed-citation><mixed-citation xml:lang="en">Desai MY, Cremer PC, Schoenhagen P. Thoracic Aortic Calcifcation: Diagnostic, Prognostic, and Management Considerations. JACC Cardiovasc Imaging. 2018;11(7):1012-1026. https://doi.org/10.1016/j.jcmg.2018.03.023</mixed-citation></citation-alternatives></ref><ref id="cit370"><label>370</label><citation-alternatives><mixed-citation xml:lang="ru">Joint Task Force on the Management of Valvular Heart Disease of the European Society of Cardiology (ESC); European Association for CardioThoracic Surgery (EACTS), Vahanian A, et al. Guidelines on the management of valvular heart disease (version 2012). Eur Heart J. 2012;33(19):2451-2496. https://doi.org/10.1093/eurheartj/ehs109</mixed-citation><mixed-citation xml:lang="en">Joint Task Force on the Management of Valvular Heart Disease of the European Society of Cardiology (ESC); European Association for CardioThoracic Surgery (EACTS), Vahanian A, et al. Guidelines on the management of valvular heart disease (version 2012). Eur Heart J. 2012;33(19):2451-2496. https://doi.org/10.1093/eurheartj/ehs109</mixed-citation></citation-alternatives></ref><ref id="cit371"><label>371</label><citation-alternatives><mixed-citation xml:lang="ru">Zafar MR, Mustafa SF, Miller TW, Alkhawlani T, Sharma UC. Outcomes after transcatheter aortic valve replacement in cancer survivors with prior chest radiation therapy: a systematic review and meta-analysis. Cardiooncology. 2020;6:8. Published 2020 Jul 14. https://doi.org/10.1186/s40959-020-00062-y</mixed-citation><mixed-citation xml:lang="en">Zafar MR, Mustafa SF, Miller TW, Alkhawlani T, Sharma UC. Outcomes after transcatheter aortic valve replacement in cancer survivors with prior chest radiation therapy: a systematic review and meta-analysis. Cardiooncology. 2020;6:8. Published 2020 Jul 14. https://doi.org/10.1186/s40959-020-00062-y</mixed-citation></citation-alternatives></ref><ref id="cit372"><label>372</label><citation-alternatives><mixed-citation xml:lang="ru">De Bruin ML, Dorresteijn LD, van’t Veer MB, et al. Increased risk of stroke and transient ischemic attack in 5-year survivors of Hodgkin lymphoma. J Natl Cancer Inst. 2009;101(13):928-937. https://doi.org/10.1093/jnci/djp147</mixed-citation><mixed-citation xml:lang="en">De Bruin ML, Dorresteijn LD, van’t Veer MB, et al. Increased risk of stroke and transient ischemic attack in 5-year survivors of Hodgkin lymphoma. J Natl Cancer Inst. 2009;101(13):928-937. https://doi.org/10.1093/jnci/djp147</mixed-citation></citation-alternatives></ref><ref id="cit373"><label>373</label><citation-alternatives><mixed-citation xml:lang="ru">Yuan H, Gaber MW, Boyd K, Wilson CM, Kiani MF, Merchant TE. Effects of fractionated radiation on the brain vasculature in a murine model: blood-brain barrier permeability, astrocyte proliferation, and ultrastructural changes. Int J Radiat Oncol Biol Phys. 2006;66(3):860-866. https://doi.org/10.1016/j.ijrobp.2006.06.043</mixed-citation><mixed-citation xml:lang="en">Yuan H, Gaber MW, Boyd K, Wilson CM, Kiani MF, Merchant TE. Effects of fractionated radiation on the brain vasculature in a murine model: blood-brain barrier permeability, astrocyte proliferation, and ultrastructural changes. Int J Radiat Oncol Biol Phys. 2006;66(3):860-866. https://doi.org/10.1016/j.ijrobp.2006.06.043</mixed-citation></citation-alternatives></ref><ref id="cit374"><label>374</label><citation-alternatives><mixed-citation xml:lang="ru">Louis EL, McLoughlin MJ, Wortzman G. Chronic damage to medium and large arteries following irradiation. J Can Assoc Radiol. 1974;25(2):94-104</mixed-citation><mixed-citation xml:lang="en">Louis EL, McLoughlin MJ, Wortzman G. Chronic damage to medium and large arteries following irradiation. J Can Assoc Radiol. 1974;25(2):94-104</mixed-citation></citation-alternatives></ref><ref id="cit375"><label>375</label><citation-alternatives><mixed-citation xml:lang="ru">Fajardo LF. The pathology of ionizing radiation as defned by morphologic patterns. Acta Oncol. 2005;44(1):13-22. https://doi.org/10.1080/02841860510007440</mixed-citation><mixed-citation xml:lang="en">Fajardo LF. The pathology of ionizing radiation as defned by morphologic patterns. Acta Oncol. 2005;44(1):13-22. https://doi.org/10.1080/02841860510007440</mixed-citation></citation-alternatives></ref><ref id="cit376"><label>376</label><citation-alternatives><mixed-citation xml:lang="ru">Jurado JA, Bashir R, Burket MW. Radiation-induced peripheral artery disease. Catheter Cardiovasc Interv. 2008;72(4):563-568. https://doi.org/10.1002/ccd.21681</mixed-citation><mixed-citation xml:lang="en">Jurado JA, Bashir R, Burket MW. Radiation-induced peripheral artery disease. Catheter Cardiovasc Interv. 2008;72(4):563-568. https://doi.org/10.1002/ccd.21681</mixed-citation></citation-alternatives></ref><ref id="cit377"><label>377</label><citation-alternatives><mixed-citation xml:lang="ru">European Stroke Organisation, Tendera M, Aboyans V, et al. ESC Guidelines on the diagnosis and treatment of peripheral artery diseases: Document covering atherosclerotic disease of extracranial carotid and vertebral, mesenteric, renal, upper and lower extremity arteries: the Task Force on the Diagnosis and Treatment of Peripheral Artery Diseases of the European Society of Cardiology (ESC). Eur Heart J. 2011;32(22):2851-2906. https://doi.org/10.1093/eurheartj/ehr211</mixed-citation><mixed-citation xml:lang="en">European Stroke Organisation, Tendera M, Aboyans V, et al. ESC Guidelines on the diagnosis and treatment of peripheral artery diseases: Document covering atherosclerotic disease of extracranial carotid and vertebral, mesenteric, renal, upper and lower extremity arteries: the Task Force on the Diagnosis and Treatment of Peripheral Artery Diseases of the European Society of Cardiology (ESC). Eur Heart J. 2011;32(22):2851-2906. https://doi.org/10.1093/eurheartj/ehr211</mixed-citation></citation-alternatives></ref><ref id="cit378"><label>378</label><citation-alternatives><mixed-citation xml:lang="ru">Fokkema M, den Hartog AG, Bots ML, van der Tweel I, Moll FL, de Borst GJ. Stenting versus surgery in patients with carotid stenosis after previous cervical radiation therapy: systematic review and meta-analysis. Stroke. 2012;43(3):793-801. https://doi.org/10.1161/STROKEAHA.111.633743</mixed-citation><mixed-citation xml:lang="en">Fokkema M, den Hartog AG, Bots ML, van der Tweel I, Moll FL, de Borst GJ. Stenting versus surgery in patients with carotid stenosis after previous cervical radiation therapy: systematic review and meta-analysis. Stroke. 2012;43(3):793-801. https://doi.org/10.1161/STROKEAHA.111.633743</mixed-citation></citation-alternatives></ref><ref id="cit379"><label>379</label><citation-alternatives><mixed-citation xml:lang="ru">Gujral DM, Shah BN, Chahal NS, Senior R, Harrington KJ, Nutting CM. Clinical features of radiation-induced carotid atherosclerosis. Clin Oncol (R Coll Radiol). 2014;26(2):94-102. https://doi.org/10.1016/j.clon.2013.10.002</mixed-citation><mixed-citation xml:lang="en">Gujral DM, Shah BN, Chahal NS, Senior R, Harrington KJ, Nutting CM. Clinical features of radiation-induced carotid atherosclerosis. Clin Oncol (R Coll Radiol). 2014;26(2):94-102. https://doi.org/10.1016/j.clon.2013.10.002</mixed-citation></citation-alternatives></ref><ref id="cit380"><label>380</label><citation-alternatives><mixed-citation xml:lang="ru">Ness KK, Armstrong GT. Screening for cardiac autonomic dysfunction among Hodgkin lymphoma survivors treated with thoracic radiation. J Am Coll Cardiol. 2015;65(6):584-585. https://doi.org/10.1016/j.jacc.2014.11.036</mixed-citation><mixed-citation xml:lang="en">Ness KK, Armstrong GT. Screening for cardiac autonomic dysfunction among Hodgkin lymphoma survivors treated with thoracic radiation. J Am Coll Cardiol. 2015;65(6):584-585. https://doi.org/10.1016/j.jacc.2014.11.036</mixed-citation></citation-alternatives></ref><ref id="cit381"><label>381</label><citation-alternatives><mixed-citation xml:lang="ru">Armanious MA, Mishra S, Fradley MG. Electrophysiologic Toxicity of Chemoradiation. Curr Oncol Rep. 2018;20(6):45. Published 2018 Apr 11. https://doi.org/10.1007/s11912-018-0691-0</mixed-citation><mixed-citation xml:lang="en">Armanious MA, Mishra S, Fradley MG. Electrophysiologic Toxicity of Chemoradiation. Curr Oncol Rep. 2018;20(6):45. Published 2018 Apr 11. https://doi.org/10.1007/s11912-018-0691-0</mixed-citation></citation-alternatives></ref><ref id="cit382"><label>382</label><citation-alternatives><mixed-citation xml:lang="ru">Adler Y, Charron P, Imazio M, et al. 2015 ESC Guidelines for the diagnosis and management of pericardial diseases: The Task Force for the Diagnosis and Management of Pericardial Diseases of the European Society of Cardiology (ESC)Endorsed by: The European Association for Cardio-Thoracic Surgery (EACTS). Eur Heart J. 2015;36(42):2921-2964. https://doi.org/10.1093/eurheartj/ehv318</mixed-citation><mixed-citation xml:lang="en">Adler Y, Charron P, Imazio M, et al. 2015 ESC Guidelines for the diagnosis and management of pericardial diseases: The Task Force for the Diagnosis and Management of Pericardial Diseases of the European Society of Cardiology (ESC)Endorsed by: The European Association for Cardio-Thoracic Surgery (EACTS). Eur Heart J. 2015;36(42):2921-2964. https://doi.org/10.1093/eurheartj/ehv318</mixed-citation></citation-alternatives></ref><ref id="cit383"><label>383</label><citation-alternatives><mixed-citation xml:lang="ru">Stewart JR, Fajardo LF, Gillette SM, Constine LS. Radiation injury to the heart. Int J Radiat Oncol Biol Phys. 1995;31(5):1205-1211. https://doi.org/10.1016/0360-3016(94)00656-6</mixed-citation><mixed-citation xml:lang="en">Stewart JR, Fajardo LF, Gillette SM, Constine LS. Radiation injury to the heart. Int J Radiat Oncol Biol Phys. 1995;31(5):1205-1211. https://doi.org/10.1016/0360-3016(94)00656-6</mixed-citation></citation-alternatives></ref><ref id="cit384"><label>384</label><citation-alternatives><mixed-citation xml:lang="ru">Applefeld MM, Wiernik PH. Cardiac disease after radiation therapy for Hodgkin’s disease: analysis of 48 patients. Am J Cardiol. 1983;51(10):1679-1681. https://doi.org/10.1016/0002-9149(83)90209-6</mixed-citation><mixed-citation xml:lang="en">Applefeld MM, Wiernik PH. Cardiac disease after radiation therapy for Hodgkin’s disease: analysis of 48 patients. Am J Cardiol. 1983;51(10):1679-1681. https://doi.org/10.1016/0002-9149(83)90209-6</mixed-citation></citation-alternatives></ref><ref id="cit385"><label>385</label><citation-alternatives><mixed-citation xml:lang="ru">Maisch B, Ristic A, Pankuweit S. Evaluation and management of pericardial effusion in patients with neoplastic disease. Prog Cardiovasc Dis. 2010;53(2):157-163. https://doi.org/10.1016/j.pcad.2010.06.003</mixed-citation><mixed-citation xml:lang="en">Maisch B, Ristic A, Pankuweit S. Evaluation and management of pericardial effusion in patients with neoplastic disease. Prog Cardiovasc Dis. 2010;53(2):157-163. https://doi.org/10.1016/j.pcad.2010.06.003</mixed-citation></citation-alternatives></ref><ref id="cit386"><label>386</label><citation-alternatives><mixed-citation xml:lang="ru">Welch TD, Ling LH, Espinosa RE, et al. Echocardiographic diagnosis of constrictive pericarditis: Mayo Clinic criteria. Circ Cardiovasc Imaging. 2014;7(3):526-534. https://doi.org/10.1161/CIRCIMAGING.113.001613</mixed-citation><mixed-citation xml:lang="en">Welch TD, Ling LH, Espinosa RE, et al. Echocardiographic diagnosis of constrictive pericarditis: Mayo Clinic criteria. Circ Cardiovasc Imaging. 2014;7(3):526-534. https://doi.org/10.1161/CIRCIMAGING.113.001613</mixed-citation></citation-alternatives></ref><ref id="cit387"><label>387</label><citation-alternatives><mixed-citation xml:lang="ru">Bertog SC, Thambidorai SK, Parakh K, et al. Constrictive pericarditis: etiology and cause-specifc survival after pericardiectomy. J Am Coll Cardiol. 2004;43(8):1445-1452. https://doi.org/10.1016/j.jacc.2003.11.048</mixed-citation><mixed-citation xml:lang="en">Bertog SC, Thambidorai SK, Parakh K, et al. Constrictive pericarditis: etiology and cause-specifc survival after pericardiectomy. J Am Coll Cardiol. 2004;43(8):1445-1452. https://doi.org/10.1016/j.jacc.2003.11.048</mixed-citation></citation-alternatives></ref><ref id="cit388"><label>388</label><citation-alternatives><mixed-citation xml:lang="ru">Bentzen SM, Constine LS, Deasy JO, et al. Quantitative Analyses of Normal Tissue Effects in the Clinic (QUANTEC): an introduction to the scientifc issues. Int J Radiat Oncol Biol Phys. 2010;76(3 Suppl):S3-S9. https://doi.org/10.1016/j.ijrobp.2009.09.040</mixed-citation><mixed-citation xml:lang="en">Bentzen SM, Constine LS, Deasy JO, et al. Quantitative Analyses of Normal Tissue Effects in the Clinic (QUANTEC): an introduction to the scientifc issues. Int J Radiat Oncol Biol Phys. 2010;76(3 Suppl):S3-S9. https://doi.org/10.1016/j.ijrobp.2009.09.040</mixed-citation></citation-alternatives></ref><ref id="cit389"><label>389</label><citation-alternatives><mixed-citation xml:lang="ru">Prosnitz RG, Chen YH, Marks LB. Cardiac toxicity following thoracic radiation. Semin Oncol. 2005;32(2 Suppl 3):S71-S80. https://doi.org/10.1053/j.seminoncol.2005.03.013</mixed-citation><mixed-citation xml:lang="en">Prosnitz RG, Chen YH, Marks LB. Cardiac toxicity following thoracic radiation. Semin Oncol. 2005;32(2 Suppl 3):S71-S80. https://doi.org/10.1053/j.seminoncol.2005.03.013</mixed-citation></citation-alternatives></ref><ref id="cit390"><label>390</label><citation-alternatives><mixed-citation xml:lang="ru">Louwe RJ, Wendling M, van Herk MB, Mijnheer BJ. Three-dimensional heart dose reconstruction to estimate normal tissue complication probability after breast irradiation using portal dosimetry. Med Phys. 2007;34(4):1354-1363. https://doi.org/10.1118/1.2713216</mixed-citation><mixed-citation xml:lang="en">Louwe RJ, Wendling M, van Herk MB, Mijnheer BJ. Three-dimensional heart dose reconstruction to estimate normal tissue complication probability after breast irradiation using portal dosimetry. Med Phys. 2007;34(4):1354-1363. https://doi.org/10.1118/1.2713216</mixed-citation></citation-alternatives></ref><ref id="cit391"><label>391</label><citation-alternatives><mixed-citation xml:lang="ru">McDonald MW, Godette KD, Whitaker DJ, Davis LW, Johnstone PA. Three-year outcomes of breast intensity-modulated radiation therapy with simultaneous integrated boost. Int J Radiat Oncol Biol Phys. 2010;77(2):523-530. https://doi.org/10.1016/j.ijrobp.2009.05.042</mixed-citation><mixed-citation xml:lang="en">McDonald MW, Godette KD, Whitaker DJ, Davis LW, Johnstone PA. Three-year outcomes of breast intensity-modulated radiation therapy with simultaneous integrated boost. Int J Radiat Oncol Biol Phys. 2010;77(2):523-530. https://doi.org/10.1016/j.ijrobp.2009.05.042</mixed-citation></citation-alternatives></ref><ref id="cit392"><label>392</label><citation-alternatives><mixed-citation xml:lang="ru">Tan W, Liu D, Xue C, et al. Anterior myocardial territory may replace the heart as organ at risk in intensity-modulated radiotherapy for left-sided breast cancer. Int J Radiat Oncol Biol Phys. 2012;82(5):1689-1697. https://doi.org/10.1016/j.ijrobp.2011.03.009</mixed-citation><mixed-citation xml:lang="en">Tan W, Liu D, Xue C, et al. Anterior myocardial territory may replace the heart as organ at risk in intensity-modulated radiotherapy for left-sided breast cancer. Int J Radiat Oncol Biol Phys. 2012;82(5):1689-1697. https://doi.org/10.1016/j.ijrobp.2011.03.009</mixed-citation></citation-alternatives></ref><ref id="cit393"><label>393</label><citation-alternatives><mixed-citation xml:lang="ru">Baycan D, Karacetin D, Balkanay AY, Barut Y. Field-in-feld IMRT versus 3D-CRT of the breast. Cardiac vessels, ipsilateral lung, and contralateral breast absorbed doses in patients with left-sided lumpectomy: a dosimetric comparison. Jpn J Radiol. 2012;30(10):819-823. https://doi.org/10.1007/s11604-012-0126-z</mixed-citation><mixed-citation xml:lang="en">Baycan D, Karacetin D, Balkanay AY, Barut Y. Field-in-feld IMRT versus 3D-CRT of the breast. Cardiac vessels, ipsilateral lung, and contralateral breast absorbed doses in patients with left-sided lumpectomy: a dosimetric comparison. Jpn J Radiol. 2012;30(10):819-823. https://doi.org/10.1007/s11604-012-0126-z</mixed-citation></citation-alternatives></ref><ref id="cit394"><label>394</label><citation-alternatives><mixed-citation xml:lang="ru">Bruzzaniti V, Abate A, Pinnarò P, et al. Dosimetric and clinical advantages of deep inspiration breath-hold (DIBH) during radiotherapy of breast cancer. J Exp Clin Cancer Res. 2013;32(1):88. Published 2013 Nov 7. https://doi.org/10.1186/1756-9966-32-88</mixed-citation><mixed-citation xml:lang="en">Bruzzaniti V, Abate A, Pinnarò P, et al. Dosimetric and clinical advantages of deep inspiration breath-hold (DIBH) during radiotherapy of breast cancer. J Exp Clin Cancer Res. 2013;32(1):88. Published 2013 Nov 7. https://doi.org/10.1186/1756-9966-32-88</mixed-citation></citation-alternatives></ref><ref id="cit395"><label>395</label><citation-alternatives><mixed-citation xml:lang="ru">Xu Q, Chen Y, Grimm J, et al. Dosimetric investigation of accelerated partial breast irradiation (APBI) using CyberKnife. Med Phys. 2012;39(11):6621-6628. https://doi.org/10.1118/1.4757616</mixed-citation><mixed-citation xml:lang="en">Xu Q, Chen Y, Grimm J, et al. Dosimetric investigation of accelerated partial breast irradiation (APBI) using CyberKnife. Med Phys. 2012;39(11):6621-6628. https://doi.org/10.1118/1.4757616</mixed-citation></citation-alternatives></ref><ref id="cit396"><label>396</label><citation-alternatives><mixed-citation xml:lang="ru">Bartlett FR, Colgan RM, Donovan EM, et al. The UK HeartSpare Study (Stage IB): randomised comparison of a voluntary breath-hold technique and prone radiotherapy after breast conserving surgery. Radiother Oncol. 2015;114(1):66-72. https://doi.org/10.1016/j.radonc.2014.11.018</mixed-citation><mixed-citation xml:lang="en">Bartlett FR, Colgan RM, Donovan EM, et al. The UK HeartSpare Study (Stage IB): randomised comparison of a voluntary breath-hold technique and prone radiotherapy after breast conserving surgery. Radiother Oncol. 2015;114(1):66-72. https://doi.org/10.1016/j.radonc.2014.11.018</mixed-citation></citation-alternatives></ref><ref id="cit397"><label>397</label><citation-alternatives><mixed-citation xml:lang="ru">Utehina O. Healthy tissue sparing postoperative radiotherapy for treatment of early stage breast cancer. – Riga, Summary of the doctoral thesis, 2009, p.32.</mixed-citation><mixed-citation xml:lang="en">Utehina O. Healthy tissue sparing postoperative radiotherapy for treatment of early stage breast cancer. – Riga, Summary of the doctoral thesis, 2009, p.32.</mixed-citation></citation-alternatives></ref><ref id="cit398"><label>398</label><citation-alternatives><mixed-citation xml:lang="ru">Трофимова О.П., Чебан О.И., Михина З.П., Кардиоваскулярные осложнения у больных РМЖ после органосохраняющего лечения “Медицинская радиология и радиационная безопасность”, 2015г., №1, с.33-38</mixed-citation><mixed-citation xml:lang="en">Трофимова О.П., Чебан О.И., Михина З.П., Кардиоваскулярные осложнения у больных РМЖ после органосохраняющего лечения “Медицинская радиология и радиационная безопасность”, 2015г., №1, с.33-38</mixed-citation></citation-alternatives></ref><ref id="cit399"><label>399</label><citation-alternatives><mixed-citation xml:lang="ru">Piepoli MF, Hoes AW, Agewall S, et al. 2016 European Guidelines on cardiovascular disease prevention in clinical practice: The Sixth Joint Task Force of the European Society of Cardiology and Other Societies on Cardiovascular Disease Prevention in Clinical Practice (constituted by representatives of 10 societies and by invited experts)Developed with the special contribution of the European Association for Cardiovascular Prevention &amp; Rehabilitation (EACPR). Eur Heart J. 2016;37(29):2315-2381. https://doi.org/10.1093/eurheartj/ehw106</mixed-citation><mixed-citation xml:lang="en">Piepoli MF, Hoes AW, Agewall S, et al. 2016 European Guidelines on cardiovascular disease prevention in clinical practice: The Sixth Joint Task Force of the European Society of Cardiology and Other Societies on Cardiovascular Disease Prevention in Clinical Practice (constituted by representatives of 10 societies and by invited experts)Developed with the special contribution of the European Association for Cardiovascular Prevention &amp; Rehabilitation (EACPR). Eur Heart J. 2016;37(29):2315-2381. https://doi.org/10.1093/eurheartj/ehw106</mixed-citation></citation-alternatives></ref><ref id="cit400"><label>400</label><citation-alternatives><mixed-citation xml:lang="ru">Taylor C, Correa C, Duane FK, et al. Estimating the Risks of Breast Cancer Radiotherapy: Evidence From Modern Radiation Doses to the Lungs and Heart and From Previous Randomized Trials. J Clin Oncol. 2017;35(15):1641-1649. https://doi.org/10.1200/JCO.2016.72.0722</mixed-citation><mixed-citation xml:lang="en">Taylor C, Correa C, Duane FK, et al. Estimating the Risks of Breast Cancer Radiotherapy: Evidence From Modern Radiation Doses to the Lungs and Heart and From Previous Randomized Trials. J Clin Oncol. 2017;35(15):1641-1649. https://doi.org/10.1200/JCO.2016.72.0722</mixed-citation></citation-alternatives></ref><ref id="cit401"><label>401</label><citation-alternatives><mixed-citation xml:lang="ru">Copeland KA, Hosmane VR, Jurkovitz C, et al. Frequency of severe valvular disease caused by mediastinal radiation among patients undergoing valve surgery in a community-based, regional academic medical center. Clin Cardiol. 2013;36(4):217-221. https://doi.org/10.1002/clc.22106</mixed-citation><mixed-citation xml:lang="en">Copeland KA, Hosmane VR, Jurkovitz C, et al. Frequency of severe valvular disease caused by mediastinal radiation among patients undergoing valve surgery in a community-based, regional academic medical center. Clin Cardiol. 2013;36(4):217-221. https://doi.org/10.1002/clc.22106</mixed-citation></citation-alternatives></ref><ref id="cit402"><label>402</label><citation-alternatives><mixed-citation xml:lang="ru">Ewer MS, Lenihan DJ. Left ventricular ejection fraction and cardiotoxicity: is our ear really to the ground?. J Clin Oncol. 2008;26(8):1201-1203. https://doi. org/10.1200/JCO.2007.14.8742</mixed-citation><mixed-citation xml:lang="en">Ewer MS, Lenihan DJ. Left ventricular ejection fraction and cardiotoxicity: is our ear really to the ground?. J Clin Oncol. 2008;26(8):1201-1203. https://doi. org/10.1200/JCO.2007.14.8742</mixed-citation></citation-alternatives></ref><ref id="cit403"><label>403</label><citation-alternatives><mixed-citation xml:lang="ru">Lenihan DJ, Cardinale DM. Late cardiac effects of cancer treatment [published correction appears in J Clin Oncol. 2012 Dec 20;30(36):4590]. J Clin Oncol. 2012;30(30):3657-3664. https://doi.org/10.1200/JCO.2012.45.2938</mixed-citation><mixed-citation xml:lang="en">Lenihan DJ, Cardinale DM. Late cardiac effects of cancer treatment [published correction appears in J Clin Oncol. 2012 Dec 20;30(36):4590]. J Clin Oncol. 2012;30(30):3657-3664. https://doi.org/10.1200/JCO.2012.45.2938</mixed-citation></citation-alternatives></ref><ref id="cit404"><label>404</label><citation-alternatives><mixed-citation xml:lang="ru">Machann W, Beer M, Breunig M, et al. Cardiac magnetic resonance imaging fndings in 20-year survivors of mediastinal radiotherapy for Hodgkin’s disease. Int J Radiat Oncol Biol Phys. 2011;79(4):1117-1123. https://doi.org/10.1016/j.ijrobp.2009.12.054</mixed-citation><mixed-citation xml:lang="en">Machann W, Beer M, Breunig M, et al. Cardiac magnetic resonance imaging fndings in 20-year survivors of mediastinal radiotherapy for Hodgkin’s disease. Int J Radiat Oncol Biol Phys. 2011;79(4):1117-1123. https://doi.org/10.1016/j.ijrobp.2009.12.054</mixed-citation></citation-alternatives></ref><ref id="cit405"><label>405</label><citation-alternatives><mixed-citation xml:lang="ru">Koppelmans V, Vernooij MW, Boogerd W, et al. Prevalence of cerebral smallvessel disease in long-term breast cancer survivors exposed to both adjuvant radiotherapy and chemotherapy. J Clin Oncol. 2015;33(6):588-593. https://doi.org/10.1200/JCO.2014.56.8345</mixed-citation><mixed-citation xml:lang="en">Koppelmans V, Vernooij MW, Boogerd W, et al. Prevalence of cerebral smallvessel disease in long-term breast cancer survivors exposed to both adjuvant radiotherapy and chemotherapy. J Clin Oncol. 2015;33(6):588-593. https://doi.org/10.1200/JCO.2014.56.8345</mixed-citation></citation-alternatives></ref><ref id="cit406"><label>406</label><citation-alternatives><mixed-citation xml:lang="ru">Аляутдин РН, ред. Фармакология. Иллюстрированный учебник. М.: ГЭОТАР-Медиа; 2019</mixed-citation><mixed-citation xml:lang="en">Аляутдин РН, ред. Фармакология. Иллюстрированный учебник. М.: ГЭОТАР-Медиа; 2019</mixed-citation></citation-alternatives></ref><ref id="cit407"><label>407</label><citation-alternatives><mixed-citation xml:lang="ru">Yang Y. Cancer immunotherapy: harnessing the immune system to battle cancer. J Clin Invest. 2015;125(9):3335-3337. https://doi.org/10.1172/JCI83871</mixed-citation><mixed-citation xml:lang="en">Yang Y. Cancer immunotherapy: harnessing the immune system to battle cancer. J Clin Invest. 2015;125(9):3335-3337. https://doi.org/10.1172/JCI83871</mixed-citation></citation-alternatives></ref><ref id="cit408"><label>408</label><citation-alternatives><mixed-citation xml:lang="ru">Zhang L, Reynolds KL, Lyon AR, Palaskas N, Neilan TG. The Evolving Immunotherapy Landscape and the Epidemiology, Diagnosis, and Management of Cardiotoxicity: JACC: CardioOncology Primer. JACC CardioOncol. 2021;3(1):35-47. https://doi.org/10.1016/j.jaccao.2020.11.012</mixed-citation><mixed-citation xml:lang="en">Zhang L, Reynolds KL, Lyon AR, Palaskas N, Neilan TG. The Evolving Immunotherapy Landscape and the Epidemiology, Diagnosis, and Management of Cardiotoxicity: JACC: CardioOncology Primer. JACC CardioOncol. 2021;3(1):35-47. https://doi.org/10.1016/j.jaccao.2020.11.012</mixed-citation></citation-alternatives></ref><ref id="cit409"><label>409</label><citation-alternatives><mixed-citation xml:lang="ru">Brahmer JR, Lacchetti C, Schneider BJ, et al. Management of ImmuneRelated Adverse Events in Patients Treated With Immune Checkpoint Inhibitor Therapy: American Society of Clinical Oncology Clinical Practice Guideline. J Clin Oncol. 2018;36(17):1714-1768. https://doi.org/10.1200/JCO.2017.77.6385</mixed-citation><mixed-citation xml:lang="en">Brahmer JR, Lacchetti C, Schneider BJ, et al. Management of ImmuneRelated Adverse Events in Patients Treated With Immune Checkpoint Inhibitor Therapy: American Society of Clinical Oncology Clinical Practice Guideline. J Clin Oncol. 2018;36(17):1714-1768. https://doi.org/10.1200/JCO.2017.77.6385</mixed-citation></citation-alternatives></ref><ref id="cit410"><label>410</label><citation-alternatives><mixed-citation xml:lang="ru">Noseda R, Ruinelli L, Gaag LCV, Ceschi A. Pre-Existing Cardiovascular Conditions as Clinical Predictors of Myocarditis Reporting with Immune Checkpoint Inhibitors: A VigiBase Study. Cancers (Basel). 2020;12(11):3480. Published 2020 Nov 23. https://doi.org/10.3390/cancers12113480</mixed-citation><mixed-citation xml:lang="en">Noseda R, Ruinelli L, Gaag LCV, Ceschi A. Pre-Existing Cardiovascular Conditions as Clinical Predictors of Myocarditis Reporting with Immune Checkpoint Inhibitors: A VigiBase Study. Cancers (Basel). 2020;12(11):3480. Published 2020 Nov 23. https://doi.org/10.3390/cancers12113480</mixed-citation></citation-alternatives></ref><ref id="cit411"><label>411</label><citation-alternatives><mixed-citation xml:lang="ru">Choi J, Lee SY. Clinical Characteristics and Treatment of ImmuneRelated Adverse Events of Immune Checkpoint Inhibitors. Immune Netw. 2020;20(1):e9. Published 2020 Feb 17. https://doi.org/10.4110/in.2020.20.e9</mixed-citation><mixed-citation xml:lang="en">Choi J, Lee SY. Clinical Characteristics and Treatment of ImmuneRelated Adverse Events of Immune Checkpoint Inhibitors. Immune Netw. 2020;20(1):e9. Published 2020 Feb 17. https://doi.org/10.4110/in.2020.20.e9</mixed-citation></citation-alternatives></ref><ref id="cit412"><label>412</label><citation-alternatives><mixed-citation xml:lang="ru">Patel RP, Parikh R, Gunturu KS, et al. Cardiotoxicity of Immune Checkpoint Inhibitors. Curr Oncol Rep. 2021;23(7):79. Published 2021 May 3. https://doi.org/10.1007/s11912-021-01070-6</mixed-citation><mixed-citation xml:lang="en">Patel RP, Parikh R, Gunturu KS, et al. Cardiotoxicity of Immune Checkpoint Inhibitors. Curr Oncol Rep. 2021;23(7):79. Published 2021 May 3. https://doi.org/10.1007/s11912-021-01070-6</mixed-citation></citation-alternatives></ref><ref id="cit413"><label>413</label><citation-alternatives><mixed-citation xml:lang="ru">Chen DY, Huang WK, Chien-Chia Wu V, et al. Cardiovascular toxicity of immune checkpoint inhibitors in cancer patients: A review when cardiology meets immuno-oncology. J Formos Med Assoc. 2020;119(10):1461-1475. https://doi.org/10.1016/j.jfma.2019.07.025</mixed-citation><mixed-citation xml:lang="en">Chen DY, Huang WK, Chien-Chia Wu V, et al. Cardiovascular toxicity of immune checkpoint inhibitors in cancer patients: A review when cardiology meets immuno-oncology. J Formos Med Assoc. 2020;119(10):1461-1475. https://doi.org/10.1016/j.jfma.2019.07.025</mixed-citation></citation-alternatives></ref><ref id="cit414"><label>414</label><citation-alternatives><mixed-citation xml:lang="ru">Mahmood SS, Fradley MG, Cohen JV, et al. Myocarditis in Patients Treated With Immune Checkpoint Inhibitors. J Am Coll Cardiol. 2018;71(16):1755-1764. https://doi.org/10.1016/j.jacc.2018.02.037</mixed-citation><mixed-citation xml:lang="en">Mahmood SS, Fradley MG, Cohen JV, et al. Myocarditis in Patients Treated With Immune Checkpoint Inhibitors. J Am Coll Cardiol. 2018;71(16):1755-1764. https://doi.org/10.1016/j.jacc.2018.02.037</mixed-citation></citation-alternatives></ref><ref id="cit415"><label>415</label><citation-alternatives><mixed-citation xml:lang="ru">Palaskas N, Lopez-Mattei J, Durand JB, Iliescu C, Deswal A. Immune Checkpoint Inhibitor Myocarditis: Pathophysiological Characteristics, Diagnosis, and Treatment. J Am Heart Assoc. 2020;9(2):e013757. https://doi.org/10.1161/JAHA.119.013757</mixed-citation><mixed-citation xml:lang="en">Palaskas N, Lopez-Mattei J, Durand JB, Iliescu C, Deswal A. Immune Checkpoint Inhibitor Myocarditis: Pathophysiological Characteristics, Diagnosis, and Treatment. J Am Heart Assoc. 2020;9(2):e013757. https://doi.org/10.1161/JAHA.119.013757</mixed-citation></citation-alternatives></ref><ref id="cit416"><label>416</label><citation-alternatives><mixed-citation xml:lang="ru">Ganatra S, Neilan TG. Immune Checkpoint Inhibitor-Associated Myocarditis. Oncologist. 2018;23(8):879-886. https://doi.org/10.1634/theoncologist.2018-0130</mixed-citation><mixed-citation xml:lang="en">Ganatra S, Neilan TG. Immune Checkpoint Inhibitor-Associated Myocarditis. Oncologist. 2018;23(8):879-886. https://doi.org/10.1634/theoncologist.2018-0130</mixed-citation></citation-alternatives></ref><ref id="cit417"><label>417</label><citation-alternatives><mixed-citation xml:lang="ru">Drobni ZD, Alvi RM, Taron J, et al. Association Between Immune Checkpoint Inhibitors With Cardiovascular Events and Atherosclerotic Plaque. Circulation. 2020;142(24):2299-2311. https://doi.org/10.1161/CIRCULATIONAHA.120.049981</mixed-citation><mixed-citation xml:lang="en">Drobni ZD, Alvi RM, Taron J, et al. Association Between Immune Checkpoint Inhibitors With Cardiovascular Events and Atherosclerotic Plaque. Circulation. 2020;142(24):2299-2311. https://doi.org/10.1161/CIRCULATIONAHA.120.049981</mixed-citation></citation-alternatives></ref><ref id="cit418"><label>418</label><citation-alternatives><mixed-citation xml:lang="ru">Altan M, Toki MI, Gettinger SN, et al. Immune Checkpoint Inhibitor-Associated Pericarditis. J Thorac Oncol. 2019;14(6):1102-1108. https://doi.org/10.1016/j.jtho.2019.02.026</mixed-citation><mixed-citation xml:lang="en">Altan M, Toki MI, Gettinger SN, et al. Immune Checkpoint Inhibitor-Associated Pericarditis. J Thorac Oncol. 2019;14(6):1102-1108. https://doi.org/10.1016/j.jtho.2019.02.026</mixed-citation></citation-alternatives></ref><ref id="cit419"><label>419</label><citation-alternatives><mixed-citation xml:lang="ru">Chen C, Chen T, Liang J, et al. Cardiotoxicity Induced by Immune Checkpoint Inhibitors: A Pharmacovigilance Study From 2014 to 2019 Based on FAERS. Front Pharmacol. 2021;12:616505. Published 2021 Feb 12. https://doi.org/10.3389/fphar.2021.616505</mixed-citation><mixed-citation xml:lang="en">Chen C, Chen T, Liang J, et al. Cardiotoxicity Induced by Immune Checkpoint Inhibitors: A Pharmacovigilance Study From 2014 to 2019 Based on FAERS. Front Pharmacol. 2021;12:616505. Published 2021 Feb 12. https://doi.org/10.3389/fphar.2021.616505</mixed-citation></citation-alternatives></ref><ref id="cit420"><label>420</label><citation-alternatives><mixed-citation xml:lang="ru">Naidoo J, Page DB, Li BT, et al. Toxicities of the anti-PD-1 and anti-PD-L1 immune checkpoint antibodies [published correction appears in Ann Oncol. 2016 Jul;27(7):1362]. Ann Oncol. 2015;26(12):2375-2391. https://doi.org/10.1093/annonc/mdv383</mixed-citation><mixed-citation xml:lang="en">Naidoo J, Page DB, Li BT, et al. Toxicities of the anti-PD-1 and anti-PD-L1 immune checkpoint antibodies [published correction appears in Ann Oncol. 2016 Jul;27(7):1362]. Ann Oncol. 2015;26(12):2375-2391. https://doi.org/10.1093/annonc/mdv383</mixed-citation></citation-alternatives></ref><ref id="cit421"><label>421</label><citation-alternatives><mixed-citation xml:lang="ru">Moslehi JJ, Salem JE, Sosman JA, Lebrun-Vignes B, Johnson DB. Increased reporting of fatal immune checkpoint inhibitor-associated myocarditis. Lancet. 2018;391(10124):933. https://doi.org/10.1016/S0140-6736(18)30533-6</mixed-citation><mixed-citation xml:lang="en">Moslehi JJ, Salem JE, Sosman JA, Lebrun-Vignes B, Johnson DB. Increased reporting of fatal immune checkpoint inhibitor-associated myocarditis. Lancet. 2018;391(10124):933. https://doi.org/10.1016/S0140-6736(18)30533-6</mixed-citation></citation-alternatives></ref><ref id="cit422"><label>422</label><citation-alternatives><mixed-citation xml:lang="ru">Upadhrasta S, Elias H, Patel K, Zheng L. Managing cardiotoxicity associated with immune checkpoint inhibitors. Chronic Dis Transl Med. 2019;5(1):6-14. Published 2019 Mar 21. https://doi.org/10.1016/j.cdtm.2019.02.004</mixed-citation><mixed-citation xml:lang="en">Upadhrasta S, Elias H, Patel K, Zheng L. Managing cardiotoxicity associated with immune checkpoint inhibitors. Chronic Dis Transl Med. 2019;5(1):6-14. Published 2019 Mar 21. https://doi.org/10.1016/j.cdtm.2019.02.004</mixed-citation></citation-alternatives></ref><ref id="cit423"><label>423</label><citation-alternatives><mixed-citation xml:lang="ru">Salem JE, Manouchehri A, Moey M, et al. Cardiovascular toxicities associated with immune checkpoint inhibitors: an observational, retrospective, pharmacovigilance study. Lancet Oncol. 2018;19(12):1579-1589. https://doi.org/10.1016/S1470-2045(18)30608-9</mixed-citation><mixed-citation xml:lang="en">Salem JE, Manouchehri A, Moey M, et al. Cardiovascular toxicities associated with immune checkpoint inhibitors: an observational, retrospective, pharmacovigilance study. Lancet Oncol. 2018;19(12):1579-1589. https://doi.org/10.1016/S1470-2045(18)30608-9</mixed-citation></citation-alternatives></ref><ref id="cit424"><label>424</label><citation-alternatives><mixed-citation xml:lang="ru">Oren O, Yang EH, Molina JR, Bailey KR, Blumenthal RS, Kopecky SL. Cardiovascular Health and Outcomes in Cancer Patients Receiving Immune Checkpoint Inhibitors. Am J Cardiol. 2020;125(12):1920-1926. https://doi.org/10.1016/j.amjcard.2020.02.016</mixed-citation><mixed-citation xml:lang="en">Oren O, Yang EH, Molina JR, Bailey KR, Blumenthal RS, Kopecky SL. Cardiovascular Health and Outcomes in Cancer Patients Receiving Immune Checkpoint Inhibitors. Am J Cardiol. 2020;125(12):1920-1926. https://doi.org/10.1016/j.amjcard.2020.02.016</mixed-citation></citation-alternatives></ref><ref id="cit425"><label>425</label><citation-alternatives><mixed-citation xml:lang="ru">Dal’bo N, Patel R, Parikh R, et al. Cardiotoxicity of Contemporary Anticancer Immunotherapy. Curr Treat Options Cardiovasc Med. 2020;22(12):62. https://doi.org/10.1007/s11936-020-00867-1</mixed-citation><mixed-citation xml:lang="en">Dal’bo N, Patel R, Parikh R, et al. Cardiotoxicity of Contemporary Anticancer Immunotherapy. Curr Treat Options Cardiovasc Med. 2020;22(12):62. https://doi.org/10.1007/s11936-020-00867-1</mixed-citation></citation-alternatives></ref><ref id="cit426"><label>426</label><citation-alternatives><mixed-citation xml:lang="ru">Ganatra S, Parikh R, Neilan TG. Cardiotoxicity of Immune Therapy. Cardiol Clin. 2019;37(4):385-397. https://doi.org/10.1016/j.ccl.2019.07.008</mixed-citation><mixed-citation xml:lang="en">Ganatra S, Parikh R, Neilan TG. Cardiotoxicity of Immune Therapy. Cardiol Clin. 2019;37(4):385-397. https://doi.org/10.1016/j.ccl.2019.07.008</mixed-citation></citation-alternatives></ref><ref id="cit427"><label>427</label><citation-alternatives><mixed-citation xml:lang="ru">Bonaca MP, Olenchock BA, Salem JE, et al. Myocarditis in the Setting of Cancer Therapeutics: Proposed Case Defnitions for Emerging Clinical Syndromes in Cardio-Oncology. Circulation. 2019;140(2):80-91. https://doi.org/10.1161/CIRCULATIONAHA.118.034497</mixed-citation><mixed-citation xml:lang="en">Bonaca MP, Olenchock BA, Salem JE, et al. Myocarditis in the Setting of Cancer Therapeutics: Proposed Case Defnitions for Emerging Clinical Syndromes in Cardio-Oncology. Circulation. 2019;140(2):80-91. https://doi.org/10.1161/CIRCULATIONAHA.118.034497</mixed-citation></citation-alternatives></ref><ref id="cit428"><label>428</label><citation-alternatives><mixed-citation xml:lang="ru">Zlotoff DA, Hassan MZO, Zafar A, et al. Electrocardiographic features of immune checkpoint inhibitor associated myocarditis. J Immunother Cancer. 2021;9(3):e002007. https://doi.org/10.1136/jitc-2020-002007</mixed-citation><mixed-citation xml:lang="en">Zlotoff DA, Hassan MZO, Zafar A, et al. Electrocardiographic features of immune checkpoint inhibitor associated myocarditis. J Immunother Cancer. 2021;9(3):e002007. https://doi.org/10.1136/jitc-2020-002007</mixed-citation></citation-alternatives></ref><ref id="cit429"><label>429</label><citation-alternatives><mixed-citation xml:lang="ru">Awadalla M, Mahmood SS, Groarke JD, et al. Global Longitudinal Strain and Cardiac Events in Patients With Immune Checkpoint Inhibitor-Related Myocarditis. J Am Coll Cardiol. 2020;75(5):467-478. https://doi.org/10.1016/j.jacc.2019.11.049</mixed-citation><mixed-citation xml:lang="en">Awadalla M, Mahmood SS, Groarke JD, et al. Global Longitudinal Strain and Cardiac Events in Patients With Immune Checkpoint Inhibitor-Related Myocarditis. J Am Coll Cardiol. 2020;75(5):467-478. https://doi.org/10.1016/j.jacc.2019.11.049</mixed-citation></citation-alternatives></ref><ref id="cit430"><label>430</label><citation-alternatives><mixed-citation xml:lang="ru">Zhang L, Awadalla M, Mahmood SS, et al. Cardiovascular magnetic resonance in immune checkpoint inhibitor-associated myocarditis. Eur Heart J. 2020;41(18):1733-1743. https://doi.org/10.1093/eurheartj/ehaa051</mixed-citation><mixed-citation xml:lang="en">Zhang L, Awadalla M, Mahmood SS, et al. Cardiovascular magnetic resonance in immune checkpoint inhibitor-associated myocarditis. Eur Heart J. 2020;41(18):1733-1743. https://doi.org/10.1093/eurheartj/ehaa051</mixed-citation></citation-alternatives></ref><ref id="cit431"><label>431</label><citation-alternatives><mixed-citation xml:lang="ru">Российское кардиологическое общество (РКО). Миокардиты. Клинические рекомендации 2020 https://scardio.ru/content/Guidelines/2020/Clinic_rekom_Miokardit.pdf</mixed-citation><mixed-citation xml:lang="en">Российское кардиологическое общество (РКО). Миокардиты. Клинические рекомендации 2020 https://scardio.ru/content/Guidelines/2020/Clinic_rekom_Miokardit.pdf</mixed-citation></citation-alternatives></ref><ref id="cit432"><label>432</label><citation-alternatives><mixed-citation xml:lang="ru">Barry T, Gallen R, Freeman C, et al. Successful Treatment of SteroidRefractory Checkpoint Inhibitor Myocarditis with Globulin Derived-Therapy: A Case Report and Literature Review. Am J Med Sci. 2021;362(4):424-432. https://doi.org/10.1016/j.amjms.2021.04.018</mixed-citation><mixed-citation xml:lang="en">Barry T, Gallen R, Freeman C, et al. Successful Treatment of SteroidRefractory Checkpoint Inhibitor Myocarditis with Globulin Derived-Therapy: A Case Report and Literature Review. Am J Med Sci. 2021;362(4):424-432. https://doi.org/10.1016/j.amjms.2021.04.018</mixed-citation></citation-alternatives></ref><ref id="cit433"><label>433</label><citation-alternatives><mixed-citation xml:lang="ru">Kristensen SD, Knuuti J, Saraste A, et al. 2014 ESC/ESA Guidelines on noncardiac surgery: cardiovascular assessment and management: The Joint Task Force on non-cardiac surgery: cardiovascular assessment and management of the European Society of Cardiology (ESC) and the European Society of Anaesthesiology (ESA). Eur Heart J. 2014;35(35):2383-2431. https://doi.org/10.1093/eurheartj/ehu282</mixed-citation><mixed-citation xml:lang="en">Kristensen SD, Knuuti J, Saraste A, et al. 2014 ESC/ESA Guidelines on noncardiac surgery: cardiovascular assessment and management: The Joint Task Force on non-cardiac surgery: cardiovascular assessment and management of the European Society of Cardiology (ESC) and the European Society of Anaesthesiology (ESA). Eur Heart J. 2014;35(35):2383-2431. https://doi.org/10.1093/eurheartj/ehu282</mixed-citation></citation-alternatives></ref><ref id="cit434"><label>434</label><citation-alternatives><mixed-citation xml:lang="ru">Заболотских И.Б., Баутин А.Е., Григорьев Е.В., Грицан А.И., Лебединский К.М., Потиевская В.И., Руднов В.А., Субботин В.В., Хороненко В.Э., Шадрин Р.В. Периоперационное ведение пациентов с артериальной гипертензией. Методические рекомендации. Вестник интенсивной терапии им. А.И. Салтанова. 2020;2:7–33 https://doi.org/10.21320/1818-474X-2020-2-7-33</mixed-citation><mixed-citation xml:lang="en">Заболотских И.Б., Баутин А.Е., Григорьев Е.В., Грицан А.И., Лебединский К.М., Потиевская В.И., Руднов В.А., Субботин В.В., Хороненко В.Э., Шадрин Р.В. Периоперационное ведение пациентов с артериальной гипертензией. Методические рекомендации. Вестник интенсивной терапии им. А.И. Салтанова. 2020;2:7–33 https://doi.org/10.21320/1818-474X-2020-2-7-33</mixed-citation></citation-alternatives></ref><ref id="cit435"><label>435</label><citation-alternatives><mixed-citation xml:lang="ru">Заболотских И. Б., Потиевская В. И., Баутин А. Е., Григорьев Е. В., Григорьев С. В., Грицан А. И., Киров М. Ю., Лебединский К. М., Субботин В. В. Периоперационное ведение пациентов с ишемической болезнью сердца. Анестезиология и реаниматология. 2020;(3):5-16. https://doi.org/10.17116/anaesthesiology20200315</mixed-citation><mixed-citation xml:lang="en">Заболотских И. Б., Потиевская В. И., Баутин А. Е., Григорьев Е. В., Григорьев С. В., Грицан А. И., Киров М. Ю., Лебединский К. М., Субботин В. В. Периоперационное ведение пациентов с ишемической болезнью сердца. Анестезиология и реаниматология. 2020;(3):5-16. https://doi.org/10.17116/anaesthesiology20200315</mixed-citation></citation-alternatives></ref><ref id="cit436"><label>436</label><citation-alternatives><mixed-citation xml:lang="ru">Valgimigli M, Bueno H, Byrne RA, et al. 2017 ESC focused update on dual antiplatelet therapy in coronary artery disease developed in collaboration with EACTS: The Task Force for dual antiplatelet therapy in coronary artery disease of the European Society of Cardiology (ESC) and of the European Association for Cardio-Thoracic Surgery (EACTS). Eur Heart J. 2018;39(3):213-260. https://doi.org/10.1093/eurheartj/ehx419</mixed-citation><mixed-citation xml:lang="en">Valgimigli M, Bueno H, Byrne RA, et al. 2017 ESC focused update on dual antiplatelet therapy in coronary artery disease developed in collaboration with EACTS: The Task Force for dual antiplatelet therapy in coronary artery disease of the European Society of Cardiology (ESC) and of the European Association for Cardio-Thoracic Surgery (EACTS). Eur Heart J. 2018;39(3):213-260. https://doi.org/10.1093/eurheartj/ehx419</mixed-citation></citation-alternatives></ref><ref id="cit437"><label>437</label><citation-alternatives><mixed-citation xml:lang="ru">Colombo R. Myocardial injury after non cardiac surgery: troponin assay is not enough… We need perioperative bearings. Minerva Anestesiol. 2018;84(10):1131-1133. https://doi.org/10.23736/S0375-9393.18.13164-6</mixed-citation><mixed-citation xml:lang="en">Colombo R. Myocardial injury after non cardiac surgery: troponin assay is not enough… We need perioperative bearings. Minerva Anestesiol. 2018;84(10):1131-1133. https://doi.org/10.23736/S0375-9393.18.13164-6</mixed-citation></citation-alternatives></ref><ref id="cit438"><label>438</label><citation-alternatives><mixed-citation xml:lang="ru">Ujueta F, Berger JS, Smilowitz N. Coronary Angiography in Patients With Perioperative Myocardial Injury After Non-Cardiac Surgery. J Invasive Cardiol. 2018;30(9):E90-E92.</mixed-citation><mixed-citation xml:lang="en">Ujueta F, Berger JS, Smilowitz N. Coronary Angiography in Patients With Perioperative Myocardial Injury After Non-Cardiac Surgery. J Invasive Cardiol. 2018;30(9):E90-E92.</mixed-citation></citation-alternatives></ref><ref id="cit439"><label>439</label><citation-alternatives><mixed-citation xml:lang="ru">Заболотских И.Б., Лебединский К.М., Потиевская В.И., Баутин А.Е., Еременко А.А., Алексеева Ю.М., Дорогинин С.В. Периоперационное ведение пациентов с желудочковыми тахиаритмиями. Анестезиология и реаниматология (Медиа Сфера). 2020. № 6. С. 6-22. https://doi.org/10.17116/anaesthesiology20200616</mixed-citation><mixed-citation xml:lang="en">Заболотских И.Б., Лебединский К.М., Потиевская В.И., Баутин А.Е., Еременко А.А., Алексеева Ю.М., Дорогинин С.В. Периоперационное ведение пациентов с желудочковыми тахиаритмиями. Анестезиология и реаниматология (Медиа Сфера). 2020. № 6. С. 6-22. https://doi.org/10.17116/anaesthesiology20200616</mixed-citation></citation-alternatives></ref><ref id="cit440"><label>440</label><citation-alternatives><mixed-citation xml:lang="ru">Болдуева С. А., Шабров А.В., Лебедев Д. С и др. Прогнозирование и профилактика незапной кардиальной смерти у больных, перенесших инфаркт миокарда. Кардиоваскулярная терапия и профилактика 2008; 7 (3): 56–62). / Bolduyeva SA, Shabrov AV, Lebedev DS, et al. Forecasting and prevention of sudden cardiac death at the patients who had a myocardial infarction. Cardiovascular therapy and prevention 2008; 7 (3): 56–62. In Russ.</mixed-citation><mixed-citation xml:lang="en">Болдуева С. А., Шабров А.В., Лебедев Д. С и др. Прогнозирование и профилактика незапной кардиальной смерти у больных, перенесших инфаркт миокарда. Кардиоваскулярная терапия и профилактика 2008; 7 (3): 56–62). / Bolduyeva SA, Shabrov AV, Lebedev DS, et al. Forecasting and prevention of sudden cardiac death at the patients who had a myocardial infarction. Cardiovascular therapy and prevention 2008; 7 (3): 56–62. In Russ.</mixed-citation></citation-alternatives></ref><ref id="cit441"><label>441</label><citation-alternatives><mixed-citation xml:lang="ru">Green DH, Townsend P, Bagshaw O, Stokes MA. Nodal rhythm and bradycardia during inhalation induction with sevoﬂurane in infants: a comparison of incremental and high-concentration techniques. Br J Anaesth. 2000;85(3):368-370. https://doi.org/10.1093/bja/85.3.368</mixed-citation><mixed-citation xml:lang="en">Green DH, Townsend P, Bagshaw O, Stokes MA. Nodal rhythm and bradycardia during inhalation induction with sevoﬂurane in infants: a comparison of incremental and high-concentration techniques. Br J Anaesth. 2000;85(3):368-370. https://doi.org/10.1093/bja/85.3.368</mixed-citation></citation-alternatives></ref><ref id="cit442"><label>442</label><citation-alternatives><mixed-citation xml:lang="ru">Owczuk R, Wujtewicz MA, Sawicka W, Lasek J, Wujtewicz M. The Inﬂuence of desﬂurane on QTc interval. Anesth Analg. 2005;101(2):. https://doi.org/10.1213/01.ANE.0000154198.41162.FA</mixed-citation><mixed-citation xml:lang="en">Owczuk R, Wujtewicz MA, Sawicka W, Lasek J, Wujtewicz M. The Inﬂuence of desﬂurane on QTc interval. Anesth Analg. 2005;101(2):. https://doi.org/10.1213/01.ANE.0000154198.41162.FA</mixed-citation></citation-alternatives></ref><ref id="cit443"><label>443</label><citation-alternatives><mixed-citation xml:lang="ru">Reiz S, Nath S. Cardiotoxicity of local anaesthetic agents. Br J Anaesth. 1986;58(7):736-746. https://doi.org/10.1093/bja/58.7.736</mixed-citation><mixed-citation xml:lang="en">Reiz S, Nath S. Cardiotoxicity of local anaesthetic agents. Br J Anaesth. 1986;58(7):736-746. https://doi.org/10.1093/bja/58.7.736</mixed-citation></citation-alternatives></ref><ref id="cit444"><label>444</label><citation-alternatives><mixed-citation xml:lang="ru">Буров Н.Е., Потапов В.Н. Ксенон в медицине: очерки по истории и применению медицинского ксенона. М.: Пульс, 2012. [Burov N.E., Potapov V.N. Xenon in medicine: essays in history and use of medical xenon. M.: Pul’s, 2012. (In Russ)]</mixed-citation><mixed-citation xml:lang="en">Буров Н.Е., Потапов В.Н. Ксенон в медицине: очерки по истории и применению медицинского ксенона. М.: Пульс, 2012. [Burov N.E., Potapov V.N. Xenon in medicine: essays in history and use of medical xenon. M.: Pul’s, 2012. (In Russ)]</mixed-citation></citation-alternatives></ref><ref id="cit445"><label>445</label><citation-alternatives><mixed-citation xml:lang="ru">Hogan Q. Токсичность местных анестетиков. Reg Anesth, 21(6S):43-50,1996. Hogan Q. Local anesthetic toxicity: an update. Reg Anesth. 1996;21(6 Suppl):43-50.</mixed-citation><mixed-citation xml:lang="en">Hogan Q. Токсичность местных анестетиков. Reg Anesth, 21(6S):43-50,1996. Hogan Q. Local anesthetic toxicity: an update. Reg Anesth. 1996;21(6 Suppl):43-50.</mixed-citation></citation-alternatives></ref><ref id="cit446"><label>446</label><citation-alternatives><mixed-citation xml:lang="ru">Дж. Эдвард Морган. Клиническая анестезиология, 2001.</mixed-citation><mixed-citation xml:lang="en">Дж. Эдвард Морган. Клиническая анестезиология, 2001.</mixed-citation></citation-alternatives></ref><ref id="cit447"><label>447</label><citation-alternatives><mixed-citation xml:lang="ru">Rosenblatt MA, Abel M, Fischer GW, Itzkovich CJ, Eisenkraft JB. Successful use of a 20% lipid emulsion to resuscitate a patient after a presumed bupivacaine-related cardiac arrest. Anesthesiology. 2006;105(1):217-218. https://doi.org/10.1097/00000542-200607000-00033</mixed-citation><mixed-citation xml:lang="en">Rosenblatt MA, Abel M, Fischer GW, Itzkovich CJ, Eisenkraft JB. Successful use of a 20% lipid emulsion to resuscitate a patient after a presumed bupivacaine-related cardiac arrest. Anesthesiology. 2006;105(1):217-218. https://doi.org/10.1097/00000542-200607000-00033</mixed-citation></citation-alternatives></ref><ref id="cit448"><label>448</label><citation-alternatives><mixed-citation xml:lang="ru">Weinberg G. Lipid infusion resuscitation for local anesthetic toxicity: proof of clinical effcacy. Anesthesiology. 2006;105(1):7-8. https://doi.org/10.1097/00000542-200607000-00005</mixed-citation><mixed-citation xml:lang="en">Weinberg G. Lipid infusion resuscitation for local anesthetic toxicity: proof of clinical effcacy. Anesthesiology. 2006;105(1):7-8. https://doi.org/10.1097/00000542-200607000-00005</mixed-citation></citation-alternatives></ref><ref id="cit449"><label>449</label><citation-alternatives><mixed-citation xml:lang="ru">Edwards R, Winnie AP, Ramamurthy S. Acute hypocapneic hypokalemia: an latrogenic anesthetic complication. Anesth Analg. 1977;56(6):786-792. https://doi.org/10.1213/00000539-197711000-00009</mixed-citation><mixed-citation xml:lang="en">Edwards R, Winnie AP, Ramamurthy S. Acute hypocapneic hypokalemia: an latrogenic anesthetic complication. Anesth Analg. 1977;56(6):786-792. https://doi.org/10.1213/00000539-197711000-00009</mixed-citation></citation-alternatives></ref><ref id="cit450"><label>450</label><citation-alternatives><mixed-citation xml:lang="ru">Samuels MA. The brain-heart connection. Circulation. 2007;116(1):77-84. https://doi.org/10.1161/CIRCULATIONAHA.106.678995</mixed-citation><mixed-citation xml:lang="en">Samuels MA. The brain-heart connection. Circulation. 2007;116(1):77-84. https://doi.org/10.1161/CIRCULATIONAHA.106.678995</mixed-citation></citation-alternatives></ref><ref id="cit451"><label>451</label><citation-alternatives><mixed-citation xml:lang="ru">Алексин А.А., Хороненко В.Э. Послеоперационная фибрилляция предсердий при хирургических вмешательствах на легких. Вестник Анестезиологии и Реаниматологии 2014, №2.- С. 71-78.</mixed-citation><mixed-citation xml:lang="en">Алексин А.А., Хороненко В.Э. Послеоперационная фибрилляция предсердий при хирургических вмешательствах на легких. Вестник Анестезиологии и Реаниматологии 2014, №2.- С. 71-78.</mixed-citation></citation-alternatives></ref><ref id="cit452"><label>452</label><citation-alternatives><mixed-citation xml:lang="ru">Guzzetti S, Costantino G, Vernocchi A, Sada S, Fundarò C. First diagnosis of colorectal or breast cancer and prevalence of atrial fbrillation. Intern Emerg Med. 2008;3(3):227-231. https://doi.org/10.1007/s11739-008-0124-4</mixed-citation><mixed-citation xml:lang="en">Guzzetti S, Costantino G, Vernocchi A, Sada S, Fundarò C. First diagnosis of colorectal or breast cancer and prevalence of atrial fbrillation. Intern Emerg Med. 2008;3(3):227-231. https://doi.org/10.1007/s11739-008-0124-4</mixed-citation></citation-alternatives></ref><ref id="cit453"><label>453</label><citation-alternatives><mixed-citation xml:lang="ru">Onaitis M, D’Amico T, Zhao Y, O’Brien S, Harpole D. Risk factors for atrial fbrillation after lung cancer surgery: analysis of the Society of Thoracic Surgeons general thoracic surgery database. Ann Thorac Surg. 2010;90(2):368-374. https://doi.org/10.1016/j.athoracsur.2010.03.100</mixed-citation><mixed-citation xml:lang="en">Onaitis M, D’Amico T, Zhao Y, O’Brien S, Harpole D. Risk factors for atrial fbrillation after lung cancer surgery: analysis of the Society of Thoracic Surgeons general thoracic surgery database. Ann Thorac Surg. 2010;90(2):368-374. https://doi.org/10.1016/j.athoracsur.2010.03.100</mixed-citation></citation-alternatives></ref><ref id="cit454"><label>454</label><citation-alternatives><mixed-citation xml:lang="ru">Ponikowski P., A. Voors A., D. Anker S., Bueno H., G. F. Cleland J., J. S . Coats A., Falk V., González-Juanatey J., Harjola V., A. Jankowska E., Jessup M., Linde C., Nihoyannopoulos P., T . Parissis J., Pieske B., P. Riley J., M. C. Rosano G., M. Ruilope L., Ruschitzka F., H. Rutten F., van der Meer P. РЕКОМЕНДАЦИИ ESC ПО ДИАГНОСТИКЕ И ЛЕЧЕНИЮ ОСТРОЙ И ХРОНИЧЕСКОЙ СЕРДЕЧНОЙ НЕДОСТАТОЧНОСТИ 2016. Российский кардиологический журнал. 2017;(1):7-81. https://doi.org/10.15829/1560-4071-2017-1-7-81</mixed-citation><mixed-citation xml:lang="en">Ponikowski P., A. Voors A., D. Anker S., Bueno H., G. F. Cleland J., J. S . Coats A., Falk V., González-Juanatey J., Harjola V., A. Jankowska E., Jessup M., Linde C., Nihoyannopoulos P., T . Parissis J., Pieske B., P. Riley J., M. C. Rosano G., M. Ruilope L., Ruschitzka F., H. Rutten F., van der Meer P. РЕКОМЕНДАЦИИ ESC ПО ДИАГНОСТИКЕ И ЛЕЧЕНИЮ ОСТРОЙ И ХРОНИЧЕСКОЙ СЕРДЕЧНОЙ НЕДОСТАТОЧНОСТИ 2016. Российский кардиологический журнал. 2017;(1):7-81. https://doi.org/10.15829/1560-4071-2017-1-7-81</mixed-citation></citation-alternatives></ref><ref id="cit455"><label>455</label><citation-alternatives><mixed-citation xml:lang="ru">Заболотских И.Б., Баутин А.Е., Замятин М.Н., Лебединский К.М., Потиевская В.И., Трембач Н.В. Периоперационное ведение пациентов с хронической сердечной недостаточностью. Анестезиология и реаниматология (Медиа Сфера). 2021. № 3. С. 6-27.</mixed-citation><mixed-citation xml:lang="en">Заболотских И.Б., Баутин А.Е., Замятин М.Н., Лебединский К.М., Потиевская В.И., Трембач Н.В. Периоперационное ведение пациентов с хронической сердечной недостаточностью. Анестезиология и реаниматология (Медиа Сфера). 2021. № 3. С. 6-27.</mixed-citation></citation-alternatives></ref><ref id="cit456"><label>456</label><citation-alternatives><mixed-citation xml:lang="ru">Дербугов В.Н., Потапов А.Л., Потиевская В.И., Хмелевский Я.М. Применение экзогенного фосфокреатина у пациентов пожилого и старческого возраста, оперируемых по поводу колоректального рака. Общая реаниматология. 2017;13(4):38-45. https://doi.org/10.15360/1813-9779-2017-4-38-45</mixed-citation><mixed-citation xml:lang="en">Дербугов В.Н., Потапов А.Л., Потиевская В.И., Хмелевский Я.М. Применение экзогенного фосфокреатина у пациентов пожилого и старческого возраста, оперируемых по поводу колоректального рака. Общая реаниматология. 2017;13(4):38-45. https://doi.org/10.15360/1813-9779-2017-4-38-45</mixed-citation></citation-alternatives></ref><ref id="cit457"><label>457</label><citation-alternatives><mixed-citation xml:lang="ru">Заболотских И.Б., Киров М.Ю., Афончиков В.С., Буланов А.Ю., Григорьев Е.В., Грицан А.И., Замятин М.Н., Курапеев И.С., Лебединский К.М., Ломиворотов В.В., Лубнин А.Ю., Овечкин А.М., Потиевская В.И., Ройтман Е.В., Синьков С.В., Субботин В.В., Шулутко Е.М. Периоперационное ведение пациентов, получающих длительную антитромботическую терапию. Клинические рекомендации федерации анестезиологов и реаниматологов. Вестник интенсивной терапии имени А.И. Салтанова. 2019. № 1. С. 7-19</mixed-citation><mixed-citation xml:lang="en">Заболотских И.Б., Киров М.Ю., Афончиков В.С., Буланов А.Ю., Григорьев Е.В., Грицан А.И., Замятин М.Н., Курапеев И.С., Лебединский К.М., Ломиворотов В.В., Лубнин А.Ю., Овечкин А.М., Потиевская В.И., Ройтман Е.В., Синьков С.В., Субботин В.В., Шулутко Е.М. Периоперационное ведение пациентов, получающих длительную антитромботическую терапию. Клинические рекомендации федерации анестезиологов и реаниматологов. Вестник интенсивной терапии имени А.И. Салтанова. 2019. № 1. С. 7-19</mixed-citation></citation-alternatives></ref><ref id="cit458"><label>458</label><citation-alternatives><mixed-citation xml:lang="ru">Сомонова О. В., Антух Э. А., Долгушин Б. И., Елизарова А. Л., Сакаева Д. Д., Сельчук В. Ю. и соавт. Практические рекомендации по профилактике и лечению тромбоэмболических осложнений у онкологических больных. Злокачественные опухоли: Практические рекомендации RUSSCO #3s2, 2020 (том 10).47.</mixed-citation><mixed-citation xml:lang="en">Сомонова О. В., Антух Э. А., Долгушин Б. И., Елизарова А. Л., Сакаева Д. Д., Сельчук В. Ю. и соавт. Практические рекомендации по профилактике и лечению тромбоэмболических осложнений у онкологических больных. Злокачественные опухоли: Практические рекомендации RUSSCO #3s2, 2020 (том 10).47.</mixed-citation></citation-alternatives></ref><ref id="cit459"><label>459</label><citation-alternatives><mixed-citation xml:lang="ru">Agnelli G, Buller HR, Cohen A, et al. Oral apixaban for the treatment of acute venous thromboembolism. N Engl J Med. 2013;369(9):799-808. https://doi.org/10.1056/NEJMoa1302507</mixed-citation><mixed-citation xml:lang="en">Agnelli G, Buller HR, Cohen A, et al. Oral apixaban for the treatment of acute venous thromboembolism. N Engl J Med. 2013;369(9):799-808. https://doi.org/10.1056/NEJMoa1302507</mixed-citation></citation-alternatives></ref><ref id="cit460"><label>460</label><citation-alternatives><mixed-citation xml:lang="ru">Nunnelee JD. Review of an article: oral rivaroxaban for symptomatic venous thromboembolism. The EINSTEIN Investigators et al. N Engl J Med 2010; 363(26):2499-2510. J Vasc Nurs. 2011;29(2):89. https://doi.org/10.1016/j.jvn.2011.03.002</mixed-citation><mixed-citation xml:lang="en">Nunnelee JD. Review of an article: oral rivaroxaban for symptomatic venous thromboembolism. The EINSTEIN Investigators et al. N Engl J Med 2010; 363(26):2499-2510. J Vasc Nurs. 2011;29(2):89. https://doi.org/10.1016/j.jvn.2011.03.002</mixed-citation></citation-alternatives></ref><ref id="cit461"><label>461</label><citation-alternatives><mixed-citation xml:lang="ru">EINSTEIN–PE Investigators, Büller HR, Prins MH, et al. Oral rivaroxaban for the treatment of symptomatic pulmonary embolism. N Engl J Med. 2012;366(14):1287-1297. https://doi.org/10.1056/NEJMoa1113572</mixed-citation><mixed-citation xml:lang="en">EINSTEIN–PE Investigators, Büller HR, Prins MH, et al. Oral rivaroxaban for the treatment of symptomatic pulmonary embolism. N Engl J Med. 2012;366(14):1287-1297. https://doi.org/10.1056/NEJMoa1113572</mixed-citation></citation-alternatives></ref><ref id="cit462"><label>462</label><citation-alternatives><mixed-citation xml:lang="ru">Schulman S, Kearon C, Kakkar AK, et al. Dabigatran versus warfarin in the treatment of acute venous thromboembolism. N Engl J Med. 2009;361(24):2342-2352. https://doi.org/10.1056/NEJMoa0906598</mixed-citation><mixed-citation xml:lang="en">Schulman S, Kearon C, Kakkar AK, et al. Dabigatran versus warfarin in the treatment of acute venous thromboembolism. N Engl J Med. 2009;361(24):2342-2352. https://doi.org/10.1056/NEJMoa0906598</mixed-citation></citation-alternatives></ref><ref id="cit463"><label>463</label><citation-alternatives><mixed-citation xml:lang="ru">Schulman S, Kakkar AK, Goldhaber SZ, et al. Treatment of acute venous thromboembolism with dabigatran or warfarin and pooled analysis. Circulation. 2014;129(7):764-772. https://doi.org/10.1161/CIRCULATIONAHA.113.004450</mixed-citation><mixed-citation xml:lang="en">Schulman S, Kakkar AK, Goldhaber SZ, et al. Treatment of acute venous thromboembolism with dabigatran or warfarin and pooled analysis. Circulation. 2014;129(7):764-772. https://doi.org/10.1161/CIRCULATIONAHA.113.004450</mixed-citation></citation-alternatives></ref><ref id="cit464"><label>464</label><citation-alternatives><mixed-citation xml:lang="ru">Hokusai-VTE Investigators, Büller HR, Décousus H, et al. Edoxaban versus warfarin for the treatment of symptomatic venous thromboembolism [published correction appears in N Engl J Med. 2014 Jan 23;370(4):390]. N Engl J Med. 2013;369(15):1406-1415. https://doi.org/10.1056/NEJMoa1306638</mixed-citation><mixed-citation xml:lang="en">Hokusai-VTE Investigators, Büller HR, Décousus H, et al. Edoxaban versus warfarin for the treatment of symptomatic venous thromboembolism [published correction appears in N Engl J Med. 2014 Jan 23;370(4):390]. N Engl J Med. 2013;369(15):1406-1415. https://doi.org/10.1056/NEJMoa1306638</mixed-citation></citation-alternatives></ref><ref id="cit465"><label>465</label><citation-alternatives><mixed-citation xml:lang="ru">Schulman S, Konstantinides S, Hu Y, Tang LV. Venous Thromboembolic Diseases: Diagnosis, Management and Thrombophilia Testing: Observations on NICE Guideline [NG158]. Thromb Haemost. 2020;120(8):1143-1146. https://doi.org/10.1055/s-0040-1712913</mixed-citation><mixed-citation xml:lang="en">Schulman S, Konstantinides S, Hu Y, Tang LV. Venous Thromboembolic Diseases: Diagnosis, Management and Thrombophilia Testing: Observations on NICE Guideline [NG158]. Thromb Haemost. 2020;120(8):1143-1146. https://doi.org/10.1055/s-0040-1712913</mixed-citation></citation-alternatives></ref><ref id="cit466"><label>466</label><citation-alternatives><mixed-citation xml:lang="ru">Bitar ZI, Maadarani OS, Mohsen MJ, Alkazemi NU. Bariatric Surgery can Lower the Effcacy of DOACs. Eur J Case Rep Intern Med. 2020;7(12):001954. Published 2020 Sep 29. https://doi.org/10.12890/2020_001954</mixed-citation><mixed-citation xml:lang="en">Bitar ZI, Maadarani OS, Mohsen MJ, Alkazemi NU. Bariatric Surgery can Lower the Effcacy of DOACs. Eur J Case Rep Intern Med. 2020;7(12):001954. Published 2020 Sep 29. https://doi.org/10.12890/2020_001954</mixed-citation></citation-alternatives></ref></ref-list><fn-group><fn fn-type="conflict"><p>The authors declare that there are no conflicts of interest present.</p></fn></fn-group></back></article>
